Parsoid/Language conversion/Preprocessor fixups/enwiki

enwiki[edit]

552 articles, 106 other pages.

Chemical names[edit]

en:Glutathione
| IUPACName=(2''S'')-2-Amino-4-{[(1''R'')-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid
en:Clarithromycin
| IUPAC_name = (3''R'',4''S'',5''S'',6''R'',7''R'',9''R'',11''S'',12''R'',13''S'',14''R'')-6-{[(2''S'',3''R'',4''S'',6''R'') -4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy} -14-ethyl-12,13-dihydroxy-4-{[(2''R'',4''R'',5''S'',6''S'')-5-hydroxy -4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7 -methoxy-3,5,7,9,11,13-hexamethyl -1-oxacyclotetradecane-2,10-dione
en:Azadirachtin
| IUPACName = Dimethyl (2a''R'',3''S'',4''S'',''R'',''S'',7a''S'',8''S'',10''R'',10a''S'',10b''R'')-10-(acetyloxy)-3,5-dihydroxy-4-[(1''S'',2''S'',6''S'',8''S'',9''R'',11''S'')-2-hydroxy-11-methyl-5,7,10-trioxatetracyclo[6.3.1.02,6.09,11]dodec-3-en-9-yl]-4-methyl-8-{[(2''E'')-2-methylbut-2-enoyl]oxy}octahydro-1''H''-furo[3',4':4,4a]naphtho[1,8-''bc'']furan-5,10a(8''H'')-dicarboxylate
en:Azadirachtin
| OtherNames = Dimethyl (2a''R'',3''S'',4''S'',4a''R'',5''S'',7a''S'',8''S'',10''R'',10a''S'',10b''R'')-10-acetoxy-3,5-dihydroxy-4-[(1a''R'',''S'',3a''S'',6a''S'',7''S'',7a''S'')-6a-hydroxy-7a-methyl-3a,6a,7,7a-tetrahydro-2,7-methanofuro[2,3-''b'']oxireno[''e'']oxepin- 1a(2''H'')-yl]-4-methyl-8-{[(2''E'')-2-methylbut-2-enoyl]oxy}octahydro-1''H''-naphtho[1,8''a-c'':4,5-''b'c''']difuran-5,10a(8''H'')-dicarboxylate
en:Fluvoxamine
| IUPAC_name = 2-{[(''E'')-{5-Methoxy-1-[4-(trifluoromethyl)phenyl] pentylidene}amino]oxy}ethanamine<ref>{{cite web|title=Luvox|work=ChemSpider|publisher=Royal Society of Chemistry|accessdate=21 October 2013|url=http://www.chemspider.com/Chemical-Structure.4481878}}</ref>
en:Glimepiride
| IUPAC_name = 3-Ethyl-4-methyl-''N''-[2-(4-{[(''trans''-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1''H''-pyrrole-1-carboxamide
en:Gentamicin
| IUPAC_name = (3''R'',4''R'',5''R'')-2-{[(1''S'',2''S'',3''R'',4''S'',6''R'')-4,6- diamino-3-{[(2''R'',3''R'',6''S'')- 3-amino-6-[(1''R'')- 1-(methylamino)ethyl]oxan-2-yl]oxy}- 2-hydroxycyclohexyl]oxy}-5-methyl- 4-(methylamino)oxane-3,5-diol
en:Methotrexate
| IUPAC_name = (2''S'')-2-[(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid
en:Sodium stearoyl lactylate
| OtherNames = octadecanoic acid, 2-(1-carboxyethoxy)-1-methyl-2-oxoethyl ester, sodium salt; sodium 2-{[2-(stearoyloxy)propanoyl]oxy}propanoate; sodium stearoyl lactylate; sodium stearoyl-2-lactylate; sodium stearyl-2-lactylate; sodium 2-stearoyllactylate; sodium stelate; stearoyl-2-lactylic acid, sodium salt; sodium alpha-(alpha-(stearoyloxy)propionyloxy)propionate; sodium 2-(1-carboxyethoxy)-1-methyl-2-oxoethyloctadecanoate; [[stearic acid]], ester with lactate of [[lactic acid]], sodium salt; stearic acid ester with lactic acid bimol. ester sodium salt; sodium 2-(1-carboxylatoethoxy)-1-methyl-2-oxoethyl stearate
en:Imatinib
| IUPAC_name = 4-[(4-methylpiperazin-1-yl)methyl]-''N''-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
en:Dofetilide
| IUPAC_name = ''N''-[4-(2-{[2-(4-methane sulfonamidophenoxy)ethyl] (methyl)amino}ethyl)phenyl]methanesulfonamide
en:Amiodarone
| IUPAC_name = (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine
en:Aztreonam
| IUPAC_name = 2-{[(1''Z'')-1-(2-Amino-1,3-thiazol-4-yl)-2-{[(2''S'',3''S'')-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy-2-methylpropanoic acid
en:Enalapril
| IUPAC_name = (2''S'')-1-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid
en:Atenolol
| IUPAC_name = (''RS'')-2-{4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide
en:Dantrolene
| IUPAC_name = 1-{[5-(4-nitrophenyl)-2-furyl]methylideneamino} imidazolidine-2,4-dione
en:Suramin
| IUPAC_name = 8,8'-{Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]}di(1,3,5-naphthalenetrisulfonic acid)
en:Hydroxyzine
| IUPAC_name = (±)-2-(2-{4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl}ethoxy)ethanol
en:Enalaprilat
| IUPAC_name = (2''S'')-1-[(2''S'')-2-{[(1''S'')-1-carboxy-3-phenylpropyl]amino}propanoyl]pyrrolidine-2-carboxylic acid
en:Imidacloprid
| IUPACName =''N''-{1-[(6-Chloro-3-pyridyl)methyl]-4,5-dihydroimidazol-2-yl}nitramide
en:Atazanavir
| IUPAC_name = methyl ''N''-[(1''S'')-1-{[(2''S'',3''S'')-3-hydroxy-4-[(2''S'')-2-[(methoxycarbonyl)amino]-3,3-dimethyl-''N'''-{[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate
en:Ritonavir
| IUPAC_name = 1,3-thiazol-5-ylmethyl ''N''-[(2''S'',3''S'',5''S'')-3-hydroxy-5-[(2''S'')-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate
en:Bacitracin
| IUPAC_name = (4''R'')-4-[(2''S'')-2-({2-[(1''S'')-1-amino-2-methylbutyl]- 4,5-dihydro-1,3-thiazol-5-yl}formamido)-4-methylpentanamido]-4-{[(1''S'')- 1-{[(3''S'',6''R'',9''S'',12''R'',15''S'',18''R'',21''S'')- 18-(3-aminopropyl)-12-benzyl-15-(butan-2-yl)-3-(carbamoylmethyl)- 6-(carboxymethyl)-9-(1''H''-imidazol-5-ylmethyl)-2,5,8,11,14,17,20- heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}- 2-methylbutyl]carbamoyl}butanoic acid
en:Sotalol
| IUPAC_name = (''RS'')-''N''-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide
en:Folinic acid
| IUPAC_name = (''2S'')-2-{[4-[(2-amino-5-formyl-4-oxo-5,6,7,8- tetrahydro-1''H''-pteridin-6-yl)methylamino] benzoyl]amino}pentanedioic acid
en:Bleomycin
| IUPAC_name = (3-{[(2'-{(5''S'',8''S'',9''S'',10''R'',13''S'')-15-{6-amino-2- [(1''S'')-3-amino-1-{[(2''S'')-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl] -5-methylpyrimidin-4-yl}-13-[{[(2''R'',3''S'',4''S'',5''S'',6''S'')-3- {[(2''R'',3''S'',4''S'',5''R'',6''R'')-4-(carbamoyloxy)-3,5-dihydroxy-6- (hydroxymethyl)tetrahydro-2''H''-pyran-2-yl]oxy} -4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2''H''-pyran-2-yl]oxy} (1''H''-imidazol-5-yl)methyl]-9-hydroxy-5-[(1''R'')-1-hydroxyethyl]-8,10-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazapentadec-1-yl}-2,4'-bi-1,3-thiazol-4-yl)carbonyl]amino}propyl)(dimethyl)sulfonium
en:Acepromazine
| IUPAC_name = 1-{10-[3-(Dimethylamino)propyl]-10''H''-phenothiazin-2-yl}ethanone
en:Esmolol
| IUPAC_name = methyl (''RS'')-3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate
en:Ketanserin
| IUPAC_name = 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1''H'',3''H'')-dione
en:Epoxide hydrolase
[[Leukotriene A4 hydrolase]] (LTA4H) acts primarily, if not exclusively, to hydrolyze [[leukotriene A4]] (LTA4, i.e. 5S,6S-oxido-7''E'',9''E'',11''Z'',14''Z''-eicosatetetraenoic acid; [[IUPAC]] name 4-{(2S,3S)-3-[(1E,3E,5Z,8Z)-1,3,5,8-Tetradecatetraen-1-yl]-2-oxiranyl}butanoic acid) to its diol metabolite, [[leukotriene B4]] (LTB4, i.e. 5''S'',12''R''-dihydroxy-6''Z'',8''E'',10''E'',14''Z''-icosatetraenoic acid; IUPA name 5S,6Z,8E,10E,12R,14Z)-5,12-Dihydroxy-6,8,10,14-icosatetraenoic acid). LTB4 is an important recruiter and activator of [[leukocytes]] involved in mediation in inflammatory responses and diseases. The enzyme also possess [[aminopeptidase]] activity, degrading, for example, the leukocyte [[chemotactic factor]] tripeptide, Pro-Gly-Pro (PGP); the function of the aminopeptidase activity of LTA4AH is unknown but has been proposed to be involved in limiting inflammatory reactions caused by this or other aminopeptidase-susceptible peptides.<ref>{{cite journal | vauthors = Paige M, Wang K, Burdick M, Park S, Cha J, Jeffery E, Sherman N, Shim YM | title = Role of leukotriene A4 hydrolase aminopeptidase in the pathogenesis of emphysema | journal = Journal of Immunology | volume = 192 | issue = 11 | pages = 5059–68 | date = June 2014 | pmid = 24771855 | doi = 10.4049/jimmunol.1400452 | pmc=4083682}}</ref><ref>{{cite journal | vauthors = Appiah-Kubi P, Soliman ME | title = Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses | journal = Journal of Biomolecular Structure & Dynamics | pages = 1–16 | date = January 2016 | pmid = 26555301 | doi = 10.1080/07391102.2015.1117991 }}</ref><ref>{{cite journal | vauthors = Calışkan B, Banoglu E | title = Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors | journal = Expert Opinion on Drug Discovery | volume = 8 | issue = 1 | pages = 49–63 | date = January 2013 | pmid = 23095029 | doi = 10.1517/17460441.2013.735228 }}</ref>
en:Indometacin
| IUPAC_name = 2-{1-[(4-Chlorophenyl)carbonyl]-5-methoxy-2-methyl-1''H''-indol-3-yl}acetic acid
en:Sulfasalazine
| IUPAC_name = 2-hydroxy-5-[(''E'')-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid
en:Salmeterol
| IUPAC_name = (''RS'')-2-(hydroxymethyl)-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol
en:Fulvestrant
| IUPAC_name = (7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
en:Pralatrexate
| IUPAC_name = ''N''-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid
en:Aminopterin
| IUPACName = 2-[ [4-{[(2,4-Diaminopteridin-6-yl)methyl]amino}benzoyl]amino]pentanedioic acid
en:Pemetrexed
| IUPAC_name = (2''S'')-2-{[4-[2-(2-amino-4-oxo-1,7-dihydro pyrrolo[2,3-''d'']pyrimidin-5-yl)ethyl]benzoyl]amino} pentanedioic acid
en:Sudan IV
| OtherNames = 1-{2-Methyl-4-[(2-methylphenyl)diazenyl]phenyl}azonaphthalen-2-ol Sudan R, C.I. Solvent Red 24, C.I. 26105, Lipid Crimson, Oil Red, Oil Red BB, Fat Red B, Oil Red IV, Scarlet Red, Scarlet Red N.F, Scarlet Red Scharlach, Scarlet R
en:Avizafone
| IUPAC_name = (2''S'')-2,6-diamino-''N''-{[(2-benzoyl-4-chlorophenyl)methylcarbamoyl]methyl}hexanamide
en:Doramectin
| IUPAC_name = (1''R'',2''S'',4''S'',5''S'',6''R'',8''R'',10''E'',12''R'',13''S'',14''E'',20''R'',21''R'',24''S'')-6-cyclohexyl-21',24'-dihydroxy-12'-{[(2''R'',4''S'',5''S'',6''S'')-5-{[(2''S'',4''S'',5''S'',6''S'')-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-5,6-dihydro-3',7',19'-trioxaspiro[pyran-2,6'-tetracyclo[15.6.1.14,8.020,24]pentacosane]-10',14',16',22'-tetraen-2'-one
en:Telmisartan
| IUPAC_name = 2-(4-{[4-Methyl-6-(1-methyl-1''H''-1,3-benzodiazol-2-yl)-2-propyl-1''H''-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid
en:Fumonisin B1
| IUPACName = (2''S'',2''S'')-2,2'-{[(5''S'',6''R'',7''R'',9''R'',11''S'',16''R'',18''S'',19''S'')-19-Amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}disuccinic acid
en:Palytoxin
| IUPACName = (2S,3R,5R,6E,8R,9S)-10-[(2R,3R,4R,5S,6R)-6-[(1S,2R,3S,4S,5R,11S)-11-{[(1R,3S,5S,7R)-5-[(8S)-9-[(2R,3R,4R,5R,6S)-6-[(2S,3S,4E,6S,9R,10R)-10-[(2S,4R,5S,6R)-6-[(2R,3R)-4-[(2R,3S,4R,5R,6S)-6-[(2S,3Z,5E,8R,9S,10R,12Z,17S,18R,19R,20R)-20-{[(2R,3R,4R,5S,6R)-6-[(1Z,3R,4R)-5-[(1S,3R,5R,7R)-7-{2-[(2R,3R,5S)-5-(aminomethyl)-3-hydroxyoxolan-2-yl]ethyl}-2,6-dioxabicyclo[3.2.1]octan-3-yl]-3,4-dihydroxypent-1-en-1-yl]-3,4,5-trihydroxyoxan-2-yl]methyl}-2,8,9,10,17,18,19-heptahydroxy-14-methylidenehenicosa-3,5,12-trien-1-yl]-3,4,5-trihydroxyoxan-2-yl]-2,3-dihydroxybutyl]-4,5-dihydroxyoxan-2-yl]-2,6,9,10-tetrahydroxy-3-methyldec-4-en-1-yl]-3,4,5,6-tetrahydroxyoxan-2-yl]-8-hydroxynonyl]-1,3-dimethyl-6,8-dioxabicyclo[3.2.1]octan-7-yl]methyl}-1,2,3,4,5-pentahydroxydodecyl]-3,4,5-trihydroxyoxan-2-yl]-2,5,8,9-tetrahydroxy-N-[(1E)-2-[(3-hydroxypropyl)-C-hydroxycarbonimidoyl]eth-1-en-1-yl]-3,7-dimethyldec-6-enimidic acid
en:UBP-302
| IUPACName=2-{[3-[(2''S'')-2-amino-2-carboxyethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2''H'')-yl]methyl}benzoic acid
en:Taurocholic acid
| IUPACName =2-{[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic acid
en:Levocetirizine
| IUPAC_name = 2-(2-{4-[(''R'')-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
en:Nafarelin
| IUPAC_name = (2''R'')-''N''-[(2''R'')-5-carbamimidamido-1-[(2''S'')-2-[(carbamoylmethyl)carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[(2''R'')-2-[(2''R'')-2-[(2''R'')-3-hydroxy-2-[(2''S'')-2-[(2''S'')-3-(1''H''-imidazol-4-yl)-2-{[(2''R'')-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1''H''-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(naphthalen-2-yl)propanamido]-4-methylpentanamide
en:Docetaxel
| IUPAC_name = 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2''R'',3''S'')-3-[(''tert''-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
en:Iotrolan
| IUPAC_name = 2,4,6-triiodo-5-{''N''-methyl-2-[methyl({2,4,6-triiodo-3,5-''bis''[(1,3,4-trihydroxybutan-2-yl)carbamoyl]phenyl})carbamoyl]acetamido}-1-''N'',3-''N-bis''(1,3,4-trihydroxybutan-2-yl)benzene-1,3-dicarboxamide
en:Terlipressin
| IUPAC_name = 1-{[(4''R'',7''S'',10''S'',13''S'',16''S'',19''R'')-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-''N''-(2-amino-2-oxoethyl)-L-lysinamide
en:Trazodone
| IUPAC_name = 2-{3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-''a'']pyridin-3(2''H'')-one
en:Quinupristin
| IUPAC_name = ''N''-{(6''R'',9''S'',10''R'',13''S'',15a''S'',18''R'',22''S'',24a''S'')-18-
en:Valsartan
| IUPAC_name = (''S'')-3-methyl-2-(''N''-{[2'-(2''H''-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid
en:Tobramycin
| IUPAC_name = (2''S'',3''R'',4''S'',5''S'',6''R'')-4-amino-2-{[(1''S'',2''S'',3''R'',4''S'',6''R'')-4,6-diamino-3-{[(2''R'',3''R'',5''S'',6''R'')-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
en:Rutin
| IUPACName = 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2''S'',3''R'',4''S'',5''S'',6''R'')-3,4,5-trihydroxy-6-({[(2''R'',3''R'',4''R'',5''R'',6''S'')-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4''H''-chromen-4-one
en:Dobutamine
| IUPAC_name = (''RS'')-4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
en:Cilastatin
| IUPAC_name = (''Z'')-7-[(2''R'')-2-Amino-3-hydroxy-3-oxopropyl]sulfanyl-2-{[(1''S'')-2,2-dimethylcyclopropanecarbonyl]amino}hept-2-enoic acid
en:Tamsulosin
| IUPAC_name = (''R'')-5-(2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide
en:Bromhexine
| IUPAC_name = 2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline
en:Anidulafungin
| IUPAC_name = ''N''-[(3''S'',6''S'',9''S'',11''R'',15''S'',18''S'',20''R'',21''R'',24''S'',25''S'',26''S'')-6-[(1''S'',2''R'')-1,2-Dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-''bis''[(1''R'')-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide
en:Iloprost
| IUPAC_name = 5-{(''E'')-(1''S'',5''S'',6''R'',7''R'')-7-hydroxy-6[(''E'')-(3''S'',4''RS'')-3-hydroxy-4-methyl-1-octen-6-inyl]-bicyclo[3.3.0]octan-3-ylidene}pentanoic acid
en:Labetalol
| IUPAC_name = (''RS'')-2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
en:Acebutolol
| IUPAC_name = (''RS'')-''N''-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide
en:Practolol
| IUPAC_name = (''RS'')-''N''-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide
en:Rivaroxaban
| IUPAC_name = (''S'')-5-chloro-''N''-{[2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]oxazolidin-5-yl]methyl} thiophene-2-carboxamide
en:Azlocillin
| IUPAC_name = (2''S'',5''R'',6''R'')-3,3-dimethyl-7-oxo-6-{[(2''R'')-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
en:Indinavir
| IUPAC_name = (2''S'')-1-[(2''S'',4''R'')-4-benzyl-2-hydroxy-4-{[(1''S'',2''R'')-2-hydroxy-2,3-dihydro-1''H''-inden-1-yl]carbamoyl}butyl]-''N-tert''-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
en:Trandolapril
| IUPAC_name = (2''S'',3''aR'',7''aS'')-1-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1''H''-indole-2-carboxylic acid
en:Fumonisin B2
| IUPACName=(2''R'',2''R'')-2,2'-{[(5''R'',6''S'',7''S'',9''S'',16''R'',18''S'',19''S'')-19-amino-16,18-dihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}disuccinic acid
en:Arimoclomol
| IUPAC_name = N-{[(2''R'')-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide
en:Thioacetazone
| IUPAC_name = ''N''-{4-[(Ethanethioamidoimino)methyl]phenyl}acetamide
en:Rescinnamine
| IUPAC_name = methyl (3β,16β,17α,18β,20α)-11,17-dimethoxy-18-{[(2''E'')-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy}yohimban-16-carboxylate
en:Parecoxib
| IUPAC_name = ''N''-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl] sulfonyl}propanamide
en:Perindopril
| IUPAC_name = (2''S'',3''aS'',7''aS'')-1-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1''H''-indole-2-carboxylic acid
en:Thiamphenicol
| IUPAC_name = 2,2-dichloro-''N''-{(1''R'',2''R'')-2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl}acetamide
en:Atracurium besilate
| IUPAC_name = 2,2'-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] dibenzenesulfonate
en:Nebivolol
| IUPAC_name = (1''RS'',1' ''RS'')-1,1'-[(2''RS'',2' ''SR'')-bis(6-fluoro-3,4-dihydro-2''H''-1-benzopyran-2-yl)]-2,2'-iminodiethanol OR 1-(6-Fluorochroman-2-yl)-{[2-(6-fluorochroman-2-yl)-2-hydroxy-ethyl]amino}ethanol OR 2,2'-Azanediylbis(1-(6-fluorochroman-2-yl)ethanol) OR 1-(6-Fluoro-3,4-dihydro-2''H''-1-benzopyran-2-yl)-2-{[2-(6-fluoro-3,4-dihydro-2''H''-1-benzopyran-2-yl)-2-hydroxyethyl]amino}ethan-1-ol
en:Acrivastine
| IUPAC_name = (''E'')-3-{6-[(''E'')-1-(4-methylphenyl)-3-pyrrolidin-1-yl- prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
en:Loxoprofen
| IUPAC_name = (''RS'')-2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid
en:Bezafibrate
| IUPAC_name = 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid
en:Levormeloxifene
| IUPACName = 1-(2-{4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy}ethyl)pyrrolidine
en:Propantheline bromide
| IUPAC_name = ''N''-isopropyl-''N''-methyl-''N''-{2-[(9''H''-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide
en:CHAPS detergent
| OtherNames = 3-{Dimethyl[3-(4-{5,9,16-trihydroxy-2,15- 
en:Aceprometazine
| IUPAC_name = 1-{10-[2-(dimethylamino)propyl]-10''H''-phenothiazin-2-yl}ethanone
en:Dabigatran
| IUPAC_name = Ethyl ''N''-[(2-{[(4-{''N''{{'}}-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1''H''-benzimidazol-5-yl)carbonyl]-''N''-2-pyridinyl-β-alaninate
en:Fotemustine
| IUPAC_name = (''RS'')-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino} ethyl)phosphonate
en:Indoramin
| IUPAC_name = ''N''-{1-[2-(1''H''-indol-3-yl)ethyl]piperidin-4-yl}benzamide
en:Globoidnan A
| IUPACName=(2''R'')-(3,4-dihydroxyphenyl)-2-{[4-(3,4-dihydroxyphenyl)-6,7-dihydroxy-2-naphthoyl]oxy}propanoic acid
en:Ibutilide
| IUPAC_name = ''N''-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
en:Iodixanol
| IUPAC_name = 5-{''N''-[3-(''N''-{3,5-''bis''[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-1-''N'',3-''N-bis''(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
en:Beraprost
| IUPAC_name = 4-{(1''R'',2''R'',3a''S'',8b''S'')-2-Hydroxy-1-[(1''E'',3''S'')-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1''H''-benzo[''b'']cyclopenta[''d'']furan-5-yl}butanoic acid
en:Flibanserin
| IUPAC_name = 1-(2-{4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2''H''-benzimidazol-2-one
en:Niaprazine
| IUPAC_name = ''N''-{4-[4-(4-fluorophenyl)piperazin- 1-yl]butan- 2-yl}pyridine- 3-carboxamide
en:Antrafenine
| IUPAC_name = 2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl 2-{[7-(trifluoromethyl)quinolin-4-yl]amino}benzoate
en:Dihydropteroate
| IUPACName = 4-{[(2-amino-4-oxo-1,4,7,8-tetrahydropteridin-6-yl)methyl]amino}benzoic acid
en:Maraviroc
| IUPAC_name = 4,4-Difluoro-''N''-{(1''S'')-3-[3-(3-isopropyl- 5-methyl-4''H''-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide
en:Tetrahydrofolic acid
| IUPACName = (2''S'')-2-{[4-({[(6''S'')-2-amino-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid
en:Dihydrofolic acid
| IUPACName = ''N''-(4-{[(2-amino-4-oxo-1,4,7,8-tetrahydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
en:Methallylescaline
| IUPACName = 2-{3,5-dimethoxy-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}ethanamine
en:Anatoxin-a
| IUPACName=1-{9-azabicyclo[4.2.1]non-2-en-2-yl}ethan-1-one
en:Thiofentanyl
| IUPAC_name = ''N''-phenyl-''N''-{1-[2-(2-thienyl)ethyl]piperidin-4-yl}propanamide
en:Photobiotin
| IUPACName = ''N''-{3-[{3-[(4-Azido-2-nitrophenyl)amino]propyl}(methyl)amino]propyl}-5-[(3a''S'',6a''R'')-2-oxohexahydro-1''H''-thieno[3,4-''d'']imidazol-4-yl]pentanamide
en:Leukotriene A4
| IUPACName = 4-{(2S,3S)-3-[(1E,3E,5Z,8Z)-1,3,5,8-Tetradecatetraen-1-yl]-2-oxiranyl}butanoic acid
en:10-Formyltetrahydrofolate
| IUPACName=(2''S'')-2-{[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1''H''-pteridin-6-yl) methyl(formyl)amino]benzoyl]amino}pentanedioic acid
en:5-Formiminotetrahydrofolate
| IUPACName=(2''S'')-2-{[4-[(2-Amino-5-methanimidoyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino}pentanedioic acid
en:Amorolfine
| IUPAC_name = (±)-(2''R'',6''S'')-''rel''-2,6-Dimethyl-4-{2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl}morpholine
en:Fenoterol
| IUPAC_name = (''RR'',''SS'')-5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol
en:Azoxystrobin
| IUPACName=Methyl (2''E'')-2-(2-{[6-(2-cyanophenoxy)pyrimidin-4-yl]oxy}phenyl)-3-methoxyacrylate
en:Mafosfamide
| IUPACName=2-{(2-[bis(2-chloroethyl)amino]-2-oxido-1,3,2-oxazaphosphinan-4-yl}thio)ethanesulfonic acid
en:Mafosfamide
| OtherNames=2-{[2-[bis(2-chloroethyl)amino]-2-oxo-1-oxa-3-aza-2λ5-phosphacyclohex-4-yl}sulfanyl]ethanesulfonic acid
en:Dimetindene
| IUPAC_name = (''RS'')-dimethyl(2-{3-[1-(pyridin-2-yl)ethyl]-1''H''-inden-2-yl}ethyl)amine
en:Neltenexine
| IUPAC_name = ''N''-(2,4-dibromo-6-{[(4-hydroxycyclohexyl)amino]methyl}phenyl)thiophene-2-carboxamide
en:Stepronin
| IUPAC_name = ''N''-{2-[(2-thienylcarbonyl)thio]propanoyl}glycine
en:Distigmine
| IUPAC_name = (1-methylpyridin-1-ium-3-yl) ''N''-methyl-''N''-{6-[methyl- (1-methylpyridin-1-ium-3-yl)oxycarbonylamino] hexyl}carbamate dibromide
en:Rokitamycin
| IUPAC_name = (2''S'',3''S'',4''R'',6''S'')-6-{[(2''R'',3''S'',4''R'',5''R'',6''S'')-6-{[(4''R'',5''S'',6''S'',7''R'',9''R'',10''R'',11''E'',13''E'',16''R'')-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-2,4-dimethyl-4-propoxyoxan-3-yl butanoate
en:Miocamycin
| IUPAC_name = (2''S'',3''S'',4''R'',6''S'')-6-{[(2''R'',3''S'',4''R'',5''R'',6''S'')-6-{[(4''S'',5''R'',6''S'',7''R'',9''R'',10''R'',11''E'',13''E'',16''R'')-10-(acetyloxy)-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-4-propoxy-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-2,4-dimethyl-3-propoxyoxan-4-yl acetate
en:Midecamycin
| IUPAC_name = (2''S'',3''S'',4''R'',6''S'')-6-{[(2''R'',3''S'',4''R'',5''R'',6''S'')-4-(dimethylamino)-5-hydroxy-6-{[(4''R'',6''S'',7''R'',9''R'',10''R'',11''E'',13''E'',16''R'')-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-4-(propanoyloxy)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl propanoate
en:Nifurtoinol
| IUPAC_name = 3-(hydroxymethyl)-1-{[(1''E'')-(5-nitro-2-furyl) methylene]amino}imidazolidine-2,4-dione
en:Isoxsuprine
| IUPAC_name = 4-{1-Hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl}phenol
en:Ronifibrate
| IUPAC_name = 3-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}propyl nicotinate
en:Terizidone
| IUPAC_name = 4,4'-{1,4-Phenylenebis[(''E'')methylylidene (''E'')azanylylidene]}bis(1,2-oxazolidin-3-one)
en:Xamoterol
| IUPAC_name = (''RS'')-''N''-(2-{[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)morpholine-4-carboxamide
en:Angiotensinamide
| IUPAC_name = 2-[(1-{2-[2-(2-{2-[2-(2-amino-3-carbamoylpropanamido)-5-[(diaminomethylidene)amino]pentanamido]-3-methylbutanamido}-3-(4-hydroxyphenyl)propanamido)-3-methylbutanamido]-3-(1''H''-imidazol-5-yl)propanoyl}pyrrolidin-2-yl)formamido]-3-phenylpropanoic acid
en:Alatrofloxacin
| IUPAC_name = 7-[(1''R'',5''S'')-6-{[(2''S'')-1-{[(2''S'')-2-Aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
en:Micafungin
| IUPAC_name = {5-[(1''S'',2''S'')-2-[(3''S'',6''S'',9''S'',11''R'',15''S'',18''S'',20''R'',21''R'',24''S'',25''S'',26''S'')-3-[(1''R'')-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1''R'')-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzene)amido]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid
en:Fenticonazole
| IUPAC_name = 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)phenyl]methoxy}ethyl]-1''H''-imidazole
en:Theodrenaline
| IUPAC_name = (''RS'')-7-(2-{[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino}ethyl)-1,3-dimethyl-3,7-dihydro-1''H''-purine-2,6-dione
en:Arbutamine
| IUPAC_name = 4-[(1''R'')-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol
en:Prenalterol
| IUPAC_name = 4-{[(2''S'')-2-hydroxy-3-(isopropylamino)propyl]oxy}phenol
en:Befunolol
| IUPAC_name = (''RS'')-1-{7-[2-hydroxy-3-(propan-2-ylamino)propoxy]- 1-benzofuran-2-yl}ethanone
en:Ciramadol
| IUPAC_name = 3-{(''R'')-Dimethylamino-[(1''R'',2''R'')-2-hydroxycyclohexyl]}methyl]phenol
en:Sulfentrazone
| IUPACName = ''N''-{2,4-Dichloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1''H''-1,2,4-triazol-1-yl]phenyl}methanesulfonamide
en:Niflumic acid
| IUPAC_name = 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid
en:Morniflumate
| IUPAC_name = 2-morpholin-4-ylethyl 2-{[3-(trifluoromethyl)phenyl]amino}nicotinate
en:Flufenamic acid
| IUPAC_name = 2-{[3-(Trifluoromethyl)phenyl]amino}benzoic acid
en:Alminoprofen
| IUPAC_name = 2-{4-[(2-Methylprop-2-en-1-yl)amino]phenyl}propanoic acid
en:Proglumetacin
| IUPAC_name = 3-{4-[2-({[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1''H''-indol-3-yl]acetyl}oxy)ethyl]piperazin-1-yl}propyl ''N''2-benzoyl-''N,N''-dipropyl-α-glutaminate
en:Methomyl
| IUPACName =(''E'',''Z'')-methyl ''N''-{[(methylamino)carbonyl]oxy}ethanimidothioate
en:Gluconasturtiin
| IUPACName={[3-phenyl-1-{[(2''S'',3''R'',4''S'',5''S'',6''R'')-3,4,5-trihydroxy-6- (hydroxymethyl)-2-tetrahydropyranyl]thio}propylidene]amino} hydrogen sulfate
en:SB-277,011-A
| IUPAC_name = ''N''-{''trans''-4-[2-(6-cyano-3,4-dihydroisoquinolin-2(1''H'')-yl)ethyl]cyclohexyl}quinoline-4-carboxamide
en:GYKI-52895
| IUPAC_name = 4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline
en:Lapaquistat
| IUPAC_name = (1-{[(3''R'',5''S'')-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl}piperidin-4-yl)acetic acid
en:Arctiin
| IUPACName =(3''R'',4''R'')-4-[(3,4-dimethoxyphenyl)methyl]-3-{[3-methoxy-4-[(2''S'',3''R'',4''S'',5''S'',6''R'')-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl}oxolan-2-one
en:Brostallicin
| IUPACName = 4-[(2-Bromoacryloyl)amino]-''N''-{5-[(5-{[5-({2-[(diaminomethylene)amino]ethyl}carbamoyl)-1-methyl-1''H''-pyrrol-3-yl]carbamoyl}-1-methyl-1''H''-pyrrol-3-yl)carbamoyl]-1-methyl-1''H''-pyrrol-3-yl}-1-methyl-1''H''-pyrrole-2-carboxamide
en:Rilpivirine
| IUPAC_name = 4-{[4-({4-[(''E'')-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
en:Aplaviroc
| IUPAC_name = 4-(4-{[(3''R'')-1-butyl-3-[(''R'')-cyclohexylhydroxymethyl]-2,5-dioxo- 1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid
en:Telavancin
| IUPAC_name = (1''S'',2''R'',18''R'',19''R'',22''S'',25''R'',28''R'',40''S'')-22-(2-Amino-2-oxoethyl)-5,15-dichloro-48-{[2-''O''-(3-{[2-(decylamino)ethyl]amino}-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}-2,18,32,35,37-pentahydroxy-19-[(''N''-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-36-{[(phosphonomethyl)amino]methyl}-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
en:Sisomicin
| IUPAC_name = (2''R'',3''R'',4''R'',5''R'')-2-{[(1''S'',2''S'',3''R'',4''S'',6''R'')-4,6-diamino-3-{[(2''S'',3''R'')-3-amino-6-(aminomethyl)-3,4-dihydro-2''H''-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol
en:Vernakalant
| IUPAC_name = (3''R'')-1-{(1''R'',2''R'')-2-[2-(3,4-dimethoxyphenyl) ethoxy]cyclohexyl}pyrrolidin-3-ol
en:Muraglitazar
| IUPAC_name = ''N''-[(4-Methoxyphenoxy)carbonyl]-''N''-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}glycine
en:Otamixaban
| IUPAC_name = Methyl (2''R'',3''R'')-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate
en:Taranabant
| IUPAC_name = ''N''-[(2''S'',3''S'')-4-(4-chlorophenyl)-3-(3-cyanophenyl)-2-butanyl]-2-methyl-2-{[5-(trifluoromethyl)-2-pyridinyl]oxy}propanamide
en:Cinepazet
| IUPAC_name = Ethyl 2-{4-[(2''Z'')-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]piperazin-1-yl}acetate
en:Etafenone
| IUPAC_name = 1-(3-{2-[2-(diethylamino)ethoxy]phenyl}phenyl)propan-1-one
en:Regadenoson
| IUPAC_name = 2-{4-[(methylamino)carbonyl]- 1''H''-pyrazol-1-yl}[[adenosine]]
en:Isavuconazole
| IUPAC_name = 4-{2-[(1''R'',2''R'')-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1''H''-1,2,4-triazol-1-yl)propyl]-1,3-thiazol-4-yl}benzonitrile
en:Pramiconazole
| IUPAC_name = 1-{4-[4-(4-{[(2''R'',4''S'')-2-(2,4-difluorophenyl)-2-(1''H''-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one
en:Rimiterol
| IUPAC_name = 4-{(''S'')-hydroxy[(2''R'')-piperidin-2-yl]methyl}benzene-1,2-diol
en:Carbuterol
| IUPAC_name = (''RS'')-{5-[2-(tert-butylamino)-1-hydroxyethyl]-2-hydroxyphenyl}urea
en:Laniquidar
| IUPAC_name = methyl 11-(1-{2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl}piperidin-4-ylidene)-6,11-dihydro-5''H''-imidazo[2,1-''b''][3]benzazepine-3-carboxylate
en:Flesinoxan
| IUPAC_name = 4-fluoro-''N''-(2-{4-[(2''S'')-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide
en:Pozanicline
| IUPAC_name = 2-Methyl-3-{[(2''S'')-pyrrolidin-2-yl]methoxy}pyridine
en:Solabegron
| IUPAC_name = 3'-[(2-{[(2''R'')-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]-3-biphenylcarboxylic acid
en:CCK-4
| IUPAC_name = (3''S'')-3-[(2''S'')-2-amino-3-phenylpropanamido]-3-{[(1''S'')-1-{[(1''S'')-1-carboxy -2-(indol-3-yl)ethyl]carbamoyl}-3-(methylsulfanyl)propyl]carbamoyl}propanoic acid
en:Phosphoribosylaminoimidazolesuccinocarboxamide
| OtherNames = SAICAR; 2-[(5-Amino-1-{3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl}imidazol-4-yl)formamido]butanedioic acid; ''N''-{[5-Amino-1-(5-''O''-phosphono-β-D-ribofuranosyl)-1''H''-imidazol-4-yl]carbonyl}-L-aspartic acid
en:Kitasamycin
| IUPAC_name = [(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-{[(2S,3R,4R,5S,6R)-5-{[(2S,4R,5S,6S)-4,5-Dihydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-7-yl]acetaldehyde (non-preferred name)
en:Croconazole
| IUPAC_name = 1-(1-{2-[(3-chlorophenyl)methoxy]phenyl}ethenyl)-1''H''-imidazole
en:Hexoprenaline
| IUPAC_name = (±)-4,4'-{Hexane-1,6-diyl''bis''[imino(1-hydroxyethane-2,1-diyl)]}dibenzene-1,2-diol
en:Reproterol
| IUPAC_name = (''RS'')-7-(3-{[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino}propyl)-1,3-dimethyl-3,7-dihydro-1''H''-purine-2,6-dione
en:Nifekalant
| IUPAC_name = 6-[(2-{(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino}ethyl)amino]-1,3-dimethylpyrimidine-2,4(1''H'',3''H'')-dione
en:Buphenine
| IUPAC_name = 4-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]propyl}phenol
en:ROD-188
| IUPAC_name = (5''R'')-5-{(1''R'')-2-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydroisoquinolin-1-yl}dihydrofuran-2(3''H'')-one
en:Amidephrine
| IUPAC_name =(''RS'')-''N''-{3-[1-hydroxy-2-(methylamino)ethyl]phenyl}methanesulfonamide
en:Guanoclor
| IUPAC_name = 2-{[2-(2,6-Dichlorophenoxy)ethyl]amino}guanidine
en:Cadralazine
| IUPAC_name = Ethoxy-''N'''-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}carbohydrazide
en:SB-242084
| IUPAC_name = 6-chloro-5-methyl-''N''-{6-[(2-methylpyridin-3-yl)oxy]pyridin-3-yl}indoline-1-carboxamide
en:Sofalcone
| IUPAC_name = [5-[(3-Methylbut-2-en-1-yl)oxy]-2-((2''E'')-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}prop-2-enoyl)phenoxy]acetic acid
en:Tranilast
| IUPAC_name = 2-{[(2''E'')-3-(3,4-dimethoxyphenyl)prop-2- enoyl]amino}benzoic acid
en:Bekanamycin
| IUPAC_name = (2''S'',3''R'',4''S'',5''S'',6''R'')-4-amino-2-{[(2''S'',3''R'',4''S'',6''R'')-4,6-diamino-3-{[(2''R'',3''R'',4''R'',5''S'',6''R'')-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol
en:Nafamostat
| IUPAC_name = 6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate
en:Cinanserin
| IUPAC_name = (2''E'')-''N''-(2-{[3-(dimethylamino)propyl]thio}phenyl)-3-phenylacrylamide
en:Sivelestat
| IUPAC_name = ''N''-{2-[({4-[(2,2-dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine
en:Demoxytocin
| IUPAC_name = 2-[(1-{[13-(butan-2-yl)-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}pyrrolidin-2-yl)formamido]-''N''-(carbamoylmethyl)-4-methylpentanamide
en:SR 59230A
| IUPACName=(2''S'')-1-(2-Ethylphenoxy)-3-{[(1''S'')-1,2,3, 4-tetrahydronaphthalen-1-yl]amino}propan-2-ol
en:Lurasidone
| IUPAC_name = (3a''R'',4''S'',7''R'',7a''S'')-2-{(1''R'',2''R'')-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2''H''-isoindole-1,3-dione
en:Clinofibrate
| IUPAC_name = 2-(4-{1-[4-(1-carboxy-1-methylpropoxy)phenyl]cyclohexyl}phenoxy)-2-methylbutanoic acid
en:Ceruletide
| IUPAC_name = (3''S'')-3-{[(1''S'')-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2''S'')-2-[(2''S'')-2-{2-[(3''R'')-2-[(2''S'')-2-[(2''S'')-2-[(2''S'')-4-carbamoyl-2-{[(2''S'')-5-oxopyrrolidin-2-yl]formamido}butanamido]-3-carboxypropanamido]-3-[4-(sulfooxy)phenyl]propanamido]-3-hydroxybutanamido]acetamido}-3-(1''H''-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid
en:Ibodutant
| IUPAC_name = ''N''α-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-''N''-{[1-(tetrahydro-2''H''-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide
en:Sulfamazone
| IUPAC_name = (1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-{[4-[(6- methoxypyridazin-3-l)sulfamoyl]phenyl]amino} methanesulfonic acid
en:RPL-554
| IUPAC_name = ''N''-{2-[(2''E'')-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2''H''-pyrimido[6,1-''a'']-isoquinolin-3(4''H'')-yl]ethyl}urea
en:Leteprinim
| IUPAC_name = 4-{[3-(6-oxo-3,6-dihydro-9''H''-purin-9-yl)propanoyl]amino}benzoic acid
en:Tiflorex
| IUPAC_name = (''RS'')-''N''-ethyl-1-{3-[(trifluoromethyl)thio]phenyl}propan-2-amine
en:Tafluprost
| IUPAC_name = Isopropyl (5''Z'')-7-{(1''R'',2''R'',3''R'',5''S'')-2-[(1''E'')-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate
en:Pitolisant
| IUPACName=1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine
en:Ioglicic acid
| IUPAC_name = 3-acetamido-2,4,6-triiodo-5-{[(methylcarbamoyl)methyl]carbamoyl}benzoic acid
en:Iocarmic acid
| IUPAC_name = 3-(5-{[3-carboxy-2,4,6-triiodo-5-(methylcarbamoyl)phenyl]carbamoyl}pentanamido)-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
en:Ioxaglic acid
| IUPAC_name = 3-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodo-5-(2-{[2,4,6-triiodo-3-(methylcarbamoyl)-5-(''N''-methylacetamido)phenyl]formamido}acetamido)benzoic acid
en:Iotroxic acid
| IUPAC_name = 3-{2-[2-(2-{[(3-carboxy-2,4,6-triiodophenyl)carbamoyl]methoxy}ethoxy)ethoxy]acetamido}-2,4,6-triiodobenzoic acid
en:Ioglycamic acid
| IUPAC_name = 3-(2-{[(3-carboxy-2,4,6-triiodophenyl)carbamoyl]methoxy}acetamido)-2,4,6-triiodobenzoic acid
en:Prednimustine
| IUPAC_name = (11β)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoate
en:Larotaxel
| IUPAC_name = (2α,5β,7β,10β,13α)-4,10-Diacetoxy-1-hydroxy-13-{[(2''R'',3''S'')-2-hydroxy-3-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-3-phenylpropanoyl]oxy}-9-oxo-5,20-epoxy-7,19-cyclotax-11-en-2-yl benzoate
en:Dauricine
| IUPACName=4-{[(1''R'')-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-2-(4-{[(1''R'')-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenoxy)phenol
en:Hopantenic acid
| IUPACName = 4-{[(2''R'')-2,4-Dihydroxy-3,3-dimethylbutanoyl]amino}butanoic acid{{citation needed|date=July 2012}}
en:Arsenamide
| IUPACName=2,2'-{[(4-Carbamoylphenyl)arsanediyl]bis(sulfanyl)} diacetic acid
en:BSPP (drug)
| IUPAC_name =2,6-di-tert-butyl-4-{[1-(hydroxymethyl)cyclopentyl]methyl}phenol
en:Cinaciguat
| IUPAC_name = 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl) phenyl]methoxy}phenyl)ethyl]amino}methyl) benzoic acid
en:Naluzotan
| IUPAC_name = ''N''-(3-{4-[4-(1-cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide
en:CataCXium F sulf
| IUPACName = (±)-Dicyclohexyl-{9-[3-(4-sulfonylphenyl)propyl]-2-sulfonylfluoren-9-yl}phosphonium hydrogensulfate
en:Lodenafil
| IUPAC_name = 5-(2-Ethoxy-5-{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}phenyl)-1-methyl-3-propyl-1,4-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
en:Tecovirimat
| IUPAC_name = ''N''-{3,5-Dioxo-4- azatetracyclo[5.3.2.0{2,6}.0{8,10}]dodec-11-en-4- yl}-4-(trifluoromethyl)benzamide
en:A-84,543
| IUPAC_name = 3-{[(2''S'')-1-Methyl-2-pyrrolidinyl]methoxy}pyridine
en:Combretastatin A-4 phosphate
| IUPAC_name = Phosphoric acid mono-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenyl} ester
en:Radezolid
| IUPAC_name = ''N''-{[(5''S'')-3-(2-fluoro-4′-{[(1''H''-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
en:Nopaline
| IUPACName = ''N''-{1-Carboxy-4-[(diaminomethylene)amino]butyl}glutamic acid<ref>PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/108012</ref>
en:Tedatioxetine
| IUPAC_name = 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
en:Lesopitron
| IUPAC_name = 2-{4-[4-(4-chloro-1''H''-pyrazol-1-yl)butyl]piperazin-1-yl}pyrimidine
en:Sunepitron
| IUPAC_name = 1-{[2-(pyrimidin-2-yl)octahydro-2''H''-pyrido[1,2-a]pyrazin-7-yl]methyl}pyrrolidine-2,5-dione
en:Etolorex
| IUPAC_name = 2-{[1-(4-chlorophenyl)-2-methylpropan-2-yl]amino}ethanol
en:AH-7921
| IUPAC_name = 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide
en:Tolgabide
| IUPAC_name = 4-{[(''E'')-(3-Chloro-5-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)(4-chlorophenyl)methyl]amino}butanamide
en:Ciladopa
| IUPAC_name = 2-{4-[(2''S'')-2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]piperazin-1-yl}cyclohepta-2,4,6-trien-1-one
en:Nifurquinazol
| IUPAC_name = 2,2'-{[2-(5-nitrofuran-2-yl)quinazolin-4-yl]imino}diethanol
en:Mubritinib
| IUPAC_name = 1-(4-{4-[(2-{(''E'')-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1''H''-1,2,3-triazole
en:Lorpiprazole
| IUPAC_name = (5a''R'',8a''S'')-3-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-5,5a,6,7,8,8a-hexahydrocyclopenta[3,4]pyrrolo[2,1-c][1,2,4]triazole
en:Sonepiprazole
| IUPAC_name = 4-(4-{2-[(1''S'')-3,4-dihydro-1''H''-isochromen-1-yl]ethyl}piperazin-1-yl)benzenesulfonamide
en:Cabazitaxel
| IUPAC_name = (1''S'',2''S'',3''R'',4''S'',7''R'',9''S'',10''S'',12''R'',15''S'')-4-(Acetyloxy)-15-{[(2''R'',3''S'')-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl benzoate
en:Metaflumizone
| IUPAC_name = (''EZ'')-2-{2-(4-Cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene} -N-[4-(trifluoromethoxy)phenyl]hydrazinecarboxamide
en:Febrifugine
| IUPACName = 3-{3-[(2''R'',3''S'')-3-Hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3''H'')-one
en:S-14671
| IUPAC_name = ''N''-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}thiophene-2-carboxamide
en:Dactolisib
| IUPACName = 2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1''H''-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile
en:Gabapentin enacarbil
| IUPAC_name = (1-{[({(1''RS'')-1-[isobutyryloxy]ethoxy}carbonyl) amino]methyl}cyclohexyl)acetic acid
en:Panuramine
| IUPAC_name = ''N''-{[1-(naphthalen-2-ylmethyl)piperidin-4-yl]carbamoyl}benzamide
en:Azaloxan
| IUPAC_name = 1-(1-{2-[(2''S'')-2,3-dihydro-1,4-benzodioxin-2-yl]ethyl}piperidin-4-yl)imidazolidin-2-one
en:Crenolanib
| IUPACName = 1-(2-{5-[(3-Methyloxetan-3-yl)methoxy]-1''H''-benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine
en:Fursultiamine
| IUPAC_name = ''N''-[(4-amino-2-methylpyrimidin-5-yl)methyl]-''N''-{(1''E'')-4-hydroxy-1-methyl-2-[(tetrahydrofuran-2-ylmethyl)disulfanyl]but-1-en-1-yl}formamide
en:Cobicistat
| IUPAC_name = 1,3-thiazol-5-ylmethyl [(2''R'',5''R'')-5-{[(2''S'')-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate
en:Candoxatril
| IUPACName = 4-{[(1-{3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid
en:SRT2183
| IUPAC_name = N-[2-(3-{[(3''R'')-3-hydroxypyrrolidin-1-yl]methyl}imidazo[2,1-b][1,3]thiazol-6-yl)phenyl]naphthalene-2-carboxamide
en:SRT1460
| IUPAC_name = 3,4,5-trimethoxy-N-{2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}benzamide
en:Elinogrel
| IUPAC_name = ''N''-[(5-Chlorothiophen-2-yl)sulfonyl]-''N′''-{4-[6-fluoro-7-(methylamino)-2,4-dioxo-1,4-dihydroquinazolin-3(2''H'')-yl]phenyl}urea
en:BRL-32872
| IUPACName = ''N''-(3,4-Dimethoxyphenyl)-''N''-(3-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}propyl)-4-nitrobenzamide
en:Omecamtiv mecarbil
| IUPAC_name = Methyl 4-[(2-fluoro-3-{[''N''-(6-methylpyridin-3-yl)carbamoyl]amino}phenyl)methyl]piperazine-1-carboxylate
en:Gephyrotoxin
| IUPACName = 2-{(1''R'',3a''R'',5a''R'',6''R'',9a''S'')-6-[(2''Z'')-pent-2-en-4-yn-1-yl]dodecahydropyrrolo[1,2-a]quinolin-1-yl}ethanol
en:WIN 56,098
| IUPAC_name = Anthracen-9-yl-{2-methyl-1-[2-(morpholin-4-yl)ethyl]-1''H''-indol-3-yl}methanone
en:Nintedanib
| IUPAC_name = Methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate
en:Ranbezolid
| IUPAC_name = N-{[(5''S'')-3-(3-Fluoro-4-{4-[(5-nitro-2-furyl)methyl]-1-piperazinyl}phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
en:Spiraprilat
| IUPAC_name = (8S)-7-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
en:Balanol
| IUPAC_name = 2-{[2,6-dihydroxy-4-({[(3S,4R)-3-[(4-hydroxybenzene)amido]azepan-4-yl]oxy}carbonyl)phenyl]carbonyl}-3-hydroxybenzoic acid
en:Inogatran
| IUPACName = 2-{[(2''R'')-1-[(2''S'')-2-[(4-Carbamimidamidopropyl)carbamoyl]piperidin-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino}acetic acid
en:Methanophenazine
| IUPACName = 2-{[(3''S'',6''E'',10''E'',14''E'')-3,7,11,15,19-pentamethylicosa-6,10,14,18-tetraen-1-yl]oxy}phenazine
en:PPADS
| IUPACName = 4-[(''E'')-{4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]pyridin-2-yl}diazenyl]benzene-1,3-disulfonic acid
en:Gadofosveset
| IUPAC_name = Trisodium 2-{[(2''R'')-2-[bis(2-oxido-2-oxoethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl]amino}acetate
en:Calcium stearoyl-2-lactylate
| OtherNames = E482, octadecanoic acid, 2-(1-carboxyethoxy)-1-methyl-2-oxoethyl ester, calcium salt; calcium bis(2-{[2-(stearoyloxy)propanoyl]oxy}propanoate); calcium verate; calcium stearoyl lactylate; calcium stearoyl-2-lactylate; calcium stearyl-2-lactylate; calcium stelate; stearoyl-2-lactylic acid, calcium salt; calcium alpha-(alpha-(stearoyloxy)propionyloxy)propionate; calcium 2-(1-carboxyethoxy)-1-methyl-2-oxoethyloctadecanoate; stearic acid, ester with lactate of lactic acid, calcium salt; stearic acid ester with lactic acid bimol. ester calcium salt; calcium bis(2-(1-carboxylatoethoxy)-1-methyl-2-oxoethyl) distearate
en:Canertinib
| IUPACName = ''N''-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
en:Teniloxazine
| IUPAC_name = 2-{[2-(thiophen-2-ylmethyl)phenoxy]methyl}morpholine
en:Validamycin
| IUPACName = (1''R'',2''R'',3''S'',4''S'',6''R'')-2,3-dihydroxy-6-(hydroxymethyl)-4-{[(1''S'',4''S'',5''S'',6''S'')-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}cyclohexyl β-D-glucopyranoside
en:Lumacaftor
| IUPAC_name = 3-{6-{[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino}-3-methylpyridin-2-yl}benzoic acid
en:Olodaterol
| IUPAC_name = 6-hydroxy-8-{(1''R'')-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl}-4''H''-1,4-benzoxazin-3-one
en:Rhamnolipid
| OtherNames = 3-[(3-{[6-deoxy-2-O-(6-deoxy-alpha-L-mannopyranosyl)-alpha-L-mannopyranosyl]oxy}decanoyl)oxy]decanoic acid
en:Momelotinib
| IUPACName = ''N''-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
en:Peginesatide
| IUPAC_name = Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, diester with 21''N''6,21'''N''6-{[(''N''2,''N''6-dicarboxy-L-lysyl-β-alanyl)imino]bis(1-oxo-2,1-ethanediyl)}bis[''N''-acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(1-naphthalenyl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-''N''-methylglycyl-L-lysinamide] cyclic (6→15),(6'→15')-bis(disulfide)<ref name="USAN" />
en:SIB-1553A
| IUPACName = (''R''/''S'')-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride
en:Bilastine
| IUPACName = 2-[4-(2-{4-[1-(2-Ethoxyethyl)-1''H''-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid
en:Floctafenine
| IUPAC_name = 2,3-Dihydroxypropyl 2-{[8-(trifluoromethyl)-4-quinolinyl]amino}benzoate
en:Joro toxin
| IUPACName = N1-{5-[(N-{4-[(3-aminopropyl)amino]butyl}-β-alanyl)amino]pentyl}-N2-[(2,4-dihydroxyphenyl)acetyl]-L-aspartamide
en:Brexpiprazole
| IUPAC_name = 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1''H'')-one
en:AZD1305
| IUPACName = 2-Methyl-2-propanyl (2-{7-[2-(4-cyano-2-fluorophenoxy)ethyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethyl)carbamate
en:Darexaban
| IUPACName = ''N''-(3-Hydroxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl)-4-methoxybenzamide
en:Vintafolide
| IUPAC_name =''N''-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine disulfide with methyl (5''S'',7''R'',9''S'')-5-ethyl-9-[(3a''R'',4''R'',5''S'',5a''R'',10b''R'',13a''R'')-3a-ethyl-4,5-dihydroxy-8-methoxy-6-methyl-5-({2-[(2-sulfanylethoxy)carbonyl]hydrazinyl}carbonyl)-3a,4,5,5a,6,11,12,13a-octahydro-1''H''-indolizino[8,1-''cd'']carbazol-9-yl]-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2''H''-3,7-methanoazacycloundecino[5,4-''b'']indol-9-carboxylate
en:Deltorphin I
| IUPACName = (3''S'')-3-[(2''S'')-2-[(2''R'')-2-[(2''S'')-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-3-phenylpropanamido]-3-{[(1''S'')-1-{[(1''S'')-1-[(carbamoylmethyl)carbamoyl]-2-methylpropyl]carbamoyl}-2-methylpropyl]carbamoyl}propanoic acid or L-tyrosyl-D-alanyl-L-phenylalanyl-L-α-aspartyl-L-valyl-L-valylglycinamide
en:Pingyangmycin
| IUPAC_name = (2''R'',3''S'',4''S'',5''R'',6''R'')-2-{[(2''R'',3''S'',4''S'',5''S'',6''S'')-2-{[(1''R'',2''S'')-2-[({6-Amino-2-[(1''S'')-3-amino-1-{[(2''S'')-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl]-5-methyl-4-pyrimidinyl}carbonyl)amino]-3-{[(2''R'',3''S'',4''S'')-5-{[(2''S'',3''R'')-1- ({2-[4-({3-[(4-aminobutyl)amino]propyl}carbamoyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)-3-hydroxy-1-oxo-2-butanyl]amino}-3-hydroxy-4-methyl-5-oxo-2-pentanyl]amino}-1-(1''H''-imidazol-5-yl)-3-oxopropyl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2''H''-pyran-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2''H''-pyran-4-yl carbamate
en:LBP-1 (drug)
| IUPAC_name = 2-{4-[(3-[7-chloro-1-(oxan-4-ylmethyl)indol-3-yl]-1,2,4-oxadiazol-5-yl)methyl]piperazin-1-yl}acetamide
en:Flufenacet
| IUPACName = ''N''-(4-Fluorophenyl)-''N''-isopropyl-2-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy}acetamide
en:Lividomycin
| IUPAC_name = (1''R'',2''R'',3''S'',4''R'',6''S'')-4,6-Diamino-3-hydroxy-2-{[α-D-mannopyranosyl-(1->4)-2,6-diamino-2,6-dideoxy-β-L-idopyranosyl-(1->3)-β-D-ribofuranosyl]oxy}cyclohexyl 2-amino-2,3-dideoxy-α-D-ribo-hexopyranoside
en:Fenpropimorph
| IUPACName = ''cis''-2,6-Dimethyl-4-{2-methyl-3-[4-(2-methyl-2-propanyl)phenyl]propyl}morpholine or (2''R'',6''S'')-4-[3-(4-tert-butylphenyl)-2-methylpropyl]-2,6-dimethylmorpholine
en:Masitinib
| IUPAC_name = 4-[(4-Methylpiperazin-1-yl)methyl]-''N''-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide
en:Formetanate
| IUPACName = 3-{(''E'')-[(Dimethylamino)methylene]amino}phenyl methylcarbamate
en:Formothion
| IUPACName = ''S''-{2-[Formyl(methyl)amino]-2-oxoethyl} ''O'',''O''-dimethyl phosphorodithioate
en:Fluo-3
| IUPACName = {[2-(2-{2-[Bis(carboxymethyl)amino]-5-(2,7-dichloro-6-hydroxy-3-oxo-3''H''-xanthen-9-yl)phenoxy}ethoxy)-4-methylphenyl](carboxymethyl)amino}acetic acid
en:Methyl phenkapton
| IUPACName = ''S''-{[(2,5-Dichlorophenyl)sulfanyl]methyl} ''O'',''O''-dimethyl phosphorodithioate
en:Elobixibat
| IUPAC_name = ''N''-{(2''R'')-2-[({[3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylacetyl}glycine
en:Apremilast
| IUPAC_name = ''N''-{2-[(1''S'')-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1''H''-isoindol-4-yl}acetamide
en:Development of analogs of thalidomide
The thalidomide molecule is a synthetic derivative of [[glutamic acid]] and consists of a glutarimide ring and a phthaloyl ring (Figure 5).<ref name=Man2009>{{cite journal|last=Man|first=Hon-Wah|author2=Schafer, Peter |author3=Wong, Lu Min |author4=Patterson, Rebecca T. |author5=Corral, Laura G. |author6=Raymon, Heather |author7=Blease, Kate |author8=Leisten, Jim |author9=Shirley, Michael A. |author10=Tang, Yang |author11=Babusis, Darius M. |author12=Chen, Roger |author13=Stirling, Dave |author14=Muller, George W. |title=Discovery of (''S'')-''N''-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1''H''-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor|journal=Journal of Medicinal Chemistry|date=26 March 2009|volume=52|issue=6|pages=1522–4|doi=10.1021/jm900210d|pmid=19256507}}</ref><ref name=Muller1996>{{cite journal|last=Muller|first=George W.|author2=Corral, Laura G. |author3=Shire, Mary G. |author4=Wang, Hua |author5=Moreira, Andre |author6=Kaplan, Gilla |author7= Stirling, David I. |title=Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity|journal=Journal of Medicinal Chemistry|date=1 January 1996|volume=39|issue=17|pages=3238–3240|doi=10.1021/jm9603328|pmid=8765505}}</ref> Its [[International Union of Pure and Applied Chemistry|IUPAC]] name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center<ref name=Man2009 />
en:Mirabegron
| IUPAC_name = 2-(2-Amino-1,3-thiazol-4-yl)-''N''-[4-(2-{[(2''R'')-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
en:Semax
| IUPAC_name = (2''S'')-1-[2-{[(2''S'')-1-[(2''S'')-2-{[2-{[(2''S'')-2-{[(2''S'')-2-amino-4-methylsulfanylbutanoyl]amino}-4-carboxybutanoyl]amino}-3-(1''H''-imidazol-5-yl)propanoyl]amino}-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino}acetyl]pyrrolidine-2-carboxylic acid
en:Terbufos
| IUPACName = ''O'',''O''-Diethyl ''S''-{[(2-methyl-2-propanyl)sulfanyl]methyl} phosphorodithioate
en:Trametinib
| IUPAC_name = ''N''-(3-{3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2''H'')-yl}phenyl)acetamide
en:EPI-001
| IUPAC_name = 3-(4-{2-[4-(3-Chloro-2-hydroxypropoxy)phenyl]-2-propanyl}phenoxy)-1,2-propanediol
en:TAS-108
| IUPAC_name = (1S,9R,10S,11S,14R,15R)-14-(2-{4-[(diethylamino)methyl]-2-methoxyphenoxy}ethyl)-9,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-5-ol
en:ELQ-300
| IUPACName = 6-chloro-7-methoxy-2-methyl-3-{4-[4-(trifluoromethoxy)phenoxy]phenyl}quinolin-4(1''H'')-one
en:Delamanid
| IUPAC_name = (2''R'')-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-''b''][1,3]oxazole
en:Mallotojaponin C
| IUPACName = 1,1’-{Methylenebis[2,6-dihydroxy-4-methoxy-5-(3-methyl-2-buten-1-yl)-3,1-phenylene]}diethanone
en:Encorafenib
| IUPAC_name = Methyl [(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate
en:Zeocin
| IUPACName = 2-({2-[2-{[(6-Amino-2-{3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl}-5-methyl-4-pyrimidinyl)carbonyl]amino}-3-[(5-{[1-({2-[4-({4-[(diaminomethylene)amino]butyl}carbamoyl)-4’,5’-dihydro-2,4’-bi-1,3-thiazol-2’-yl]ethyl}amino)-3-hydroxy-1-oxo-2-butanyl]amino}-3-hydroxy-4-methyl-5-oxo-2-pentanyl)amino]-1-(1''H''-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2''H''-pyran-3-yl}oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl carbamate
en:Carbomycin
| IUPACName = (2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(3R,7R,8S,9S,10R,12R,14E)-7-Acetoxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy}-4-(dimethylamino)-5-hydr oxy-2-methyltetrahydro-2H-pyran-3-yl]oxy}-4-hydroxy-2,4-dimethyltetrahydro-2H-pyran-3-yl 3-methylbutanoate
en:Vilanterol
| IUPAC_name = 4-{(1''R'')-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
en:Palbociclib
| IUPAC_name = 6-Acetyl-8-cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}pyrido[2,3-d]pyrimidin-7(8''H'')-one
en:Saroglitazar
| IUPAC_name = (2''S'')-2-Ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1''H''-pyrrol-1-yl}ethoxy)phenyl]propanoic acid
en:Bacillibactin
| IUPACName = N,N’,N’’-{[(2''R'',3''S'',6''R'',7''S'',10''R'',11''S'')-2,6,10-Trimethyl-4,8,12-trioxo-1,5,9-trioxacyclododecane-3,7,11-triyl]tris[imino(2-oxo-2,1-ethanediyl)]}tris(2,3-dihydroxybenzamide)
en:Aplysamine-2
| IUPACName = (2Z)-3-(3-Bromo-4-methoxyphenyl)-N-(2-{3,5-dibromo-4-[3-(dimethylamino)propoxy]phenyl}ethyl)-2-(hydroxyimino)propanamide
en:Pingbeinine
| IUPACName = (3β,16β,17β)-17-{(1S)-1-[(2R,5R)-5-Hydroxy-1,5-dimethyl-2-piperidinyl]ethyl}androst-5-ene-3,16-diol
en:Milataxel
| IUPACName = (2α,5β,7β,10β,13α)-4-Acetoxy-13-{[(2''R'',3''R'')-3-(2-furyl)-2-hydroxy-3-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)propanoyl]oxy}-1,10-dihydroxy-9-oxo-7-(propionyloxy)-5,20-epoxytax-11-en-2-yl benzoate
en:CI-966
| IUPAC_name = 1-(2-{bis[4-(trifluoromethyl)phenyl]methoxy}ethyl)- -3,6-dihydro-2''H''-pyridine-5-carboxylic acid
en:Atizoram
| IUPACName = 5-{3-[(1''S'',2''S'',4''R'')-Bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl}tetrahydro-2(1''H'')-pyrimidinone
en:LY-255582
| IUPACName = 3-{(3''R'',4''R'')-1-[(3''S'')-3-Cyclohexyl-3-hydroxypropyl]-3,4-dimethyl-4-piperidinyl}phenol
en:Silperisone
| IUPAC_name = 1-{[(4-Fluorobenzyl)(dimethyl)silyl]methyl}piperidine
en:Florbetaben (18F)
| IUPAC_name = 4-{(''E'')-2-[4-(2-{2-[2-(18F)Fluoroethoxy]ethoxy}ethoxy)phenyl]vinyl}-''N''-methylaniline
en:Capsinolol
| IUPAC_name = ''N''-{4-[2-Hydroxy-3-(isopropylamino)propoxy]-3-methoxybenzyl}nonanamide
en:Cinamolol
| IUPAC_name = Methyl (2''E'')-3-{2-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acrylate
en:Draquinolol
| IUPAC_name = 3-(4-{2-Hydroxy-3-[(2-methyl-2-propanyl)amino]propoxy}phenyl)-7-methoxy-2-methyl-1(2''H'')-isoquinolinone
en:Ericolol
| IUPAC_name = 3-(4-Chloro-2-{2-hydroxy-3-[(2-methyl-2-propanyl)amino]propoxy}phenyl)-2-cyclopenten-1-one
en:Foeniculoside I
| IUPACName = 2-(3-hydroxy-5-{6-hydroxy-4-[6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl]-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzofuran-3-yl}phenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
en:CERC-501
| IUPAC_name = 4-(4-{[(2''S'')-2-(3,5-Dimethylphenyl)-1-pyrrolidinyl]methyl}phenoxy)-3-fluorobenzamide
en:Fluopicolide
| IUPACName = 2,6-Dichloro-''N''-{[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl}benzamide
en:Basimglurant
| IUPAC_name = 2-chloro-4-{[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl]ethynyl}pyridine
en:Octotiamine
| IUPAC_name = methyl 6-(acetylsulfanyl)-8-{[(2E)-2-{[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino}-5-hydroxy-2-penten-3-yl]disulfanyl}octanoate
en:Etodroxizine
| IUPAC_name = 2-[2-(2-{4-[(4-Chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethoxy)ethoxy]ethanol
en:Pipoxizine
| IUPAC_name = 2-(2-{2-[4-(Diphenylmethylene)-1-piperidinyl]ethoxy}ethoxy)ethanol
en:Pawhuskin A
| IUPACName = 4-[(''E'')-2-{2-[(2''E'')-3,7-Dimethyl-2,6-octadien-1-yl]-3,5-dihydroxyphenyl}vinyl]-3-(3-methyl-2-buten-1-yl)-1,2-benzenediol
en:Leconotide
| IUPAC_name = (3S)-3-[(2S)-2-[(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-2-[(2S)-6-amino-2-[(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-3-hydroxypropanamido]hexanamido]acetamido}propanamido]hexanamido]-3-sulfanylpropanamido]-3-hydroxypropanamido]hexanamido]-4-methylpentanamido]-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanamido]-3-{[(1R)-1-{[(R)-{[(1S)-1-[({[(1S)-1-{[(R)-{[(1S)-1-[({[(1S,2R)-1-{[(1S)-1-[({[(1S)-4-carbamimidamido-1-{[(R)-carbamoyl(methanethioyl)methyl]carbamoyl}butyl]carbamoyl}methyl)carbamoyl]-2-methylpropyl]carbamoyl}-2-hydroxypropyl]carbamoyl}methyl)carbamoyl]-2-hydroxyethyl]carbamoyl}(methanethioyl)methyl]carbamoyl}-2-hydroxyethyl]carbamoyl}methyl)carbamoyl]-2-hydroxyethyl]carbamoyl}(methanethioyl)methyl]carbamoyl}-2-sulfanylethyl]carbamoyl}propanoic acid
en:Ombitasvir
| IUPAC_name = Dimethyl ''N'',''N''′-{[(2''S'',5''S'')-1-(4-''tert''-butylphenyl)pyrrolidene-2,5-diyl]-bis-{[(4,1-phenyleneazanediyl)carbonyl][(2''S'')-pyrrolidine-2,1-diyl]}[(2''S'')-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate
en:Dasabuvir
| IUPAC_name = ''N''-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2''H'')-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide
en:Ripasudil
| IUPAC_name = 4-Fluoro-5-{[(2''S'')-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline
en:Dehydrosecodine
| IUPACName = Methyl 2-{3-[2-(5-ethyl-1(2H)-pyridinyl)ethyl]-1H-indol-2-yl}acrylate
en:Radalbuvir
| IUPAC_name = 5-(3,3-Dimethylbut-1-yn-1-yl)-3-{(1''R'')-''N''-[(1''s'',4''s'')-4-hydroxy-4-({[(3''S'')-oxolan-3-yl]oxy}methyl)cyclohexyl]-4-methylcyclohex-3-ene-1-carboxamido}thiophene-2-carboxylic acid
en:Azinomycin B
| IUPACName = (1''S'')-2-{[(1''E'')-1-[(3''R'',4''R'',5''S'')-3-Acetoxy-4-hydroxy-1-azabicyclo[3.1.0]hex-2-ylidene]-2-{[(1''Z'')-1-hydroxy-3-oxo-1-buten-2-yl]amino}-2-oxoethyl]amino}-1-[(2''S'')-2-methyl-2-oxiranyl]-2-oxoethyl 3-methoxy-5-methyl-1-naphthoate
en:Osimertinib
| IUPAC_name = ''N''-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
en:Lesinurad
| IUPAC_name = 2-{[5-Bromo-4-(4-cyclopropyl-1-naphthyl)-4''H''-1,2,4-triazol-3-yl]sulfanyl}acetic acid
en:Fructoselysine
| IUPACName = (2''S'')-2-Amino-6-{[(3''S'',4''R'',5''R'')-3,4,5,6-tetrahydroxy-2-oxohexyl]amino}hexanoic acid
en:Ravidasvir
| IUPAC_name = (2''S'')-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2''S'')-2-[5-(6-{2-[(2''S'')-1-[(2''S'')-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1''H''-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1''H''-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one
en:Rociletinib
| IUPAC_name = ''N''-(3-{[2-{[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino}-5-(trifluoromethyl)-4-pyrimidinyl]amino}phenyl)acrylamide
en:PF-610355
| IUPAC_name = ''N''-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2-{[(2''R'')-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide
en:Dapivirine
| IUPAC_name = 4-{[4-(Mesitylamino)-2-pyrimidinyl]amino}benzonitrile
en:Estrone tetraacetylglucoside
| IUPAC_name = [(2R,3R,4S,5R,6S)-3,4,5-triacetyloxy-6-{[(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl]oxy}oxan-2-yl]methyl acetate
en:Velpatasvir
| IUPAC_name = Methyl {(2''S'')-1-[(2''S'',5''S'')-2-(9-{2-[(2''S'',4''S'')-1-{(2''R'')-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate
en:Martinostat
| IUPAC_name = (2''E'')-3-(4-{[(Adamantan-1-ylmethyl)(methyl)amino]methyl}phenyl)-''N''-hydroxyacrylamide
en:Brilanestrant
| IUPAC_name = (2E)-3-{4-[(1E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl]phenyl}prop-2-enoic acid
en:Elacestrant
| IUPAC_name = (6''R'')-6-{2-[Ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
en:Trofinetide
| IUPAC_name = (2S)-2-{[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino}pentanedioic acid
en:FK1012
| IUPACName = (1''R'',12''S'',13''R'',14''S'',18''E'',21''S'',23''S'',24''R'',25''R'',27''R'')-1,14-Dihydroxy-17-{(2''E'')-4-[(12''S'',13''R'',14''S'',17''R'',18''E'',21''S'',23''S'',24''R'',25''R'',27''R'')-14-hydroxy-12-{(1''E'')-1-[(1''R'',3''R'',4''R'')-4-hydroxy-3-methoxycyclohexyl]-1-propen-2-yl}-23,25-dimethoxy-13,19,21,27-tetramethyl-2,3,10,16-tetraoxo-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-en-17-yl]-2-buten-1-yl}-12-{(1''E'')-1-[(1''R'',3''R'',4''R'')-4-hydroxy-3-methoxycyclohexyl]-1-propen-2-yl}-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
en:Etacstil
| IUPAC_name = (2''E'')-3-{4-[(1''Z'')-1,2-Diphenyl-1-buten-1-yl]phenyl}acrylic acid
en:Afoxolaner
| IUPAC_name = 4-{5-[3-Chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl}-''N''-{2-oxo-2-[(2,2,2- trifluoroethyl)amino]ethyl}naphthalene-1-carboxamide
en:GS-5734
| IUPAC_name = (2''S'')-2-{(2''R'',3''R'',4''S'',5''R'')-[5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(''S'')-phosphorylamino}propionic acid 2-ethyl-butyl ester
en:Emricasan
| IUPAC_name = (3S)-3-{[(2S)-2-{[2-(2-tert-butylanilino)-2-oxoacetyl]amino}propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
en:Camicinal
| IUPAC_name = 1-{4-[(3-Fluorophenyl)amino]-1-piperidinyl}-2-(4-{[(3''S'')-3-methyl-1-piperazinyl]methyl}phenyl)ethanone
en:Estriol sulfate glucuronide
| IUPACName = (2''S'',3''S'',4''S'',5''R'')-3,4,5-Trihydroxy-6-{[(1''S'',10''R'',11''S'',13''R'',14''R'',15''S'')-14-hydroxy-15-methyl-5-(sulfooxy)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-13-yl]oxy}oxane-2-carboxylic acid
en:Olmutinib
| IUPAC_name = ''N''-{3-[(2-{[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide
en:Ovandrotone
| IUPAC_name = 3-{[(1S,2R,9R,10R,11S,15S)-2,15-dimethyl-5,14-dioxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-9-yl]sulfanyl}propanoic acid
en:Levoketoconazole
| IUPAC_name = 1-[4-(4-{[(2''S'',4''R'')-2-(2,4-Dichlorophenyl)-2-(1''H''-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-1-piperazinyl]ethanone
en:Merestinib
| IUPAC_name = ''N''-(3-Fluoro-4-{[1-methyl-6-(1''H''-pyrazol-4-yl)-1''H''-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
en:Glesatinib
| IUPAC_name = ''N''-[(3-Fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide
en:Sitravatinib
| IUPAC_name = ''N''-(3-Fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}-2-pyridinyl)thieno[3,2-''b'']pyridin-7-yl]oxy}phenyl)-''N′''-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
en:Distamycin
| IUPACName = N-{5-[(5-{[(3Z)-3-Amino-3-iminopropyl]carbamoyl}-1-methyl-1H-pyrrol-3-yl)carbamoyl]-1-methyl-1H-pyrrol-3-yl}-4-formamido-1-methyl-1H-pyrrole-2-carboxamide

Urls[edit]

en:Alan Turing
* [http://www.rkbexplorer.com/explorer/#display=person-{http://dblp.rkbexplorer.com/id/people-a27f18ebafc0d76ddb05173ce7b9873d-e0b388b7c1e0985b1371d73ee1fae8b5} Alan Turing] RKBExplorer
en:Heuristic evaluation
* [http://www.rkbexplorer.com/explorer/#display=mechanism-{http://resex.rkbexplorer.com/id/resilience-mechanism-4331d919} Heuristic Evaluation in the RKBExplorer]
en:Autonomic computing
* [http://www.rkbexplorer.com/explorer/#display=mechanism-{http://resex.rkbexplorer.com/id/resilience-mechanism-87d79b11} Autonomic Computing Architecture in the RKBExplorer]
en:Byzantine fault tolerance
* [http://www.rkbexplorer.com/explorer/#display=mechanism-{http://resex.rkbexplorer.com/id/resilience-mechanism-65b5cef4} Byzantine Fault Tolerance in the RKBExplorer]
en:Language Of Temporal Ordering Specification
* [http://www.rkbexplorer.com/explorer/#display=mechanism-{http://resex.rkbexplorer.com/id/resilience-mechanism-cf9ed8ae} LOTOS in the RKBExplorer]
en:Fault tolerance
*[http://www.rkbexplorer.com/explorer/#display=mechanism-{http://resex.rkbexplorer.com/id/resilience-mechanism-736676d7} Graceful Degradation in the RKBExplorer]
en:N-version programming
* [http://www.rkbexplorer.com/explorer/#display=mechanism-{http://resex.rkbexplorer.com/id/resilience-mechanism-e679bd05} N-version programming in the RKBExplorer]
en:Dependability benchmarking
* [http://www.rkbexplorer.com/explorer/#display=mechanism-{http://resex.rkbexplorer.com/id/resilience-mechanism-d479bbc7} Dependability Benchmarking in the RKBExplorer]
en:List of Historic Sites of Japan (Kyōto)
| align="center"|[[Hōkai-ji]] Precinct {{nihongo2|[[:ja:法界寺|法界寺]]境内}} ''Hōkaiji keidai'' || [[Fushimi-ku, Kyoto]] || || [[File:Hokaiji05s1920.jpg|150px]] || {{coord|34.934124|N|135.814929|E|display=inline|format=dms|type:landmark_region:JP_scale:10000|name=Hōkaiji Precinct}} || || [http://www.city.kyoto.jp/bunshi/bunkazai/siteisyasinn/sisekisetumei.htm#Anchor-{FKDXQD`-19879 ]

Other[edit]

en:Bulgarian language
There are three grammatical genders in Bulgarian: ''masculine'', ''feminine'' and ''neuter''. The gender of the noun can largely be inferred from its ending: nouns ending in a consonant ("zero ending") are generally masculine (for example, град {{IPA|/ɡrat/}} 'city', син {{IPA|/sin/}} 'son', мъж {{IPA|/mɤʃ/}} 'man'; those ending in –а/–я (-a/-ya) (жена {{IPA|/ʒɛˈna/}} 'woman', дъщеря {{IPA|/dɐʃtɛrˈja/}} 'daughter', улица {{IPA|/ˈulitsɐ/}} 'street') are normally feminine; and nouns ending in –е, –о are almost always neuter (дете {{IPA|/dɛtɛ/}} 'child', езеро {{IPA|/ˈɛzɛro/}} 'lake'), as are those rare words (usually loanwords) that end in –и, –у, and –ю (цунами {{IPA|/tsoˈnami/}} 'tsunami', табу {{IPA|/tɐˈbu/}} 'taboo', меню {{IPA|/mɛˈnju/}} 'menu'). Perhaps the most significant exception from the above are the relatively numerous nouns that end in a consonant and yet are feminine: these comprise, firstly, a large group of nouns with zero ending expressing quality, degree or an abstraction, including all nouns ending on –ост/–ест -{ost/est} (мъдрост {{IPA|/ˈmɤdrost/}} 'wisdom', низост {{IPA|/ˈnizost/}} 'vileness', прелест {{IPA|/ˈprɛlɛst/}} 'loveliness', болест {{IPA|/ˈbɔlɛst/}} 'sickness', любов {{IPA|/ljuˈbɔf/}} 'love'), and secondly, a much smaller group of irregular nouns with zero ending which define tangible objects or concepts (кръв {{IPA|/krɤf/}} 'blood', кост {{IPA|/kɔst/}} 'bone', вечер {{IPA|/ˈvɛtʃɛr/}} 'evening', нощ {{IPA|/nɔʃt/}} 'night'). There are also some commonly used words that end in a vowel and yet are masculine: баща 'father', дядо 'grandfather', чичо / вуйчо 'uncle', and others.
en:Endoplasmic reticulum
Abnormalities in [[XBP1]] lead to a heightened [[XBP1#Endoplasmic reticulum stress response|endoplasmic reticulum stress response]] and subsequently causes a higher susceptibility for inflammatory processes that may even contribute to [[Alzheimer's disease]].<ref name=pmid21389082>{{cite journal|last=Casas-Tinto|first=S|author2=Zhang, Y |author3=Sanchez-Garcia, J |author4=Gomez-Velazquez, M |author5=Rincon-Limas, DE |author6=Fernandez-Funez, P |title=The ER stress factor XBP1s prevents amyloid-{beta} neurotoxicity.|journal=Human Molecular Genetics|date=25 March 2011|pmid=21389082|doi=10.1093/hmg/ddr100|pmc=3090193|volume=20|issue=11|pages=2144–60}}</ref> In the [[Colon (anatomy)|colon]], XBP1 anomalies have been linked to the inflammatory bowel diseases including [[Crohn's disease]].<ref name="pmid18775308">{{cite journal |vauthors=Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS | title = XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease | journal = Cell | volume = 134 | issue = 5 | pages = 743–56 |date=September 2008 | pmid = 18775308 | doi = 10.1016/j.cell.2008.07.021 | url = | pmc = 2586148 }}</ref>
en:Oxycodone
In terms of biosynthesis, oxycodone has been found naturally in nectar extracts from the orchid family ''[[Epipactis helleborine]]''; together along with another opioid: 3-{2-{3-{3-benzyloxypropyl}-3-indol, 7,8-didehydro- 4,5-epoxy-3,6-d-morphinan.<ref>[https://www.erowid.org/references/texts/show/8710docid7639 "Why do pollinators become 'sluggish'? Nectar chemical constituents from Epipactis helleborine L. Crantz Orchidaceae".] Applied Ecology & Environmental Research. 2005;3(2):29-38. Jakubska A, Przado D, Steininger M, Aniol-Kwiatkowska A, Kadej M.</ref>
en:Positron emission tomography
The development of a number of novel probes for noninvasive, in vivo PET imaging of neuroaggregate in human brain has brought amyloid imaging to the doorstep of clinical use. The earliest amyloid imaging probes included 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP)<ref>{{cite journal | display-authors = 4 | author = Agdeppa ED | author2 = Kepe V | author3 = Liu J | author4 = Flores-Torres S | author5 = Satyamurthy N | author6 = Petric A | author7 = Cole GM | author8 = Small GW | author9 = Huang SC | author10 = Barrio JR | title = Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease | journal = J Neurosci | volume = 21 | issue = 24 | pages = RC189(1–5) | date = 2001 | pmid = 11734604 | url = http://www.jneurosci.org/content/21/24/RC189.full.pdf }}</ref> developed at the University of California, Los Angeles and N-methyl-[11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole<ref name="pmid11814781">{{cite journal | display-authors = 4 | author = Mathis CA | author2 = Bacskai BJ | author3 = Kajdasz ST | author4 = McLellan ME | author5 = Frosch MP | author6 = Hyman BT | author7 = Holt DP | author8 = Wang Y | author9 = Huang GF | author10 = Debnath ML | author11 = Klunk WE | title = A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain | journal = Bioorg. Med. Chem. Lett. | volume = 12 | issue = 3 | pages = 295–8 | date = 2002 | pmid = 11814781 | doi = 10.1016/S0960-894X(01)00734-X }}</ref> (termed [[Pittsburgh compound B]]) developed at the University of Pittsburgh. These amyloid imaging probes permit the visualization of [[amyloid]] plaques in the brains of Alzheimer's patients and could assist clinicians in making a positive clinical diagnosis of AD pre-mortem and aid in the development of novel anti-amyloid therapies. [11C]PMP (N-[11C]methylpiperidin-4-yl propionate) is a novel radiopharmaceutical used in PET imaging to determine the activity of the acetylcholinergic neurotransmitter system by acting as a substrate for acetylcholinesterase. Post-mortem examination of AD patients have shown decreased levels of acetylcholinesterase. [11C]PMP is used to map the acetylcholinesterase activity in the brain, which could allow for pre-mortem diagnosis of AD and help to monitor AD treatments.<ref>{{cite journal | display-authors = 4 | author = Kuhl DE | author2 = Koeppe RA | author3 = Minoshima S | author4 = Snyder SE | author5 = Ficaro EP | author6 = Foster NL | author7 = Frey KA | author8 = Kilbourn MR | title = In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease | journal = Neurology | volume = 52 | issue = 4 | pages = 691–9 | date = March 1999 | pmid = 10078712 | doi = 10.1212/wnl.52.4.691 | url = }}</ref> [[Avid Radiopharmaceuticals]] of [[Philadelphia]] has developed a compound called 18F-AV-45 that uses the longer-lasting radionuclide [[fluorine-18]] to detect amyloid plaques using PET scans.<ref>[[Gina Kolata|Kolata, Gina]]. [https://www.nytimes.com/2010/06/24/health/research/24scans.html "Promise Seen for Detection of Alzheimer’s"], ''[[The New York Times]]'', June 23, 2010. Accessed June 23, 2010.</ref>
en:Folic acid
| synonyms = ''N''-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid, pteroyl-L-glutamic acid, vitamin B9,<ref name="Folate 2011">{{cite journal|last1=Fenech|first1=Michael|title=Folate (vitamin B9) and vitamin B12 and their function in the maintenance of nuclear and mitochondrial genome integrity|journal=Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis|date=May 2012|volume=733|issue=1–2|pages=21–33|doi=10.1016/j.mrfmmm.2011.11.003|pmid=22093367}}</ref> vitamin Bc,<ref name="Definition of vitamin Bc">{{cite web|url=http://medical-dictionary.thefreedictionary.com/vitamin+Bc |title=Definition of vitamin Bc|publisher=Medical-dictionary.thefreedictionary.com |accessdate=9 September 2012}}</ref> vitamin M,<ref name=darby1945>{{cite journal|last1=Darby|first1=William J.|last2=Jones|first2=Edgar|title=Treatment of Sprue with Synthetic L. casei Factor (Folic Acid, Vitamin M).|journal=Experimental Biology and Medicine|date=1 November 1945|volume=60|issue=2|pages=259–262|doi=10.3181/00379727-60-15154P|url=http://ebm.sagepub.com/content/60/2/259.short|accessdate=13 December 2014}}</ref> folacin, pteroyl-L-glutamate
en:Love (band)
Lee re-emerged in 1992 with a new album entitled ''Arthur Lee & Love -{Five String Serenade}'' on the French New Rose label. The title track, "Five String Serenade", was later recorded by [[Mazzy Star]] and [[Jack White]] of [[The White Stripes]]. The album also featured a new artist he discovered from San Francisco, Keith Farrish aka Demian X Diamond. He performed live around this time in Paris, London and Liverpool. In 1993 he played shows in LA, New York and England. The following year he released a 45rpm single, "Girl on Fire" backed with "Midnight Sun", on Distortions Records. He began to tour regularly with a backup band comprising former members of Das Damen, and LA group [[Baby Lemonade]].
en:Waverly, Nebraska
Waverly Intermediate School-{W.I.S}; 3rd-5th grade:
en:John Spencer, 5th Earl Spencer

en:Alexei Alexeyevich Abrikosov
From 1991 until his retirement, he worked at [[Argonne National Laboratory]] in [[Illinois]]. Abrikosov was an Argonne Distinguished Scientist at the Condensed Matter Theory Group in Argonne’s Materials Science Division. His recent research has focused on the origins of magnetoresistance, a property of some materials that change their resistance to electrical flow under the influence of a magnetic field.<ref>[http://chemistry.anl.gov/MSDReview/Superconductivity/Abrikosov.pdf Abrikosov, A. A. “Theory of an Unusual Metal-Insulator Transition in Layered High-Tc Cuprates”, Materials Science Division, Argonne National Laboratory, United States Department of Energy,(August 28, 2003)].</ref><ref>[http://www.osti.gov/cgi-bin/rd_accomplishments/display_biblio.cgi?id=ACC0078&numPages=12&fp=N Abrikosov, A. A. “Theory of High-{Tc} Superconducting Cuprates Based on Experimental Evidence”, Materials Science Division, Argonne National Laboratory, United States Department of Energy,(Dec. 10, 1999)].</ref><ref>[http://www.osti.gov/cgi-bin/rd_accomplishments/display_biblio.cgi?id=ACC0077&numPages=48&fp=N Abrikosov, A. A. “New Developments in the Theory of HTSC (High Temperature Superconductors)”, Materials Science Division, Argonne National Laboratory, United States Department of Energy, Office of Energy Research,(Sept. 1994)].</ref><ref>[http://www.fys.uio.no/super/vortex/1957.html Abrikosov, A. A. "On the magnetic properties of superconductors of the second group", Soviet Physics JETP 5, 1174 (1957)], page scans of the original article.</ref><ref>[http://www.anl.gov/Media_Center/News/2003/news031007.htm “Argonne Scientist Wins 2003 Nobel Prize for Physics” McGregor, S., Oct. 7, 2003], press release.</ref>
en:Sleep debt
The control of wakefulness has recently been found to be strongly influenced by the recently discovered protein [[orexin]]. A 2009 study from Washington University in St. Louis has illuminated important connections between sleep debt, [[orexin]], and [[amyloid beta]], with the suggestion that the development of [[Alzheimer's disease]] could hypothetically be a result of chronic sleep debt or excessive periods of wakefulness.<ref name="kang">{{cite journal |title=Amyloid-{beta} Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle |author=J.E. Kang, M.M. Lim, R.J. Bateman, J.J. Lee, L.P. Smyth, J.R. Cirrito, N. Fujiki, S. Nishino and D.M. Holtzman |journal=Science |doi=10.1126/science.1180962 |year=2009 |pmid=19779148 |volume=326 |issue=5955 |pages=1005–7 |pmc=2789838}}</ref>
en:Chuck Knipp
Lesser-known works are his assortment of characters in an imaginary transsexual [[drag show]], a continuing web-based series,<ref>Transy Radio -{"http://www.mmmhellooo.com/2008/08/transsexual-rad.html"}</ref> featuring characters Sissy St James, Mrs. Valerie Valingtimes, Mavis McDougall, Wanda Melon, Lindsey the Mediator, "Placidia the Robot Transy" and the "Bitter Comic". Valerie Valingtimes was recently featured as the voice of a flight attendant in a remix on Rupaul's Drag Race. (Season 7, Episode 2).
en:Linezolid
[[File:Linezolid showing oxazolidinone pharmacophore.svg|thumb|left|Numbered structure of linezolid, showing the [[pharmacophore]] required for good activity (in blue) and desirable structural features (in orange).|alt=Skeletal formula of N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide, highlighting the morpholino and fluoro groups in orange, with the rest in blue. The carbon atoms of the parent chain are numbered.]]
en:John Wesley Hardin
* May 1873: Hardin killed Dewitt County Texas ex-{?}Deputy Sheriff Morgan and later killed Dewitt County Sheriff Jack Helms<ref name="Hardin Autobiography" />{{rp|79–82}}
en:List of regular polytopes and compounds
A projective regular (''n''+1)-polytope exists when an original regular ''n''-spherical tessellation, {p,q,...}, is [[centrally symmetric]]. Such a polytope is named hemi-{p,q,...}, and contain half as many elements. Coxeter gives a symbol {p,q,...}/2, while McMullen writes {p,q,...}h/2 with ''h'' as the [[coxeter number]].<ref>[https://books.google.com/books?id=JfmlMYe6MJgC&lpg=PA163&ots=IGcpn3wv_C&dq=Hemi-24-cell%20abstract%20regular%20polytope&pg=PA164#v=onepage&q=Hemi-24-cell&f=false Abstract regular polytopes, p. 162-165]</ref>
en:Schiff base
Schiff bases can be synthesized from an [[Aliphatic amine|aliphatic]] or [[aromatic]] [[amine]] and a [[carbonyl]] compound by [[nucleophilic addition]] forming a [[hemiaminal]], followed by a [[dehydration reaction|dehydration]] to generate an [[imine]]. In a typical reaction, 4,4'-diaminodiphenyl ether reacts with ''o''-[[vanillin]]:<ref>{{Cite journal| last = Jarrahpour| first = A. A.|author2=M. Zarei | title = Synthesis of 2-({[4-(4-{[(E)-1-(2-hydroxy-3-methoxyphenyl)methylidene amino}phenoxy)phenyl imino}methyl)- 6 -methoxy phenol| journal = Molbank| volume = M352| date = February 24, 2004| url = http://www.mdpi.net/molbank/molbank2004/m0352.htm| issn =1422-8599| accessdate = February 22, 2010}}</ref>
en:Afrikaner Broederbond
|-{Dr JS Gericke]Kosie
en:BSD Daemon
`--{__________)
en:Arthur Lee (musician)
Lee did not re-emerge until 1992, with a new album entitled ''Arthur Lee & Love -{Five String Serenade}'' on the French New Rose label. The title track, "Five String Serenade", was later recorded by [[Mazzy Star]] and [[Jack White]] of [[The White Stripes]]. The album also featured a new artist he discovered from San Francisco, Keith Farrish aka Demian X Diamond. He performed live around this time in Paris, London and Liverpool. In 1993 he played shows in New York and England. The following year he released a 45rpm single, "Girl on Fire" backed with "Midnight Sun", on Distortions Records. He began to tour regularly with a backup band comprising former members of Das Damen, and LA group [[Baby Lemonade]]. In 1995, Rhino Records released the compilation ''Love Story'', a two-disc set with extensive liner notes which chronicled the period 1966–1972, and reignited interest in the band. In fact, the original Love planned to reform and tour in promotion of the compilation, but Arthur's legal troubles prevented this.
en:Bobby Troup
* "Jaded Joker Theme" theme composed by Bobby Troup-1959 episode of "Perry Mason" -{The Case of Jaded Joker. co star Frankie Laine}
en:PDTV
'''PDTV''' is an [[abbreviation]] short for ''Pure Digital Television''.<ref>{{cite journal |last=Roberts |first=Rex |title=Film Review: The Intouchables |date=July 2012 |journal=Film Journal International |volume=115 |issue=7 |page=99 |url=http://www.filmjournal.com/filmjournal/content_display/reviews/specialty-releases/e3i170baf631729abb59db7226f4fcb4d08}}</ref> Often seen as part of the filename of [[TV]] shows shared through [[Peer-to-peer file sharing|P2P]] and [[Warez_scene|The Scene]] FTP systems on the [[Internet]]. In this case, PDTV refers not to container, bitrate or dimensions of the video, but the digital nature of the capture source.<ref>{{cite web |url= |title=John.Doe.S01E13.PDTV.XviD.Internal-SFM nfo file |date=2003-02-01 |author=SFM |quote=The PDTV label is given to releases with purely digital sources with direct digital stream extraction such as via a DVB-{S,T} pci card or a HDTV card. This includes non-HDTV resolution digital transmissions such as the Enhanced Digital TV format used by Fox that is captured with an HDTV card. This does NOT include captures from a digital source with an intermediate analog conversion, e.g. a digital satellite receiver box with S-Video out to a capture card.}}</ref><ref>{{cite web |url=http://scenerules.irc.gs/t.html?id=2002_TV.nfo |title=TV Release Rules 2003 |date=2002-11-16}}</ref> Non Scene European rippers often use the label '''DVBRip''' or ''DVB-rip'' to specify a purely digital rip of a [[Digital Video Broadcast]] (DVB), however all Scene groups use standardized labeling.
en:Chlorophyll a
| SystematicName = Magnesium [methyl (3S,4S,21R)-14-ethyl-4,8,13,18-tetramethyl-20-oxo-3-(3-oxo-3-{[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]oxy}propyl)-9-vinyl-21-phorbinecarboxylatato(2-)-κ2N,N']
en:Acarbose
| synonyms = (2''R'',3''R'',4''R'',5''S'',6''R'')-5-{[(2''R'',3''R'',4''R'',5''S'',6''R'')-5- {[(2''R'',3''R'',4''S'',5''S'',6''R'')-3,4-dihydroxy-6-methyl- 5-{[(1''S'',4''R'',5''S'',6''S'')-4,5,6-trihydroxy-3- (hydroxymethyl)cyclohex-2-en-1-yl]amino} tetrahydro-2''H''-pyran-2-yl]oxy}-3,4-dihydroxy- 6-(hydroxymethyl)tetrahydro-2''H''-pyran-2-yl]oxy}- 6-(hydroxymethyl)tetrahydro-2''H''-pyran-2,3,4-triol
en:Methyl orange
| PIN = Sodium 4-{[4-(dimethylamino)phenyl]diazenyl}benzene-1-sulfonate
en:Rodez
|-{
en:Song structure
Intro-{Verse-Chorus}{Verse-Chorus}-Middle 8-{Chorus}-{Chorus}-(Outro)
en:Transforming growth factor
--><ref name="dysregmarfan">{{cite journal | last1 = Matt | first1 = P | last2 = Schoenhoff | first2 = F | last3 = Habashi | first3 = J | last4 = Holm | first4 = T | last5 = Van Erp | first5 = C | last6 = Loch | first6 = D | last7 = Carlson | first7 = OD | last8 = Griswold | first8 = BF | last9 = Fu | first9 = Q | last10 = De Backer | first10 = J | last11 = Loeys | first11 = B | last12 = Huso | first12 = DL | last13 = McDonnell | first13 = NB | last14 = Van Eyk | first14 = JE | last15 = Dietz | first15 = HC | date = Aug 2009 | title = Circulating transforming growth factor-{beta} in Marfan syndrome | url = | journal = Circulation | volume = 120 | issue = 6| pages = 526–32 | pmid = 19635970 | doi=10.1161/CIRCULATIONAHA.108.841981 | pmc=2779568}}</ref><ref name="popmarfan">[http://sciencenow.sciencemag.org/cgi/content/full/2008/625/3?etoc Inhibiting TGF to help Marfan]</ref><!--
en:Ranitidine
| synonyms = Dimethyl [(5-{[(2-{[1-(methylamino)- 2-nitroethenyl]amino}ethyl)sulfanyl] methyl}furan-2-yl)methyl]amine
en:Lisinopril
| synonyms = (2''S'')-1-[(2''S'')-6-amino-2-{[(1''S'')-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
en:Thymidine kinase
<ref name="Byun_2006a">{{cite journal |vauthors=Byun Y, Thirumamagal BT, Yang W, Eriksson S, Barth RF, Tjarks W |title=Preparation and biological evaluation of 10B-enriched 3-[5-{2-(2,3-dihydroxyprop-1-yl)-o-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors |journal=Journal of Medicinal Chemistry |volume=49 |issue=18 |pages=5513–23 |year=2006 |pmid=16942024 |doi=10.1021/jm060413w |url=}}</ref>
en:Random password generator
| journal = Proceedings of the 17th {NIST}-{NCSC} National Computer Security Conference
en:Machine that always halts
It is not required that the machine be entirely free of looping capabilities, however, to guarantee halting. If we restrict loops to be of a predictably finite size (like the FOR loop in [[BASIC]]), we can express all of the [[primitive recursive functions]] (Meyer and Ritchie, 1967). An example of such a machine is provided by the [[toy programming language]] PL-{GOTO} of Brainerd and Landweber (1974).
en:List of Latin legal terms
|-{Inter alias}
en:Epidermal growth factor receptor
*[[PTPRK]],<ref name="pmid15899872">{{cite journal | vauthors = Wang SE, Wu FY, Shin I, Qu S, Arteaga CL | title = Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function | journal = Molecular and Cellular Biology | volume = 25 | issue = 11 | pages = 4703–15 | date = June 2005 | pmid = 15899872 | pmc = 1140650 | doi = 10.1128/MCB.25.11.4703-4715.2005 }}</ref>
en:Beauveria bassiana
The species is named after the [[Italy|Italian]] [[entomologist]] [[Agostino Bassi]], who discovered it in 1815 as the cause of the muscardine disease which then led to carriers transmitting it by airborne means. It was formerly also known as ''Tritirachium shiotae''. The name ''B. bassiana'' has long been used to describe a [[species complex]] of morphologically similar and closely related [[isolates]]. Rehner and Buckley <ref>{{cite journal|vauthors=Rehner SA, Buckley E |journal=Mycologia |year=2005 |title=A Beauveria phylogeny inferred from nuclear ITS and EF1-{alpha} sequences: evidence for cryptic diversification and links to Cordyceps teleomorphs |volume=97 |pages=84–98 |pmid=16389960 |issue=1 |doi=10.3852/mycologia.97.1.84}}</ref> have shown that ''B. bassiana'' consists of many distinct lineages that should be recognized as distinct phylogenetic species and the genus ''[[Beauveria]]'' was redescribed with a proposed type for ''B. bassiana'' in 2011.<ref>{{cite journal | last1 = Rehner | first1 = Stephen A. | last2 = Minnis | first2 = Andrew M. | last3 = Sung | first3 = Gi-Ho | last4 = Luangsaard | first4 = J. Jennifer | last5 = Devotto | first5 = Luis | last6 = Humber | first6 = Richard A. | year = 2011 | title = Phylogeny and systematics of the anamorphic, entomopathogenic genus ''Beauveria'' | url = | journal = Mycologia | volume = 103 | issue = | pages = 1055–1073 | doi=10.3852/10-302}}</ref> In light of this work and the known existence of [[cryptic species]], it is important to characterise [[Primary isolate|isolate]]s used to develop [[biological insecticides]].
en:List of songs about London
* "Stop London Sinking" by Si-{cut}.db ([[Douglas Benford]])
en:Terconazole
Terconazole has the chemical formula C26H31Cl2N5O3. The chemical name for terconazole is 1-{[(2''S'',4''S'')-2-(2,4-dichlorophenyl)-4-{[''p''-(4-isopropyl-1-piperazinyl)phenoxy]methyl}-1,3-dioxolan-2-yl]methyl}-1''H''-1,2,4-triazole. Terconazole has a melting point of 126.3 °C (259.34 °F). The molecular weight of terconazole is 532.462 g/mol. Terconazole is synthesized using two chemical compounds: ''cis''-[2(bromomethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl] methyl benzoate and the sodium salt of triazole, created by mixing [[triazole]] with [[sodium hydride]]. These are put in a solution and catalyzed using [[dimethyl sulfate]] at 1300 °C (2372 °F) to give many different types of triazole derivatives.<ref name="Cauwenbergh" /> These are purified using alcohol and [[chromatography]]. Terconazole is non-reactive except when exposed to strong oxidizing agents or strong bases due to the nitrogen attached to the triazole ring. It has been found to be photosensitive.<ref>{{cite journal|last1=Fromtling|first1=RA|title=Overview of Medically Important Antifungal Azole Derivatives|journal=Clinical Microbiology Reviews|date=April 1988|volume=1|issue=2|pages=187–217|pmid=3069196|pmc=358042}}</ref>
en:Melphalan
| synonyms = (2''S'')-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid
en:Methyl red
| PIN = 2-{[4-(Dimethylamino)phenyl]diazenyl}benzoic acid
en:List of fictional actors
* Zallia Z. Fairchild, Silent screen actor who tried to scare away production of [[Sandy Duncan]] movie so as not to destroy his film studio/home.-{Sandy Duncan's Jekyll and Hyde} "The New Scooby-Doo Movies".
en:Edge disjoint shortest pair algorithm
Assign S = V-{A}, where V is the set of vertices in the given graph.
en:Combinatorial design
:Notice that in the following example of a 3-{12,{4,6},1) design based on the set ''X'' = {1,2,...,12}, some pairs appear four times (such as 1,2) while others appear five times (6,12 for instance).<ref>{{harvnb|Colbourn|Dinitz|2007|loc=pg. 658, Example 63.5}}</ref>
en:Joseph Wedderburn
In 1905, Wedderburn published a paper that included three claimed proofs of a theorem stating that a noncommutative [[Finite set|finite]] [[division ring]] could not exist. The proofs all made clever use of the interplay between the [[group scheme|additive group]] of a finite [[division algebra]] ''A'', and the [[multiplicative group]] ''A''* = ''A''-{0}. Parshall (1983) notes that the first of these three proofs had a gap not noticed at the time. Meanwhile, Wedderburn's Chicago colleague Dickson also found a proof of this result but, believing Wedderburn's first proof to be correct, Dickson acknowledged Wedderburn's priority. But Dickson also noted that Wedderburn constructed his second and third proofs only after having seen Dickson's proof. Parshall concludes that Dickson should be credited with the first correct proof.
en:Chlorophyll b
| SystematicName = Magnesium [methyl (3S,4S,21R)-14-ethyl-13-formyl-4,8,18-trimethyl-20-oxo-3-(3-oxo-3-{[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]oxy}propyl)-9-vinyl-21-phorbinecarboxylatato(2-)-κ2N,N']
en:Sober (worm)
* W32/Sober-{X-Z}
en:CCL2
CCL2 can be found at the sites of tooth eruption and bone degradation. In the bone, CCL2 is expressed by mature [[osteoclast]]s and [[osteoblast]]s and it is under control of nuclear factor κB (NFκB). In the human osteoclasts, CCL2 and [[RANTES]] (regulated on activation normal T cell expressed and secreted). Both MCP-1 and RANTES induce formation of [[tartrate resistant acid phosphatase|TRAP-positive]], multinuclear cells from M-CSF-treated monocytes in the absence of RANKL, but produced osteoclasts that lacked [[cathepsin|cathepsin K]] expression and resorptive capacity. It is proposed that CCL2 and RANTES act as [[autocrine]] loop in human osteoclast [[cell differentiation|differentiation]].<ref name="Kim">{{cite journal | vauthors = Kim MS, Day CJ, Morrison NA | title = MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation | journal = The Journal of Biological Chemistry | volume = 280 | issue = 16 | pages = 16163–9 | date = Apr 2005 | pmid = 15722361 | pmc = | doi = 10.1074/jbc.M412713200 }}</ref>
en:Canavanine
| SystematicName = (2''S'')-2-amino-4-{[(diaminomethylidene)amino]oxy}butanoic acid
en:Isochrysis galbana
*[http://www.plantphysiol.org/cgi/reprint/135/2/859 www.plantphysiol.org] Expression of the Isochrysis C18-{Delta}9 Polyunsaturated Fatty Acid Specific Elongase Component Alters Arabidopsis Glycerolipid Profiles'''(pdf)'''
en:Security Identifier
<code>S-1-5-80-{SHA-1(service name in upper case)}</code>
en:Posaconazole
| synonyms = 4-{4-[4-(4-{[(5''R'')-5-(2,4-difluorophenyl)-5-(1''H''-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2''S'',3''S'')-2-hydroxypentan-3-yl]-4,5-dihydro-1''H''-1,2,4-triazol-5-one
en:Vildagliptin
| synonyms = (2''S'')-1-{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile
en:Isoleucine (data page)
|synonyms={2/α}-amino-{3/β}-methylvaleric acid 3-methyl-{/erythro-}norvaline Amino-sec-butyl-acetic acid Amino(1-methylpropyl)-acetic acid
en:La Ronde (amusement park)
|-{
en:Lesional demyelinations of the central nervous system
According to the view of most researchers, a special subset of [[lymphocyte]]s, called [[T helper cell]]s, specifically Th1 and Th17,<ref>{{cite journal |vauthors=Fransson ME, Liljenfeldt LS, Fagius J, Tötterman TH, Loskog AS |title=The T-cell pool is anergized in patients with multiple sclerosis in remission |journal= Immunology|volume= 126|issue= 1|pages= 92–101|year= 2009|pmid=18624727 |doi=10.1111/j.1365-2567.2008.02881.x |pmc=2632699}}</ref> play a key role in the development of the lesion. Under normal circumstances, these [[lymphocyte]]s can distinguish between self and non-self. However, in a person with MS, these cells recognize healthy parts of the central nervous system as foreign and attack them as if they were an invading virus, triggering [[inflammation|inflammatory]] processes and stimulating other immune cells and soluble factors like [[cytokine]]s and [[antibody|antibodies]]. Many of the myelin-recognizing T cells belong to a terminally differentiated subset called co-stimulation-independent effector-memory T cells.<ref name= "Markovic-Plese">{{cite journal |vauthors=Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R |title=CD4+CD28- costimulation-independent T cells in multiple sclerosis |journal=J. Clin. Invest. |volume=108 |issue=8 |pages=1185–94 |date=October 2001 |pmid=11602626 |pmc=209525 |doi=10.1172/JCI12516}}</ref><ref name= "Wulff">{{cite journal |vauthors=Wulff H, Calabresi PA, Allie R, etal |title=The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS |journal=J. Clin. Invest. |volume=111 |issue=11 |pages=1703–13 |date=June 2003 |pmid=12782673 |pmc=156104 |doi=10.1172/JCI16921}}</ref><ref name= "Rus">{{cite journal |vauthors=Rus H, Pardo CA, Hu L, etal |title=The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=102 |issue=31 |pages=11094–9 |date=August 2005 |pmid=16043714 |pmc=1182417 |doi=10.1073/pnas.0501770102 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=16043714}}</ref><ref name= "BeetonNeuroscientist">{{cite journal |vauthors=Beeton C, Chandy KG |title=Potassium channels, memory T cells, and multiple sclerosis |journal=Neuroscientist |volume=11 |issue=6 |pages=550–62 |date=December 2005 |pmid=16282596 |doi=10.1177/1073858405278016 |url=http://nro.sagepub.com/cgi/pmidlookup?view=long&pmid=16282596}}</ref><ref name= "Okuda">{{cite journal |vauthors=Okuda Y, Okuda M, Apatoff BR, Posnett DN |title=The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis |journal=J. Neurol. Sci. |volume=235 |issue=1-2 |pages=11–7 |date=August 2005 |pmid=15972217 |doi=10.1016/j.jns.2005.02.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-510X(05)00108-5}}</ref><ref name= "Krakauer">{{cite journal |vauthors=Krakauer M, Sorensen PS, Sellebjerg F |title=CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis |journal=J. Neuroimmunol. |volume=181 |issue=1-2 |pages=157–64 |date=December 2006 |pmid=17081623 |doi=10.1016/j.jneuroim.2006.09.006 |url=http://linkinghub.elsevier.com/retrieve/pii/S0165-5728(06)00372-9}}</ref><ref name= "Ratts">{{cite journal |vauthors=Ratts RB, Karandikar NJ, Hussain RZ, etal |title=Phenotypic characterization of autoreactive T cells in multiple sclerosis |journal=J. Neuroimmunol. |volume=178 |issue=1-2 |pages=100–10 |date=September 2006 |pmid=16901549 |doi=10.1016/j.jneuroim.2006.06.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0165-5728(06)00226-8}}</ref><ref name= "Haegele">{{cite journal |vauthors=Haegele KF, Stueckle CA, Malin JP, Sindern E |title=Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls |journal=J. Neuroimmunol. |volume=183 |issue=1-2 |pages=168–74 |date=February 2007 |pmid=17084910 |doi=10.1016/j.jneuroim.2006.09.008 |url=http://linkinghub.elsevier.com/retrieve/pii/S0165-5728(06)00376-6}}</ref><ref name= "Jilek">{{cite journal |vauthors=Jilek S, Schluep M, Rossetti AO, etal |title=CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis |journal=Clin. Immunol. |volume=123 |issue=1 |pages=105–13 |date=April 2007 |pmid=17188575 |doi=10.1016/j.clim.2006.11.004 |url=http://linkinghub.elsevier.com/retrieve/pii/S1521-6616(06)00946-6}}</ref><ref name= "Miyazaki">{{cite journal |vauthors=Miyazaki Y, Iwabuchi K, Kikuchi S, etal |title=Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis |journal=Mult. Scler. |volume=14 |issue=8 |pages=1044–55 |date=September 2008 |month= |pmid=18573819 |doi=10.1177/1352458508092809 |url=http://msj.sagepub.com/cgi/pmidlookup?view=long&pmid=18573819}}</ref><ref name= "Lünemann">{{cite journal |author=Lünemann JD, Jelcić I, Roberts S|title=EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2 |journal=J. Exp. Med. |volume=205 |issue=8 |pages=1763–73 |date=August 2008 |pmid=18663124 |pmc=2525578 |doi=10.1084/jem.20072397 |url=http://www.jem.org/cgi/pmidlookup?view=long&pmid=18663124|display-authors=etal}}</ref> Recently other type of immune cells, [[B Cell]]s, have been also implicated in the pathogenesis of MS<ref>{{cite journal |vauthors=Hauser SL, Waubant E, Arnold DL, etal |title=B-cell depletion with rituximab in relapsing-remitting multiple sclerosis |journal=N Engl J Med. |volume=358 |issue=7 |pages=676–88 |date=February 2008 |pmid=18272891 |doi=10.1056/NEJMoa0706383 }}</ref> and in the degeneration of the axons.<ref name="physorg.com">[http://www.physorg.com/news80230112.html Cause of nerve fiber damage in multiple sclerosis identified]</ref>
en:Begaljica
;Censuses<ref>Књига 9, ''Становништво, упоредни преглед броја становника 1948, 1953, 1961, 1971, 1981, 1991, 2002, подаци по насељима'', [http://webrzs.stat.gov.rs/axd/index.php Републички завод за статистику], Београд, мај 2004, -{ISBN 86-84433-14-9}</ref>
en:CHAPS detergent
| SystematicName = 3-{Dimethyl[3-(4-{5,9,16-trihydroxy-2,15- 
en:Gusperimus
* 7-{(Aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amino]]- 1-hydroxy-2-oxoethyl]heptanamide,
en:Topoisomerase inhibitor
*{{cite journal |vauthors=Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y | year = 2006 | title = Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity | url = | journal = Mol. Pharmacol. | volume = 70 | issue = | pages = 1109–1120 | doi=10.1124/mol.106.024372}}
en:José Gabriel Funes
|11HUGS: The 11 Mpc H-{alpha} and ultraviolet galaxy survey.
en:José Gabriel Funes
|An H-{alpha} imaging survey of galaxies in the local 11 Mpc volume.
en:Blob detection
| title=Shape-adapted smoothing in estimation of 3-{D} depth cues from affine distortions of local 2-{D} structure
en:Paddy Bradley
*A. {{Note label|scoring|A1|1}}{{Note label|scoring|A2|2}}Scores are recorded in the format {goal total}-{point total}; a goal is where the ball goes under the crossbar and a point is where the ball goes over the crossbar. Each goal equals three points. For example, 2-38 = 2 goals and 38 points, making a total of 2 x 3 + 38 = 44 points. See [[Gaelic football#Scoring|GAA scoring rules]] for more information.
en:Saccharopine
| ImageName = Stereo, skeletal formula of saccharopine ((2S)-2-{[(5S)-5-aminopentyl]amino})
en:Hypusine
| ImageName = Stereo, partially condensed, skeletal formula of hypusine ((2S)-2-amino, -6-{[(2S)-2-hydroxybutyl]amino})
en:Hypusine
| CASNo_Comment = (2''S'')-2-Amino, -6-{[(2''R'')-2-hydroxybutyl]amino}
en:Hypusine
| PubChem2_Comment = (2''S'')-2-Amino, -6-{[(2''R'')-2-hydroxybutyl]amino}
en:Hypusine
| PubChem3_Comment = (2''S'')-2-Amino, -6-{[(2''S'')-2-hydroxybutyl]amino}
en:Hypusine
| ChemSpiderID2_Comment = (2''S'')-2-Amino, -6-{[(2''R'')-2-hydroxybutyl]amino}
en:Hypusine
| ChemSpiderID3_Comment = (2''S'')-2-Amino, -6-{[(2''S'')-2-hydroxybutyl]amino}
en:Benzethonium chloride
| PIN = ''N''-Benzyl-''N'',''N''-dimethyl-2-{2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethanaminium chloride
en:Benzethonium chloride
| SystematicName = Benzyldimethyl(2-{2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethyl)azanium chloride
en:Sandy Bridge
|rowspan=4|[[Direct Media Interface|DMI 2.0]] PCIe 2.0<ref>{{cite web | url= http://ark.intel.com/products/63697/Intel-Core-i7-3930K-Processor-{12M-Cache-up-to-3_80-GHz} | title=Intel® Core™ i7-3930K Processor (12M Cache, up to 3.80 GHz) | accessdate=29 March 2012 }}</ref>
en:Sankar Ghosh
Jimi, E. ''et al.'' Activation of NF-{kappa}B promo tes the transition of large, CD43+ pre-B cells to small, CD43- pre-B cells. Int Immunol. 20 May 2005
en:Texistepec language
:/N-{ʔ,h}V/ → [{ʔ,h} Ṽ]
en:Texistepec language
:/N-{w,j}V/ → [{w̃, j̃}Ṽ]
en:Texistepec language
:/N-{s, ʃ}/ → [{z, ʒ}]
en:Lipoarabinomannan
LAMS capped with phosphoinositol are typically found in nonpathogenic species including [[M. smegmatis]]. In contrast to ManLAMs, PILAMs are pro-inflammatory. [[CD14]], a recognition receptor present on macrophages, associate with [[toll-like receptor 2]] (TLR2) is described to be a receptor for PILAM.<ref name=Yu1998>{{cite journal |author= Yu, Weiming|title= Soluble CD141-152 Confers Responsiveness to Both Lipoarabinomannan and Lipopolysaccharide in a Novel HL-60 Cell Bioassay |journal= Journal of Immunology|volume=161 |issue=8 |pages=4244–4251|year=1998 |pmid=9780199|display-authors=etal}}</ref> Binding of PILAM to the receptor elicits the activation of an intracellular signaling cascade which activates transcription factors that initiate transcription of proinflammatory cytokine genes. This may lead to TNF-α, IL-8, and IL-12 activation and apoptosis of macrophages.<ref name="Yann2003"/><ref name=Vignal2003>{{cite journal |author= Vignal, Cecile|title= Lipomannans, But Not Lipoarabinomannans, Purified from Mycobacterium chelonae and Mycobacterium kansasii Induce TNF-{alpha} and IL-8 Secretion by a CD14-Toll-Like Receptor 2-Dependent Mechanism |journal= Journal of Immunology |volume=171 |issue=4 |pages=10989–10994|year=2003 |pmid=12902506|display-authors=etal}}</ref>
en:Supercontinuum
In 1987 Gomes ''et al.''<ref name="Gomes:1987p990">A. S. L. Gomes, V. L. Dasilva, J. R. Taylor, B. J. Ainslie, and S. P. Craig, ''Picosecond stimulated Raman scattering in P{}O{}-{SiO}{} based single mode optical fibre,'' Opt. Commun. '''64''', 373–378 (1987).</ref> reported cascaded stimulated Raman scattering in a single mode [[Phosphosilicate glass|phosphosilicate based fibre]]. They pumped the fibre with a [[Q-switching|Q-switched]] and mode-locked Nd:YAG, which produced 130 ps pulses with 700 kW peak power. They launched up to 56 kW into the fibre and as a result of the phosphorus achieved a much broader and flatter continuum than had been achieved to that point with silica fibre. A year later Gouveia-Neto ''et al.''<ref name="Neto:1988332">A. Gouveia-Neto, A. Gomes, and J. Taylor, ''Femto soliton Raman generation,'' IEEE J. Quant. Elect. '''24''', 332–340 (1988).</ref> from the same group published a paper describing the formation and propagation of soliton waves from modulation instability. They used a 1.32 μm Nd:YAG laser which produced 100 ps pulses with 200 W peak power to pump 500 m of single mode fibre with a 7 μm core diameter. The zero dispersion wavelength of the fibre was at 1.30 μm, placing the pump just inside the anomalous dispersion regime. They noted pulses emerging with durations of less than 500 fs (solitons) and as they increased the pump power a continuum was formed stretching from 1.3 to 1.5 μm.
en:EDDS
| PubChem1_Comment = 2-[(2-{[(1''S'')-1-Carboxyethyl]amino}ethyl)amino]
en:EDDS
| PubChem2_Comment = (2''R'')-2-[(2-{[(1''R'')-1-Carboxyethyl]amino}ethyl)amino]
en:EDDS
| PubChem3_Comment = (2''S'')-2-[(2-{[(1''S'')-1-Carboxyethyl]amino}ethyl)amino]
en:EDDS
| PubChem4_Comment = (2''S'')-2-[(2-{[(1''R'')-1-Carboxyethyl]amino}ethyl)amino]
en:EDDS
| ChemSpiderID1_Comment = 2-[(2-{[(1''S'')-1-Carboxyethyl]amino}ethyl)amino]
en:EDDS
| ChemSpiderID2_Comment = (2''R'')-2-[(2-{[(1''R'')-1-Carboxyethyl]amino}ethyl)amino]
en:EDDS
| ChemSpiderID3_Comment = (2''S'')-2-[(2-{[(1''S'')-1-Carboxyethyl]amino}ethyl)amino]
en:Lotaustralin
(2''R'')-2-methyl-2-{[(2''S'',3''R'',4''S'',5''S'',6''R'')-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2''H''-pyran-2-yl]oxy}butanenitrile
en:Allylescaline
| PIN = 2-{3,5-Dimethoxy-4-[(prop-2-en-1-yl)oxy]phenyl}ethan-1-amine
en:Leukotriene A4
| SystematicName = 4-{(2S,3S)-3-[(1E,3E,5Z,8Z)-1,3,5,8-Tetradecatetraen-1-yl]-2-oxiranyl}butanoic acid
en:Beauveria
*{{cite journal | last1 = Rehner | first1 = S. A. | last2 = Buckley | first2 = E. | year = 2005 | title = A Beauveria phylogeny inferred from nuclear ITS and EF1-{alpha} sequences: evidence for cryptic diversification and links to ''Cordyceps'' teleomorphs | url = | journal = Mycologia | volume = 97 | issue = | pages = 84–98 | doi=10.3852/mycologia.97.1.84 | pmid=16389960}}
en:Abimilku
*[http://ib205.tripod.com/budge.html 3 el-Amarna letters: EA 26-([[Tushratta]]), EA 147-(Abimilku)-{'''Obverse'''), and a EA 34 (from King of [[Alashiya]]) ]; [http://www.egiptomania.com/historia/imagen/origen8.jpg EA 147 (Reverse)]; [http://www.egiptomania.com/historia/origen_hebreos.htm Article] ADDS INTERRUPT- REMOVING -->
en:Fenoterol
5-(1-Hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol is a molecule with two different stereogenic centers. Thus, four [[stereoisomer]]s may exist, the (''R'',''R'')-, (''R'',''S'')-, (''S'',''R'')- and (''S'',''S'')-stereoisomers (see the figure below). Fenoterol is a [[racemate]] of the (''R'',''R'')- and the (''S'',''S'')-[[enantiomer]]s. This racemate is 9 to 20 times more effective, as compared to the racemate of the (''R'',''S'')- and (''S'',''R'')-enantiomers.<ref name="Beale und Stephenson">{{cite journal | author = Beale J. P. | author2 = Stephenson N.C. | year = 1972 | title = X-ray analysis of Th 1165 and salbutamol | url = | journal = Journal of Pharmacy and Pharmacology | volume = 24 | issue = | pages = 277–280 }}</ref>
en:Fenoterol
[[File:Fenoterol stereoisomers.svg|thumb|left|265px|Four stereoisomers of 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol]]{{clear left}}
en:Cut-point
*A '''cutting''' of X is a set {p,U,V} where p is a cut-point of X, U and V form a [[Connected space|separation]] of X-{p}.
en:Cut-point
* If K is a continuum with points a,b and K-{a,b} isn't connected, K is homeomorphic to the unit circle.
en:Spiramycin
| synonyms = 2-[(4''R'',5''S'',6''S'',7''R'',9''R'',10''R'',11''E'',13''E'',16''R'')-6-{[(2''S'',3''R'',4''R'',5''S'',6''R'')-5-{[(2''S'',5''S'',6''S'')-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy}-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-10-{[(2''R'',5''S'',6''R'')-5-(dimethylamino)-6-methyloxan-2-yl]oxy}-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
en:Simfibrate
| synonyms = 3-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}propyl 2-(4-chlorophenoxy)-2-methylpropanoate
en:Orange 1
| CASNo_Comment = 4-{2-[(1''E'')-1-ylidene]-1-yl}
en:Orange 1
| PubChem_Comment = 4-{2-[(1''E'')-1-ylidene]-1-yl}
en:Orange 1
| PubChem1_Comment = 4-{2-[(1''Z'')-1-ylidene]-1-yl}
en:Orange 1
| ChemSpiderID_Comment = 4-{2-[(1''E'')-1-ylidene]-1-yl}
en:Orange 1
| ChemSpiderID1_Comment = 4-{2-[(1''Z'')-1-ylidene]-1-yl}
en:TRPV4
A number of TRPV4 agonists and antagonists have been identified since its discovery.<ref>{{cite journal | vauthors = Vincent F, Duncton MA | title = TRPV4 agonists and antagonists | journal = Curr Top Med Chem | volume = 11 | issue = 17 | pages = 2216–26 | year = 2011 | pmid = 21671873 | doi = }}</ref> The discovery of unselective modulators (e.g. antagonist Ruthenium Red) was followed by the apparition of more potent (agonist 4aPDD)<ref>{{cite journal | vauthors = Watanabe H, Davis JB, Smart D, Jerman JC, Smith GD, Hayes P, Vriens J, Cairns W, Wissenbach U, Prenen J, Flockerzi V, Droogmans G, Benham CD, Nilius B | title = Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives | journal = J. Biol. Chem. | volume = 277 | issue = 16 | pages = 13569–77 | date = April 2002 | pmid = 11827975 | doi = 10.1074/jbc.M200062200 }}</ref> or selective (antagonist RN-1734)<ref>{{cite journal | vauthors = Vincent F, Acevedo A, Nguyen MT, Dourado M, DeFalco J, Gustafson A, Spiro P, Emerling DE, Kelly MG, Duncton MA | title = Identification and characterization of novel TRPV4 modulators | journal = Biochem. Biophys. Res. Commun. | volume = 389 | issue = 3 | pages = 490–4 | date = November 2009 | pmid = 19737537 | doi = 10.1016/j.bbrc.2009.09.007 }}</ref> compounds, including some with bioavailability suitable for in vivo pharmacology studies such as agonist GSK1016790A<ref>{{cite journal | vauthors = Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon E, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping NJ, Westfall TD | title = N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I | journal = J. Pharmacol. Exp. Ther. | volume = 326 | issue = 2 | pages = 432–42 | date = August 2008 | pmid = 18499743 | doi = 10.1124/jpet.108.139295 }}</ref> (with ~10 fold selectivity vs TRPV1), and antagonists HC-067047<ref>{{cite journal | vauthors = Everaerts W, Zhen X, Ghosh D, Vriens J, Gevaert T, Gilbert JP, Hayward NJ, McNamara CR, Xue F, Moran MM, Strassmaier T, Uykal E, Owsianik G, Vennekens R, De Ridder D, Nilius B, Fanger CM, Voets T | title = Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 107 | issue = 44 | pages = 19084–9 | date = November 2010 | pmid = 20956320 | pmc = 2973867 | doi = 10.1073/pnas.1005333107 }}</ref> (with ~5 fold selectivity vs hERG and ~10 fold selectivity vs TRPM8) and RN-9893<ref>{{cite journal | vauthors = Wei ZL, Nguyen MT, O'Mahony DJ, Acevedo A, Zipfel S, Zhang Q, Liu L, Dourado M, Chi C, Yip V, DeFalco J, Gustafson A, Emerling DE, Kelly MG, Kincaid J, Vincent F, Duncton MA | title = Identification of orally-bioavailable antagonists of the TRPV4 ion-channel | journal = Bioorg. Med. Chem. Lett. | volume = 25 | issue = 18 | pages = 4011–5 | date = 2015 | pmid=26235950 | doi=10.1016/j.bmcl.2015.06.098}}</ref> (with ~50 fold selectivity vs TRPM8 and ~10 fold selectivity vs M1).
en:Aceclofenac
The drug works by inhibiting the action of cyclooxygenase (COX) that is involved in the production of prostaglandins (PG) which is accountable for pain, swelling, inflammation and fever. The incidence of gastric ulcerogenicity of aceclofenac has been reported to be significantly lower than that of the other frequently prescribed NSAIDs, for instance, 2-folds lesser than naproxen, 4-folds lesser than diclofenac, and 7-folds lesser than indomethacin. Aceclofenac (C16H13Cl2NO4), chemically [(2-{2, 6-dichlorophenyl) amino} phenylacetooxyacetic acid], is a crystalline powder with a molecular weight of 354.19. It is practically insoluble in water with good permeability. It is metabolized in human hepatocytes and human microsomes to form [2-(2',6'-dichloro-4'-hydroxy- phenylamino) phenyl] acetoxyacetic acid as the major metabolite, which is then further conjugated. According to the Biopharmaceutical Classification System (BCS) drug substances are classified to four classes upon their solubility and permeability. Aceclofenac falls under the BCS Class II, poorly soluble and highly permeable drug. <ref name="J.R. Karmokeretal.2016">{{cite journal |last1=Karmoker |first1=J.R. |last2=Sarkar |first2=S. |last3=Joydhar |first3=P. |last4=Chowdhury |first4=S.F.|year=2016 |title=Comparative in vitro equivalence evaluation of some Aceclofenac generic tablets marketed in Bangladesh |journal=The Pharma Innovation Journal |volume=5|pages=03-07|url=http://www.thepharmajournal.com/archives/2016/vol5issue3/PartA/5-1-7.pdf |accessdate=2016-09-01}}</ref>
en:PAK1
The levels of PAK1 activity under various experimental and physiological conditions are inhibited by PP1,<ref>{{cite journal | vauthors = He H, Hirokawa Y, Levitzki A, Maruta H | title = An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies | journal = Cancer Journal | volume = 6 | issue = 4 | pages = 243–8 | date = 1999 | pmid = 11038144 }}</ref> hPIP1,<ref>{{cite journal | vauthors = Xia C, Ma W, Stafford LJ, Marcus S, Xiong WC, Liu M | title = Regulation of the p21-activated kinase (PAK) by a human Gbeta -like WD-repeat protein, hPIP1 | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 98 | issue = 11 | pages = 6174–9 | date = May 2001 | pmid = 11371639 | doi = 10.1073/pnas.101137298 }}</ref> NESH,<ref>{{cite journal | vauthors = Ichigotani Y, Yokozaki S, Fukuda Y, Hamaguchi M, Matsuda S | title = Forced expression of NESH suppresses motility and metastatic dissemination of malignant cells | journal = Cancer Research | volume = 62 | issue = 8 | pages = 2215–9 | date = April 2002 | pmid = 11956071 }}</ref> Merlin,<ref>{{cite journal | vauthors = Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H, Maruta H | title = Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors) | journal = Cancer Letters | volume = 245 | issue = 1-2 | pages = 242–51 | date = January 2007 | pmid = 16540233 | doi = 10.1016/j.canlet.2006.01.018 }}</ref> CRIPak,<ref>{{cite journal | vauthors = Talukder AH, Meng Q, Kumar R | title = CRIPak, a novel endogenous Pak1 inhibitor | journal = Oncogene | volume = 25 | issue = 9 | pages = 1311–9 | date = March 2006 | pmid = 16278681 | doi = 10.1038/sj.onc.1209172 }}</ref> LKB1,<ref>{{cite journal | vauthors = Deguchi A, Miyoshi H, Kojima Y, Okawa K, Aoki M, Taketo MM | title = LKB1 suppresses p21-activated kinase-1 (PAK1) by phosphorylation of Thr109 in the p21-binding domain | journal = The Journal of Biological Chemistry | volume = 285 | issue = 24 | pages = 18283–90 | date = June 2010 | pmid = 20400510 | doi = 10.1074/jbc.M109.079137 }}</ref> Mesalamine,<ref>{{cite journal | vauthors = Khare V, Lyakhovich A, Dammann K, Lang M, Borgmann M, Tichy B, Pospisilova S, Luciani G, Campregher C, Evstatiev R, Pflueger M, Hundsberger H, Gasche C | title = Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1 | journal = Biochemical Pharmacology | volume = 85 | issue = 2 | pages = 234–44 | date = January 2013 | pmid = 23146664 | doi = 10.1016/j.bcp.2012.10.026 }}</ref> Glaucarubinone,<ref>{{cite journal | vauthors = Yeo D, Huynh N, Beutler JA, Christophi C, Shulkes A, Baldwin GS, Nikfarjam M, He H | title = Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases | journal = Cancer Letters | volume = 346 | issue = 2 | pages = 264–72 | date = May 2014 | pmid = 24491405 | doi = 10.1016/j.canlet.2014.01.001 }}</ref> Myricetin,<ref>{{cite journal | vauthors = Iyer SC, Gopal A, Halagowder D | title = Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma | journal = Molecular and Cellular Biochemistry | volume = 407 | issue = 1-2 | pages = 223–37 | date = September 2015 | pmid = 26104578 | doi = 10.1007/s11010-015-2471-6 }}</ref> β-elemene,<ref>{{cite journal | vauthors = Liu JS, Che XM, Chang S, Qiu GL, He SC, Fan L, Zhao W, Zhang ZL, Wang SF | title = β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation | journal = World Journal of Gastroenterology | volume = 21 | issue = 34 | pages = 9945–56 | date = September 2015 | pmid = 26379399 | doi = 10.3748/wjg.v21.i34.9945 }}</ref> miR-7,<ref>{{cite journal | vauthors = Reddy SD, Ohshiro K, Rayala SK, Kumar R | title = MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions | journal = Cancer Research | volume = 68 | issue = 20 | pages = 8195–200 | date = October 2008 | pmid = 18922890 | doi = 10.1158/0008-5472.CAN-08-2103 }}</ref> miR-let-7,<ref>{{cite journal | vauthors = Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X, Zhang Y, Huang Q, Zhang L | title = The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer | journal = Molecular Cancer Research | volume = 11 | issue = 3 | pages = 240–50 | date = March 2013 | pmid = 23339187 | doi = 10.1158/1541-7786.MCR-12-0432 }}</ref> miR-145.<ref>{{cite journal | vauthors = Kou B, Gao Y, Du C, Shi Q, Xu S, Wang CQ, Wang X, He D, Guo P | title = miR-145 inhibits invasion of bladder cancer cells by targeting PAK1 | journal = Urologic Oncology | volume = 32 | issue = 6 | pages = 846–54 | date = August 2014 | pmid = 24954107 | doi = 10.1016/j.urolonc.2014.01.003 }}</ref> In addition, various anti-PAK small molecules such as FRAX1036,<ref>{{cite journal | vauthors = Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, Behnke ML, Huang W, McKew JC, Chernoff J, Forrest WF, Haverty PM, Chin SF, Rakha EA, Green AR, Ellis IO, Caldas C, O'Brien T, Friedman LS, Koeppen H, Rudolph J, Hoeflich KP | title = Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents | journal = Breast Cancer Research | volume = 17 | pages = 59 | date = April 2015 | pmid = 25902869 | doi = 10.1186/s13058-015-0564-5 }}</ref><ref>{{cite journal | vauthors = Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, Duron S, Campbell D, Chernoff J, Field J, Marmorstein R, Kissil JL | title = FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas | journal = The Journal of Biological Chemistry | volume = 288 | issue = 40 | pages = 29105–14 | date = October 2013 | pmid = 23960073 | doi = 10.1074/jbc.M113.510933 }}</ref> OSU-03012,<ref>{{cite journal | vauthors = Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, Kulp SK, Kirschner LS, Saji M, Chen CS, Ringel MD | title = 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase | journal = Molecular Pharmacology | volume = 72 | issue = 5 | pages = 1124–31 | date = November 2007 | pmid = 17673571 | doi = 10.1124/mol.107.037556 }}</ref> and IPA-3<ref>{{cite journal | vauthors = Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR | title = An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase | journal = Chemistry & Biology | volume = 15 | issue = 4 | pages = 322–31 | date = April 2008 | pmid = 18420139 | doi = 10.1016/j.chembiol.2008.03.005 }}</ref> are currently being developed by academia and pharmaceutical industry.<ref>{{cite journal | vauthors = Crawford JJ, Hoeflich KP, Rudolph J | title = p21-Activated kinase inhibitors: a patent review | journal = Expert Opinion on Therapeutic Patents | volume = 22 | issue = 3 | pages = 293–310 | date = March 2012 | pmid = 22404134 | doi = 10.1517/13543776.2012.668758 }}</ref><ref>{{cite journal | vauthors = Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J | title = p21-activated kinase inhibitors | journal = The Enzymes | volume = 34 Pt. B | pages = 157–80 | date = 2013 | pmid = 25034104 | doi = 10.1016/B978-0-12-420146-0.00007-X }}</ref><ref>{{cite journal | vauthors = Eswaran J, Li DQ, Shah A, Kumar R | title = Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations | journal = Clinical Cancer Research | volume = 18 | issue = 14 | pages = 3743–9 | date = July 2012 | pmid = 22595609 | doi = 10.1158/1078-0432.CCR-11-1952 }}</ref>
en:Opine dehydrogenase
:(2S)-2-{[1-(R)-carboxyethyl]amino}pentanoate + NAD+ + H2O L-2-aminopentanoic acid + pyruvate + NADH + H+
en:Opine dehydrogenase
The 3 [[substrate (biochemistry)|substrates]] of this enzyme are [[(2S)-2-{[1-(R)-carboxyethyl]amino}pentanoate]], [[nicotinamide adenine dinucleotide|NAD+]], and [[water|H2O]], whereas its 4 [[product (chemistry)|products]] are [[L-2-aminopentanoic acid]], [[pyruvate]], [[nicotinamide adenine dinucleotide|NADH]], and [[hydrogen ion|H+]].
en:Opine dehydrogenase
This enzyme belongs to the family of [[oxidoreductase]]s, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The [[List of enzymes|systematic name]] of this enzyme class is '''(2S)-2-{[1-(R)-carboxyethyl]amino}pentanoate:NAD+ oxidoreductase (L-aminopentanoate-forming)'''. Other names in common use include '''(2S)-2-{[1-(R)-carboxyethyl]amino}pentanoate dehydrogenase (NAD+,''', and '''L-aminopentanoate-forming)'''.
en:Dopamine receptor D3
* PG 01037 <ref name="pmid15689168">{{cite journal | vauthors = Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH | title = Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor | journal = Journal of Medicinal Chemistry | volume = 48 | issue = 3 | pages = 839–48 | date = February 2005 | pmid = 15689168 | doi = 10.1021/jm049465g }}</ref><ref>{{cite journal | vauthors = Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, Voulalas PJ | title = Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 333 | issue = 3 | pages = 854–64 | date = June 2010 | pmid = 20228156 | doi = 10.1124/jpet.109.165084 }}</ref>
en:Melanin-concentrating hormone receptor 1
* [[SNAP-94847]]<ref name="pmid17237257">{{cite journal | vauthors = David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, Craig DA, Zhong H, Swanson CJ, Hegde LG, Ping XI, Dong D, Marzabadi MR, Gerald CP, Hen R | title = Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 321 | issue = 1 | pages = 237–48 | date = Apr 2007 | pmid = 17237257 | doi = 10.1124/jpet.106.109678 }}</ref>
en:Glycoprotein 2-beta-D-xylosyltransferase
:UDP-D-xylose + N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N- acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D- mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D- glucosaminyl}asparagine UDP + N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N- acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-[beta-D- xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl- (1->4)-N-acetyl-beta-D-glucosaminyl}asparagine
en:Glycoprotein 2-beta-D-xylosyltransferase
The 5 [[substrate (biochemistry)|substrates]] of this enzyme are [[UDP-D-xylose]], [[N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-]], [[acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-]], [[mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-]], and [[glucosaminyl}asparagine]], whereas its 5 [[product (chemistry)|products]] are [[uridine diphosphate|UDP]], [[N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-]], [[acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]]-[[beta-D-]], [[xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-]], and [[(1->4)-N-acetyl-beta-D-glucosaminyl}asparagine]].
en:Glycoprotein 2-beta-D-xylosyltransferase
This enzyme belongs to the family of [[glycosyltransferase]]s, specifically the pentosyltransferases. The [[List of enzymes|systematic name]] of this enzyme class is '''UDP-D-xylose:glycoprotein (D-xylose to the 3,6-disubstituted mannose of N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-a cetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-man nosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glu cosaminyl}asparagine) 2-beta-D-xylosyltransferase'''. Other names in common use include '''beta1,2-xylosyltransferase''', '''UDP-D-xylose:glycoprotein (D-xylose to the 3,6-disubstituted mannose''', '''of''', '''4-N-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-''', '''acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-''', '''mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-''', and '''glucosaminyl}asparagine) 2-beta-D-xylosyltransferase'''. This enzyme participates in [[glycan structures - biosynthesis 1]].
en:Glycoprotein 3-alpha-L-fucosyltransferase
:GDP-L-fucose + N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N- acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D- mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D- glucosaminyl}asparagine GDP + N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N- acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D- mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L- fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl}asparagine
en:Glycoprotein 3-alpha-L-fucosyltransferase
The 5 [[substrate (biochemistry)|substrates]] of this enzyme are [[GDP-L-fucose]], [[N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-]], [[acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-]], [[mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-]], and [[glucosaminyl}asparagine]], whereas its 5 [[product (chemistry)|products]] are [[guanosine diphosphate|GDP]], [[N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-]], [[acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-]], [[mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-]], and [[fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl}asparagine]].
en:Glycoprotein 3-alpha-L-fucosyltransferase
This enzyme belongs to the family of [[glycosyltransferase]]s, specifically the hexosyltransferases. The [[List of enzymes|systematic name]] of this enzyme class is '''GDP-L-fucose:glycoprotein (L-fucose to asparagine-linked N-acetylglucosamine of N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-a cetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-man nosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glu cosaminyl}asparagine) 3-alpha-L-fucosyl-transferase'''. Other names in common use include '''GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1,3-fucosyltransferase''', '''GDP-L-Fuc:Asn-linked GlcNAc alpha1,3-fucosyltransferase''', '''GDP-fucose:beta-N-acetylglucosamine (Fuc to''', '''(Fucalpha1->6GlcNAc)-Asn-peptide) alpha1->3-fucosyltransferase''', '''GDP-L-fucose:glycoprotein (L-fucose to asparagine-linked''', '''N-acetylglucosamine of''', '''4-N-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-''', '''acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-''', '''mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-''', and '''glucosaminyl}asparagine) 3-alpha-L-fucosyl-transferase'''. This enzyme participates in [[glycan structures - biosynthesis 1]].
en:Glycoprotein 6-alpha-L-fucosyltransferase
:GDP-L-fucose + N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N- acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D- mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D- glucosaminyl}asparagine GDP + N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N- acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D- mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L- fucosyl-(1->6)]-N-acetyl-beta-D-glucosaminyl}asparagine
en:Glycoprotein 6-alpha-L-fucosyltransferase
The 5 [[substrate (biochemistry)|substrates]] of this enzyme are [[GDP-L-fucose]], [[N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-]], [[acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-]], [[mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-]], and [[glucosaminyl}asparagine]], whereas its 5 [[product (chemistry)|products]] are [[guanosine diphosphate|GDP]], [[N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-]], [[acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-]], [[mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-]], and [[fucosyl-(1->6)]-N-acetyl-beta-D-glucosaminyl}asparagine]].
en:Glycoprotein 6-alpha-L-fucosyltransferase
This enzyme belongs to the family of [[glycosyltransferase]]s, specifically the hexosyltransferases. The [[List of enzymes|systematic name]] of this enzyme class is '''GDP-L-fucose:glycoprotein (L-fucose to asparagine-linked N-acetylglucosamine of N4-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-a cetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-man nosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glu cosaminyl}asparagine) 6-alpha-L-fucosyltransferase'''. Other names in common use include '''GDP-fucose-glycoprotein fucosyltransferase''', '''GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1->6fucosyltransferase''', '''GDP-L-fucose-glycoprotein fucosyltransferase''', '''glycoprotein fucosyltransferase''', '''guanosine diphosphofucose-glycoprotein fucosyltransferase''', '''GDP-L-fucose:glycoprotein (L-fucose to asparagine-linked''', '''N-acetylglucosamine of''', '''4-N-{N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-''', '''acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-''', '''mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-''', '''glucosaminyl}asparagine) 6-alpha-L-fucosyltransferase''', and '''FucT'''. This enzyme participates in 3 [[metabolism|metabolic pathways]]: [[n-glycan biosynthesis]], [[keratan sulfate biosynthesis]], and [[glycan structures - biosynthesis 1]].
en:Harris affine region detector
Mikolajczyk and Schmid (2002) first described the Harris affine detector as it is used today in [https://hal.inria.fr/inria-00548252/document''An Affine Invariant Interest Point Detector''].<ref name=miko02>[http://vasc.ri.cmu.edu/~hebert/04AP/mikolajc_ECCV2002.pdf Mikolajcyk, K. and Schmid, C. 2002. An affine invariant interest point detector. In ''Proceedings of the 8th International Conference on Computer Vision'', Vancouver, Canada.]</ref> Earlier works in this direction include use of [[affine shape adaptation]] by Lindeberg and Garding for computing affine invariant image descriptors and in this way reducing the influence of perspective image deformations,<ref name=lindgard97>[http://www.nada.kth.se/~tony/abstracts/LG94-ECCV.html T. Lindeberg and J. Garding (1997). "Shape-adapted smoothing in estimation of 3-{D} depth cues from affine distortions of local 2-{D} structure". Image and Vision Computing 15: pp 415—434.]</ref> the use affine adapted feature points for wide baseline matching by Baumberg<ref>[http://citeseer.ist.psu.edu/baumberg00reliable.html A. Baumberg (2000). "Reliable feature matching across widely separated views". Proceedings of IEEE Conference on Computer Vision and Pattern Recognition: pages I:1774—1781.]</ref> and the first use of scale invariant feature points by Lindeberg;<ref name=lin94>[http://www.nada.kth.se/~tony/book.html Lindeberg, Tony, Scale-Space Theory in Computer Vision, Kluwer Academic Publishers, 1994], ISBN 0-7923-9418-6</ref><ref name=lin98>[http://www.nada.kth.se/cvap/abstracts/cvap198.html T. Lindeberg (1998). "Feature detection with automatic scale selection". International Journal of Computer Vision 30 (2): pp 77—116.]</ref><ref>{{cite book
en:Dephospho-(reductase kinase) kinase
:ATP + dephospho-{[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} ADP + {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase}
en:Dephospho-(reductase kinase) kinase
Thus, the two [[substrate (biochemistry)|substrates]] of this enzyme are [[adenosine triphosphate|ATP]] and [[dephospho-{[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase}]], whereas its two [[product (chemistry)|products]] are [[adenosine diphosphate|ADP]] and [[{[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase}]].
en:Dephospho-(reductase kinase) kinase
This enzyme belongs to the family of [[transferase]]s, specifically those transferring a phosphate group to the sidechain [[oxygen]] atom of [[serine]] or [[threonine]] residues in [[protein]]s ([[protein-serine/threonine kinase]]s). The [[List of enzymes|systematic name]] of this enzyme class is '''ATP:dephospho-{[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} phosphotransferase'''. Other names in common use include '''AMP-activated kinase''', '''AMP-activated protein kinase kinase''', '''hydroxymethylglutaryl coenzyme A reductase kinase kinase''', '''hydroxymethylglutaryl coenzyme A reductase kinase kinase''', '''(phosphorylating)''', '''reductase kinase''', '''reductase kinase kinase''', and '''STK30'''.
en:TANK-binding kinase 1
*{{Cite journal |vauthors=Buss H, Dörrie A, Schmitz ML, etal |title=Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. |journal=J. Biol. Chem. |volume=279 |issue= 53 |pages= 55633–43 |year= 2005 |pmid= 15489227 |doi= 10.1074/jbc.M409825200 }}
en:IKBKE
*{{cite journal |vauthors=Buss H, Dörrie A, Schmitz ML, etal |title=Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. |journal=J. Biol. Chem. |volume=279 |issue= 53 |pages= 55633–43 |year= 2005 |pmid= 15489227 |doi= 10.1074/jbc.M409825200 }}
en:PTPRK
Use of short interfering RNA (siRNA) of PTPkappa to reduce PTPkappa protein expression in the mammary epithelial cell line, MCF10A, resulted in increased cell proliferation.<ref name="pmid15899872">{{cite journal | vauthors = Wang SE, Wu FY, Shin I, Qu S, Arteaga CL | title = Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. | journal = Mol Cell Biol | volume = 25 | issue = 11 | pages = 4703–15 | year = 2005 | pmid = 15899872 | pmc = 1140650 | doi = 10.1128/MCB.25.11.4703-4715.2005 }}</ref> PTPkappa expression, conversely, was demonstrated to reduce cell proliferation in Chinese hamster ovary cells.<ref name="pmid16263724">{{cite journal | vauthors = Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ | title = Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. | journal = J Biol Chem | volume = 280 | issue = 52 | pages = 42694–700 | year = 2005 | pmid = 16263724 | pmc = | doi = 10.1074/jbc.M507722200 }}</ref> The mechanism proposed to explain the influence of PTPkappa on cell proliferation is via PTPkappa dephosphorylation of the EGFR on tyrosines 1068 and 1173 directly. The reduction of PTPkappa expression in CHO cells with PTPkappa siRNA increased EGFR phosphorylation.<ref name="pmid16263724">{{cite journal | vauthors = Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ | title = Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. | journal = J Biol Chem | volume = 280 | issue = 52 | pages = 42694–700 | year = 2005 | pmid = 16263724 | pmc = | doi = 10.1074/jbc.M507722200 }}</ref> Therefore, the hypothesis is that PTPkappa functions as a tumor suppressor gene by dephosphorylating and inactivating EGFR.<ref name="pmid16263724">{{cite journal | vauthors = Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ | title = Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. | journal = J Biol Chem | volume = 280 | issue = 52 | pages = 42694–700 | year = 2005 | pmid = 16263724 | pmc = | doi = 10.1074/jbc.M507722200 }}</ref>
en:PTPRK
PTPkappa is expressed in human keratinocytes. TGFβ1 is a growth inhibitor in human keratinocytes. Stimulation of the cultured human keratinocyte cell line, [[HaCaT]], with TGFβ1 increases the levels of PTPkappa (PTPRK) mRNA as assayed by northern blot analysis.<ref name="pmid8941358">{{cite journal | vauthors = Yang Y, Gil M, Byun SM, Choi I, Pyun KH, Ha H | title = Transforming growth factor-beta1 inhibits human keratinocyte proliferation by upregulation of a receptor-type tyrosine phosphatase R-PTP-kappa gene expression. | journal = Biochem Biophys Res Commun | volume = 228 | issue = 3 | pages = 807–12 | year = 1996 | pmid = 8941358 | pmc = | doi = 10.1006/bbrc.1996.1736 }}</ref> TGFβ1 also increased PTPkappa mRNA and protein in normal and tumor mammary cell lines.<ref name="pmid15899872">{{cite journal | vauthors = Wang SE, Wu FY, Shin I, Qu S, Arteaga CL | title = Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. | journal = Mol Cell Biol | volume = 25 | issue = 11 | pages = 4703–15 | year = 2005 | pmid = 15899872 | pmc = 1140650 | doi = 10.1128/MCB.25.11.4703-4715.2005 }}</ref> HER2 overexpression reduced PTPkappa mRNA and protein expression.<ref name="pmid15899872">{{cite journal | vauthors = Wang SE, Wu FY, Shin I, Qu S, Arteaga CL | title = Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. | journal = Mol Cell Biol | volume = 25 | issue = 11 | pages = 4703–15 | year = 2005 | pmid = 15899872 | pmc = 1140650 | doi = 10.1128/MCB.25.11.4703-4715.2005 }}</ref>
en:PTPRK
*[[Epidermal growth factor receptor]] (EGFR),<ref name="pmid15899872">{{cite journal | vauthors = Wang SE, Wu FY, Shin I, Qu S, Arteaga CL | title = Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. | journal = Mol Cell Biol | volume = 25 | issue = 11 | pages = 4703–15 | year = 2005 | pmid = 15899872 | pmc = 1140650 | doi = 10.1128/MCB.25.11.4703-4715.2005 }}</ref>
en:PTPRK
*[[HER2]],<ref name="pmid15899872">{{cite journal | vauthors = Wang SE, Wu FY, Shin I, Qu S, Arteaga CL | title = Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. | journal = Mol Cell Biol | volume = 25 | issue = 11 | pages = 4703–15 | year = 2005 | pmid = 15899872 | pmc = 1140650 | doi = 10.1128/MCB.25.11.4703-4715.2005 }}</ref>
en:PIK3C2G
*{{cite journal |vauthors=Lee C, Tomkowicz B, Freedman BD, Collman RG |title=HIV-1 gp120-induced TNF-{alpha} production by primary human macrophages is mediated by phosphatidylinositol-3 (PI-3) kinase and mitogen-activated protein (MAP) kinase pathways. |journal=J. Leukoc. Biol. |volume=78 |issue= 4 |pages= 1016–23 |year= 2006 |pmid= 16081599 |doi= 10.1189/jlb.0105056 }}
en:WAY-100,635
WAY-100,635 has also been found to increase the analgesic effects of [[opioid]] drugs in a dose-dependent manner, in contrast to 5-HT1A agonists such as [[8-OH-DPAT]] which were found to reduce opioid analgesia.<ref name="pmid15109976">{{cite journal |vauthors=Bardin L, Colpaert FC |title=Role of spinal 5-HT(1A) receptors in morphine analgesia and tolerance in rats |journal=European Journal of Pain |volume=8 |issue=3 |pages=253–61 |date=June 2004 |pmid=15109976 |doi=10.1016/j.ejpain.2003.09.002 |url=}}</ref><ref name="pmid17393145">{{cite journal |vauthors=Berrocoso E, De Benito MD, Mico JA |title=Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats |journal=Psychopharmacology |volume=193 |issue=1 |pages=97–105 |date=July 2007 |pmid=17393145 |doi=10.1007/s00213-007-0761-8 |url=}}</ref> However, since 5-HT1A agonists were also found to reduce opioid-induced [[respiratory depression]] and WAY-100,635 was found to block this effect,<ref name="pmid10640309">{{cite journal |vauthors=Sahibzada N, Ferreira M, Wasserman AM, Taveira-DaSilva AM, Gillis RA |title=Reversal of morphine-induced apnea in the anesthetized rat by drugs that activate 5-hydroxytryptamine(1A) receptors |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=292 |issue=2 |pages=704–13 |date=February 2000 |pmid=10640309 |doi= |url=}}</ref> it is likely that 5-HT1A antagonists might worsen this side effect of opioids. Paradoxically, chronic administration of the very high efficacy 5-HT1A agonist [[befiradol]] results in potent analgesia following an initial period of [[hyperalgesia]], an effect most likely linked to desensitisation and/or downregulation of 5-HT1A receptors (i.e. analogous to a 5-HT1A antagonist-like effect).<ref name="pmid15528450">{{cite journal |vauthors=Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC |title=Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=312 |issue=3 |pages=1034–42 |date=March 2005 |month= |pmid=15528450 |doi=10.1124/jpet.104.077669 |url=}}</ref><ref name="pmid16921393">{{cite journal |vauthors=Assié MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A |title=Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat |journal=British Journal of Pharmacology |volume=149 |issue=2 |pages=170–8 |date=September 2006 |pmid=16921393 |pmc=2013794 |doi=10.1038/sj.bjp.0706859 |url=}}</ref><ref name="pmid18809418">{{cite journal |vauthors=Buritova J, Berrichon G, Cathala C, Colpaert F, Cussac D |title=Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study |journal=Neuropharmacology |volume=56 |issue=2 |pages=350–61 |date=February 2009 |pmid=18809418 |doi=10.1016/j.neuropharm.2008.09.004 |url=}}</ref>
en:Ribostamycin
| synonyms = (2''R'',3''S'',4''R'',5''R'',6''R'')-5-amino-2-(aminomethyl)-6-{[(1''R'',2''R'',3''S'',4''R'',6''S'')-4,6-diamino-2-{[(2''S'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
en:Presnyakov brothers
<ref>Original title-{Братья Пресняковы:The Best} [http://www.ozon.ru/context/detail/id/2438896/ http://www.ozon.ru]</ref>
en:List of MAJCOM wings of the United States Air Force
|-{
en:Odanacatib
| synonyms = (2''S'')-''N''-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1''S'')-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide
en:H3 receptor antagonist
Examples of selective H3 antagonists include [[clobenpropit]],<ref name="pmid18278935">{{cite journal |vauthors=Yoneyama H, Shimoda A, Araki L, etal |title=Efficient approaches to S-alkyl-N-alkylisothioureas: syntheses of histamine H3 antagonist clobenpropit and its analogues |journal=The Journal of Organic Chemistry |volume=73 |issue=6 |pages=2096–104 |date=March 2008 |pmid=18278935 |doi=10.1021/jo702181x}}</ref> [[ABT-239]],<ref name="pmid15608077">{{cite journal |vauthors=Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA |title=Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist |journal=Journal of Pharmacology and Experimental Therapeutics |volume=313 |issue=1 |pages=176–90 |date=April 2005 |pmid=15608077 |doi=10.1124/jpet.104.078402 |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=15608077 |issn=1521-0103}}</ref> [[ciproxifan]],<ref name="pmid9808693">{{cite journal |vauthors=Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J |title=Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=287 |issue=2 |pages=658–66 |date=November 1998 |pmid=9808693 |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9808693 }}</ref> [[conessine]], [[A-349,821]],<ref>{{cite journal |vauthors=Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA |title= Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist |journal=[[Biochemical Pharmacology (journal)|Biochemical Pharmacology]] |date=1 September 2004 |volume=68 |issue=5 |pages=933–45 |pmid=15294456 |doi=10.1016/j.bcp.2004.05.048}}</ref> and [[pitolisant]].<ref>{{cite journal |vauthors=Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC |title=BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology |journal=[[J Pharmacol Exp Ther.]] |date=January 2007 |volume=320 |issue=1 |pages=365–75 |pmid=17005916 |doi=10.1124/jpet.106.111039 }}</ref>
en:Muramic acid
| SystematicName = 2-{[3-Amino-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}propanoic acid
en:Man of Steel Awards
|-{
en:Hunts Point Department of Public Safety
'''HPDPS Emergency Medical Technicians'''-{EMT-B} must receive 140 hours (28 weeks) of state certified medical training with an additional 12-hour rotation in a hospital emergency room on their own time.
en:JNJ-5207852
| PIN = 1-{3-[4-(Piperidin-1-ylmethyl)phenoxy]propyl}piperidine
en:Pitolisant
'''Pitolisant''' ([[International Nonproprietary Name|INN]]) or '''tiprolisant''' ([[United States Adopted Name|USAN]]) is a [[histamine]] receptor [[inverse agonist]]/antagonist selective for the [[Histamine H3 receptor|H3]] subtype.<ref name="pmid16376822">{{cite journal |vauthors=Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ |title=Keynote review: histamine H3 receptor antagonists reach out for the clinic |journal=Drug Discov. Today |volume=10 |issue=23-24 |pages=1613–27 |date=December 2005 |pmid=16376822 |doi=10.1016/S1359-6446(05)03625-1 |url=http://linkinghub.elsevier.com/retrieve/pii/S1359-6446(05)03625-1}}</ref> It has [[stimulant]] and [[nootropic]] effects in animal studies,<ref>Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ''Journal of Pharmacology and Experimental Therapeutics''. 2007 Jan;320(1):365-75. PMID 17005916</ref> and may have several medical applications, having been researched for the treatment of [[narcolepsy]], for which it has been granted [[orphan drug]] status in the EU and US.<ref>Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. ''Neurobiology of Disease''. 2008 Apr;30(1):74-83. PMID 18295497</ref><ref name="Prous" /> It is currently in clinical trials for [[schizophrenia]] and [[Parkinson's disease]].<ref name="Prous">[http://www.prous.com/molecules/default.asp?ID=213 Prous Science: Molecule of the Month September 2011]</ref><ref>Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, Robert P, Parmentier R, Anaclet C, Lin JS, Burban A, Arrang JM, Schwartz JC. Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. ''[[Biochemical Pharmacology (journal)|Biochemical Pharmacology]]''. 2007 Apr 15;73(8):1215-24. PMID 17343831</ref><ref name="pmid18673168">{{cite journal |vauthors=Stocking EM, Letavic MA |title=Histamine H3 antagonists as wake-promoting and pro-cognitive agents |journal=Current Topics in Medicinal Chemistry |volume=8 |issue=11 |pages=988–1002 |year=2008 |pmid=18673168 |doi= 10.2174/156802608784936728|url= |issn=}}</ref>
en:ICRANet
Dyadotorus (Cherubini et al., 2009)<ref>{{Cite journal|title = ${e}^{-}-{e}^{+}$ pair creation by vacuum polarization around electromagnetic black holes|url = http://link.aps.org/doi/10.1103/PhysRevD.79.124002|journal = Physical Review D|date = 2009-06-03|pages = 124002|volume = 79|issue = 12|doi = 10.1103/PhysRevD.79.124002|first = C.|last = Cherubini|first2 = A.|last2 = Geralico|first3 = J. A.|last3 = Rueda H.|first4 = R.|last4 = Ruffini}}</ref>
en:Fenamiphos
| SystematicName = (''RS'')-{Ethoxy[3-methyl-4-(methylsulfanyl)phenoxy]phosphoryl}(propan-2-yl)amine
en:Arsthinol
| SystematicName = ''N''-{2-Hydroxy-5-[4-(hydroxymethyl)-1,3,2-dithiarsolan-2-yl]phenyl}acetamide
en:Mark O.M. Tso
284. Yang LP, Zhu XA, Tso MOM. Role of NF-{kappa}B and MAPKs in Light-Induced Photoreceptor Apoptosis. Invest Ophthalmol & Vis Sci.. 2007; 48(10): 4766-4776.
en:Broad-spectrum chemokine inhibitor
The observation that the [[chemokine]] [[CCL2]] is potentially responsible for the recruitment of macrophages to [[atherosclerosis|atherosclerotic]] lesions<ref>{{cite journal |vauthors=Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainger DJ |title=Monocyte Chemoattractant Protein-1 but Not Tumor Necrosis Factor-{alpha} Is Correlated With Monocyte Infiltration in Mouse Lipid Lesions |journal=Circulation |volume=99 |pages=2310–6 |year=1999 |url=http://circ.ahajournals.org/cgi/content/abstract/99/17/2310 |pmid=10226098 |issue=17 |doi=10.1161/01.cir.99.17.2310}}</ref> initiated a campaign of research into the a class of molecules that would inhibit the trafficking of [[leukocyte]]s and act as a new generation of anti-inflammatory agents. ‘Peptide 3’, a dodecapeptide section of [[CCL2]], designed as an allosteric inhibitor of MCP-1 induced [[leukocyte]] chemotaxis, was quickly shown by [[leukocyte]] [[Chemotaxis assay|migration assay]]<ref>{{cite journal |vauthors=Frow EK, Reckless J, Grainger DJ |title=Tools for anti-inflammatory drug design: In vitro models of leukocyte migration |journal=Med. Res. Rev. |volume=24 |pages=276–98 |year=2004 |url=http://www3.interscience.wiley.com/journal/107612924/abstract |doi=10.1002/med.10062 |pmid=14994365 |issue=3}}</ref> to be a functional inhibitor of many chemokines in vitro with similar potency.<ref>{{cite journal |vauthors=Reckless J, Grainger DJ |title=Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines |journal=Biochem. J. |volume=340 |issue=3 |pages=803–11 |year=1999 |url=http://www.biochemj.org/bj/340/bj3400803.htm |doi=10.1042/0264-6021:3400803 |pmid=10359667 |pmc=1220314}}</ref> The potency of this peptide could be increased by cyclisation and the use of the reverse sequence of D-amino acids. This peptide is called [[NR58-3.14.3]].<ref>{{cite journal |vauthors=Reckless J, Tatalick LM, Grainger DJ |title=The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo |journal=Immunology |volume=103 |pages=244–54 |year=2001 |url=http://www3.interscience.wiley.com/journal/118970294/abstract |doi=10.1046/j.1365-2567.2001.01228.x |pmid=11412312 |issue=2 |pmc=1783230}}</ref><ref>{{cite journal |vauthors=Wilbert SM, Engrissei G, Yau EK, Grainger DJ, Tatalick L, Axworthy DB |title=Quantitative analysis of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal standard |journal=Anal. Biochem. |volume=278 |pages=14–21 |year=2000 |url=http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W9V-45FK5PV-HH&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=5a35d1aef7d9014f4bee7bb9486ac378 |doi=10.1006/abio.1999.4437 |pmid=10640348 |issue=1}}</ref>
en:Agaritine
| SystematicName = 
en:Pectoral (Ancient Egypt)
:babaa-{Gard-unl. 13) ('necklace of beads', pectoral)
en:Pectoral (Ancient Egypt)
:beb-{Gard-unl. 13) (a metal pectoral or breastplate, collar) (uraeus headdress (?))
en:Pectoral (Ancient Egypt)
:hebner-{Gard-unl. 2 (similar to collar S11)) (collar, pectoral, neckband)
en:Pectoral (Ancient Egypt)
:sheb-{Gard-unl. 15) (collar, necklace, pectoral)
en:SNAP-94847
'''SNAP-94847''' is a drug used in scientific research, which is a selective, non-peptide [[Antagonist (pharmacology)|antagonist]] at the [[melanin concentrating hormone]] [[Receptor (biochemistry)|receptor]] [[Melanin-concentrating hormone receptor 1|MCH1]]. In animal studies it has been shown to produce both [[anxiolytic]] and [[antidepressant]] effects,<ref name="pmid17237257">{{cite journal |vauthors=David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, Craig DA, Zhong H, Swanson CJ, Hegde LG, Ping XI, Dong D, Marzabadi MR, Gerald CP, Hen R |title=Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=321 |issue=1 |pages=237–48 |date=April 2007 |pmid=17237257 |doi=10.1124/jpet.106.109678 |url=}}</ref><ref name="pmid18793675">{{cite journal |vauthors=Smith DG, Hegde LG, Wolinsky TD, Miller S, Papp M, Ping X, Edwards T, Gerald CP, Craig DA |title=The effects of stressful stimuli and hypothalamic-pituitary-adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents |journal=Behavioural Brain Research |volume=197 |issue=2 |pages=284–91 |date=February 2009 |pmid=18793675 |doi=10.1016/j.bbr.2008.08.026 |url=}}</ref> and also reduces food consumption suggesting a possible [[anorectic]] effect.<ref name="pmid19340414">{{cite journal |vauthors=Nair SG, Adams-Deutsch T, Pickens CL, Smith DG, Shaham Y |title=Effects of the MCH1 receptor antagonist SNAP 94847 on high-fat food-reinforced operant responding and reinstatement of food seeking in rats |journal=Psychopharmacology |volume=205 |issue=1 |pages=129–40 |date=July 2009 |pmid=19340414 |doi=10.1007/s00213-009-1523-6 |url= |pmc=3143407}}</ref>
en:Befiradol
'''Befiradol''' ('''F-13,640'''; '''NLX-112''') is a very [[potency (pharmacology)|potent]] and highly [[binding selectivity|selective]] [[5-HT1A receptor|5-HT1A receptor]] [[full agonist]]. It has powerful [[analgesic]] and [[antiallodynic]] effects comparable to those of high doses of [[opioid]] [[painkiller]]s, but with fewer and less prominent [[adverse effect|side effect]]s, as well as little or no development of [[Drug tolerance|tolerance]] with repeated use.<ref name="pmid12595749">{{cite journal |vauthors=Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC |title=Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain |journal=Pharmacology |volume=67 |issue=4 |pages=182–94 |date=April 2003 |pmid=12595749 |doi=10.1159/000068404 |url=}}</ref><ref name="pmid12694810">{{cite journal |vauthors=Bruins Slot LA, Koek W, Tarayre JP, Colpaert FC |title=Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640 |journal=European Journal of Pharmacology |volume=466 |issue=3 |pages=271–9 |date=April 2003 |pmid=12694810 |doi= 10.1016/S0014-2999(03)01566-8|url=}}</ref><ref name="pmid15528450">{{cite journal |vauthors=Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC |title=Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=312 |issue=3 |pages=1034–42 |date=March 2005 |pmid=15528450 |doi=10.1124/jpet.104.077669 |url=}}</ref><ref name="pmid16254131">{{cite journal |vauthors=Colpaert FC, Deseure K, Stinus L, Adriaensen H |title=High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=316 |issue=2 |pages=892–9 |date=February 2006 |pmid=16254131 |doi=10.1124/jpet.105.095109 |url=}}</ref><ref name="pmid17512927">{{cite journal |vauthors=Deseure K, Bréand S, Colpaert FC |title=Curative-like analgesia in a neuropathic pain model: parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT(1A) receptor agonist |journal=European Journal of Pharmacology |volume=568 |issue=1–3 |pages=134–41 |date=July 2007 |pmid=17512927 |doi=10.1016/j.ejphar.2007.04.022 |url=}}</ref> A SAR study revealed that replacement of the dihalophenyl moiety by 3-[[benzothiophene|benzothienyl]] increases maximal [[Efficacy#Pharmacology|efficacy]] from 84% to 124% (Ki=2.7 nM).<ref>{{cite journal | doi = 10.1021/jm100835q | pmid = 20860381 | volume=53 | issue=19 | title=Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists |date=October 2010 | journal=J. Med. Chem. | pages=7167–79 | vauthors=Bollinger S, Hübner H, Heinemann FW, Meyer K, Gmeiner P}}</ref>
en:List of college athletic programs in Alaska
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Arizona
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Arkansas
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in California
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Colorado
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Connecticut
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Delaware
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Washington, D.C.
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Florida
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Georgia (U.S. state)
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Hawaii
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Idaho
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Illinois
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Indiana
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Iowa
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Kansas
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Kentucky
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Louisiana
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Maine
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Maryland
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Massachusetts
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Michigan
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Minnesota
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Mississippi
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Missouri
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Montana
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Nebraska
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Nevada
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in New Hampshire
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in New Jersey
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in New Mexico
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in New York
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in North Dakota
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Ohio
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Oklahoma
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Oregon
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Pennsylvania
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Puerto Rico
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Rhode Island
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in South Dakota
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Tennessee
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Texas
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Utah
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Vermont
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Virginia
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Washington (state)
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in West Virginia
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Wisconsin
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:List of college athletic programs in Wyoming
**Schools are also alphabetized by the names they are most commonly referred to by sports media, with non-intuitive examples included in parentheses next to the school name. This means, for example, that campuses bearing the name "University of North Carolina" may variously be found at "C" (Charlotte), "N" (North Carolina, referring to the Chapel Hill campus), and "U" (the Asheville, Greensboro, Pembroke, and Wilmington campuses, all normally referred to as UNC-{campus name}).
en:Šušure
'''Šušure''', in [[Serb]] [[Serbian Cyrillic alphabet|Cyrillic]] {{lang|sr|Шушуре}}, is a village in [[Serbia]], located in the municipality of [[Sjenica]], district of [[Zlatibor District|Zlatibor]]. In 2002, it had 25 inhabitants,<ref name="stats1" >Book 1,''Population, national or ethnic origin, the data on settlements'', [http://webrzs.stat.gov.rs/axd/index.php Republic Statistical Office], Belgrade, February 2003, - (ISBN 86-84433-00-9) {{Language icon|sr|Serbian}}& {{en icon}}</ref> all [[Serbs]].<ref name="stats2" >Књига 2, ''Становништво, пол и старост, подаци по насељима'', [http://webrzs.stat.gov.rs/axd/index.php Републички завод за статистику], Београд, фебруар 2003, -{ISBN 86-84433-01-7} {{Language icon|sr|Serbian}}& {{en icon}}</ref>
en:A, B and C v Ireland
|Keywords={{hlist|(Art. 35) Admissibility criteria|(Art. 35-1) Exhaustion of domestic remedies|(Art. 8) Right to respect for private and family life|(Art. 8-1) Respect for private life,|(Art. 8-2) Interference|(Art. 8-2) Necessary in a democratic society|(Art. 8-2) Protection of morals|(Art. 8-2) Prescribed by law|Margin of appreciation|Positive obligations|Proportionality|(Art. 41) Just satisfaction-{general}|Privacy|[[Abortion]]|right to a family life}}
en:D-Fuse AV
Sprawl Mix: Si-{cut}.db and Bittonic '''Mixmasters - Episode 4 / The Audiovisual Sessions''' (2004) Moonshine - US 
en:Nopaline
| ImageName = Stereo, skeletal formula of nopaline ((2R)-2-{[(1S)-1-Carboxybutyl]amino})
en:Nopaline
| PubChem3_Comment = 2-{[(1''R'')-1-Carboxybutyl]amino}
en:Nopaline
| PubChem4_Comment = 2-{[(1''S'')-1-Carboxybutyl]amino}
en:Nopaline
| ChemSpiderID2_Comment = 2-{[(1''R'')-1-Carboxybutyl]amino}
en:Nopaline
| ChemSpiderID3_Comment = 2-{[(1''S'')-1-Carboxybutyl]amino}
en:Muldamine
| SystematicName= (3β,16α,17β)-3-Hydroxy-17-{(1''S'')-1-[(2''S'',5''S'')-5-methyl-2-piperidinyl]ethyl}androst-5-en-16-yl acetate
en:Mycosporine-like amino acid
|[(E)-{3-[(Carboxymethyl)amino]-5-hydroxy-5-(hydroxymethyl)-2-methoxy-2-cyclohexen-1-ylidene}amino]acetic acid
en:Mycosporine-like amino acid
|[(E)-{5-Hydroxy-5-(hydroxymethyl)-2-methoxy-3-[(1E)-1-propen-1-ylamino]-2-cyclohexen-1-ylidene}ammonio]acetate
en:Walking subcaucus
* [[Leonid Hurwicz]], ''A voting system reform proposal to provide for minority representation.'' April 1969. 4p. (presented to: DFL Constitutional Reform Committee-{also known as the “walking subcaucus”}.)
en:Bcr-Abl tyrosine-kinase inhibitor
<ref name="Huang2010">{{Cite journal | last1 = Huang | first1 = W. S. | last2 = Metcalf | first2 = C. A. | last3 = Sundaramoorthi | first3 = R. | last4 = Wang | first4 = Y. | last5 = Zou | first5 = D. | last6 = Thomas | first6 = R. M. | last7 = Zhu | first7 = X. | last8 = Cai | first8 = L. | last9 = Wen | first9 = D.| title = Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant | journal = Journal of Medicinal Chemistry | volume = 53 | pages = 4701–19 | year = 2010 | doi = 10.1021/jm100395q | pmid=20513156 | issue=12}}</ref>
en:Quizartinib
'''Quizartinib''' (AC220) is a small molecule [[receptor tyrosine kinase]] inhibitor that is currently under development by [[Ambit Biosciences]] for the treatment of [[acute myeloid leukaemia]]. Its molecular target is [[FLT3]], also known as CD135 which is a [[proto-oncogene]].<ref>{{cite journal |author1=Chao, Qi |author2=Sprankle, Kelly G. |author3=Grotzfeld, Robert M. |author4=Lai, Andiliy G. |author5=Carter, Todd A. |author6=Velasco, Anne Marie |author7=Gunawardane, Ruwanthi N. |author8=Cramer, Merryl D. |author9=Gardner, Michael F. |author10=James, Joyce |author11=Zarrinkar, Patrick P. |author12=Patel, Hitesh K. |author13=Bhagwat, Shripad S. | title = Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor | journal = Journal of Medicinal Chemistry | year = 2009 | volume = 52 | issue = 23 | pages = 7808–7816 | doi=10.1021/jm9007533}}</ref>
en:List of state leaders in the 18th century BC
|-{| class="wikitable"
en:2010 Fort Wayne FireHawks season
|-{(Defensive Lineman[DL]/ [Broderick Johnson][DL]
en:Ponatinib
'''Ponatinib''' (trade name '''Iclusig''' {{respell|eye|CLUE|sig}}, previously '''AP24534''') is an oral drug developed by [[ARIAD Pharmaceuticals]] for the treatment of [[chronic myeloid leukemia]] (CML) and [[Philadelphia chromosome]]–positive (Ph+) [[acute lymphoblastic leukemia]] (ALL). It is a multi-targeted [[tyrosine-kinase inhibitor]].<ref name="pmid20513156">{{cite journal |vauthors=Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC | title = Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant | journal = J. Med. Chem. | volume = 53 | issue = 12 | pages = 4701–19 | date =June 2010 | pmid = 20513156 | doi = 10.1021/jm100395q }}</ref> Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as [[imatinib]]. Ponatinib has been designed to be effective against these types of tumors.<ref name="pmid19878872">{{cite journal |vauthors=O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T | title = AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance | journal = Cancer Cell | volume = 16 | issue = 5 | pages = 401–12 |date=November 2009 | pmid = 19878872 | pmc = 2804470 | doi = 10.1016/j.ccr.2009.09.028 }}</ref>
en:Fencing at the 2012 Summer Olympics – Qualification
|-{
en:Octopine
| ImageName = Stereo, skeletal formula of octopine ((2S)-2-{[(1R)-1-carboxyethyl]amino})
en:Octopine
| CASNo_Comment = (2''S'')-2-{[(1''R'')-1-Carboxyethyl]amino}
en:Octopine
| PubChem2_Comment = (2''S'')-2-{[(1''S'')-1-Carboxyethyl]amino}
en:Octopine
| PubChem3_Comment = (2''S'')-2-{[(1''R'')-1-Carboxyethyl]amino}
en:Octopine
| ChemSpiderID2_Comment = (2''S'')-2-{[(1''R'')-1-Carboxyethyl]amino}
en:OUP-16
'''OUP-16''' is a [[histamine agonist]] selective for the [[Histamine H4 receptor|H4]] subtype.<ref>{{cite journal|last1=Hashimoto|first1=T|last2=Harusawa|first2=S|last3=Araki|first3=L|last4=Zuiderveld|first4=OP|last5=Smit|first5=MJ|last6=Imazu|first6=T|last7=Takashima|first7=S|last8=Yamamoto|first8=Y|last9=Sakamoto|first9=Y|last10=Kurihara|first10=T|last11=Leurs|first11=R|last12=Bakker|first12=RA|last13=Yamatodani|first13=A|title=A Selective Human H4-Receptor Agonist: (−)-2-Cyano-1-methyl-3-{(2''R'',5''R'')-5- [1''H''-imidazol-4(5)-yl]tetrahydrofuran-2-yl}methylguanidine|journal=Journal of Medicinal Chemistry|date=July 2003|volume=46|issue=14|pages=3162–5|doi=10.1021/jm0300025|pmid=12825954}}</ref>
en:Concussions in American football
To date, all screening procedures that examine football players for brain damage have been post mortem. In 2013, Gary Small and colleagues developed an in vivo chemical tracer that can detect tau protein build up in living players. Small and his team invented this new chemical tracer, 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile, or FDDNP, that could be used in [[Positron Emission Tomography]] (PET) scans.<ref name="Small 2013 138-144">{{cite journal|last=Small|first=G.W.|title=PET Scanning of Brain Tau in Retired National League Football Players: Preliminary Findings|journal=American Association for Geriatric Psychiatry|year=2013|volume=21|issue=2|pages=138–144}}</ref> This new tracer measures for tau protein and amyloid plaque accumulation in human brains; symptoms of repetitive brain trauma among other things. Although tracers have been developed to screen for the build-up of tau proteins in the human brain, FDDNP is the first PET tracer that can be used in vivo in human trials. FDDNP was originally developed in an effort to detect Alzheimer’s in elderly individuals, thus the article was published in the journal of the American Association for Geriatric Psychiatry. However, because there are similarities between Alzheimer’s and the effects of chronic traumatic encephelopathy (CTE), FDDNP was used to study the extent of brain trauma in consenting, retired NFL players.
en:S1RA
'''S1RA''', '''E-52862''', or '''4-(2-((5-methyl-1-(naphthalen-2-yl)-1''H''-pyrazol-3-yl)oxy)ethyl)morpholine''' is a selective [[sigma-1 receptor]] [[receptor antagonist|antagonist]], with a reported [[binding affinity]] of ''K''i = 17.0 ± 7.0 nM, selective over the [[sigma-2 receptor]] and against a panel of other 170 receptors, enzymes, transporters and ion channels.<ref name="Diaz_2012">{{cite journal |vauthors=Díaz JL, Cuberes R, Berrocal J, Contijoch M, Christmann U, Fernández A, Port A, Holenz J, Buschmann H, Laggner C, Serafini MT, Burgueño J, Zamanillo D, Merlos M, Vela JM, Almansa C | title = Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of σ1 Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862) | journal = J. Med. Chem. | volume = 55 | issue = 19 | pages = 8211–8224 | year = 2012 | month = | pmid = 22784008 | doi = 10.1021/jm3007323}}</ref><ref name="Romero_2012">{{cite journal |vauthors=Romero L, Zamanillo D, Nadal X, Sánchez-Arroyos R, Rivera-Arconada I, Dordal A, Montero A, Muro A, Bura A, Segalés C, Laloya M, Hernández E, Portillo-Salido E, Escriche M, Codony X, Encina G, Burgueño J, Merlos M, Baeyens JM, Giraldo J, López-García JA, Maldonado R, Plata-Salamán CR, Vela JM | title = Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization | journal = Br. J. Pharmacol. | volume = 166 | issue = 8 | pages = 2289–2306 | year = 2012 | month = | pmid = 22404321 | doi = 10.1111/j.1476-5381.2012.01942.x}}</ref> In preclinical studies, S1RA has demonstrated efficacy in relieving [[neuropathic pain]] and [[pain]] in other sensitizing conditions, associated with an improvement of the emotional negative state.<ref name="Romero_2012" /><ref name="Nieto_2012">{{cite journal |vauthors=Nieto FR, Cendán CM, Sánchez-Fernández C, Cobos EJ, Entrena JM, Tejada MA, Zamanillo D, Vela JM, Baeyens JM | title = Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice | journal = J. Pain | volume = 13 | issue = 11 | pages = 1107–1121 | year = 2012 | month = | pmid = 23063344 | doi = 10.1016/j.jpain.2012.08.006}}</ref><ref name="Bura_2012">{{cite journal |vauthors=Bura AS, Guegan T, Zamanillo D, Vela JM, Maldonado R | title = Operant self-administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain | journal = Eur. J. Pain | volume = 17| issue = | pages = 832–843| year = 2013 | month = | pmid = 23172791 | doi = 10.1002/j.1532-2149.2012.00251.x}}</ref><ref name="González-Cano_2012">{{cite journal |vauthors=González-Cano R, Merlos M, Baeyens JM, Cendán CM | title = σ1 receptors are involved in the visceral pain induced by intracolonic administration of capsaicin in Mice | journal = Anesthesiology | volume = 118| issue = 3| pages = 691–700| year = 2013 | month = | pmid = 23299362 | doi = 10.1097/ALN.0b013e318280a60a}}</ref>
en:List of Knights of the Order of the Elephant
* 8 January 1892: [[Chulalongkorn]] (Rama V), [[King of Siam]] (1853-{1868–1910})
en:List of Knights of the Order of the Elephant
* 27 July 1897: [[Vajiravudh]] (Rama VI), [[King of Siam]] (1881-{1910–1925}), when Crown Prince of Siam
en:List of Knights of the Order of the Elephant
* 8 February 1926: [[Prajadhipok]] (Rama VII), [[King of Siam]] (1893-{1925-1935})
en:List of Knights of the Order of the Elephant
* 6 June 1962: [[Adolf Schärf]], President of Austria (1890-{1957–1965})
en:List of Knights of the Order of the Elephant
** 12 November 1814: [[Francis II, Holy Roman Emperor]], Emperor Francis I of Austria (1768-{1792-1835}))
en:List of Knights of the Order of the Elephant
** 6 June 1962: [[Adolf Schärf]], President of Austria (1890-{1957–1965})
en:List of Knights of the Order of the Elephant
** 25 January 1818: [[Louis XVIII of France|Louis XVIII]], King of France (1755-{1814-1815-1824})
en:List of Knights of the Order of the Elephant
** 8 January 1892: [[Chulalongkorn]] (Rama V), [[King of Siam]] (1853-{1868–1910})
en:List of Knights of the Order of the Elephant
** 27 July 1897: [[Vajiravudh]] (Rama VI), King of Siam (1881-{1910–1925}), when Crown Prince of Siam
en:List of Knights of the Order of the Elephant
** 8 February 1926: [[Prajadhipok]] (Rama VII), King of Siam (1893-{1925-1935})
en:C20H26N4O5S
* [[Diabenor]], N-(2-{4-[(Cikloheksilkarbamoil)sulfamoil]fenil}etil)-5-metil-1,2-oksazol-3-karboksamid
en:4-alpha-D-((1-4)-alpha-D-glucano)trehalose trehalohydrolase
| Name = 4-alpha-D-{(1->4)-alpha-D-glucano}trehalose trehalohydrolase
en:4-alpha-D-((1-4)-alpha-D-glucano)trehalose trehalohydrolase
'''4-alpha-D-{(1->4)-alpha-D-glucano}trehalose trehalohydrolase''' ({{EC number|3.2.1.141}}, ''malto-oligosyltrehalose trehalohydrolase'') is an [[enzyme]] with [[List of enzymes|systematic name]] ''4-alpha-D-((1->4)-alpha-D-glucano)trehalose glucanohydrolase (trehalose-producing)''.<ref>{{cite journal | title = Formation of trehalose from maltooligosaccharides by a novel enzymatic system |author = Maruta, K. |author2 = Nakada, T. |author3 = Kubota, M. |author4 = Chaen, H. |author5 = Sugimoto, T. |author6 = Kurimoto, M. |author7 = Tsujisaka, Y. |journal = Biosci. Biotechnol. Biochem. |year = 1995 |volume = 59 |pages = 1829–1834 |pmid = 8534970 |doi=10.1271/bbb.59.1829}}</ref><ref>{{cite journal | title = , Kurimoto M., Tsujisaka, Y. Purification and characterization of a novel enzyme, maltooligosyl trehalose trehalohydrolase, from ''Arthrobacter sp''. Q36 |author = Nakada, T. |author2 = Maruta, K. |author3 = Mitsuzumi, H. |author4 = Kubota, M. |author5 = Chaen, H. |author6 = Sugimoto, T. |journal = Biosci. Biotechnol. Biochem. |year = 1995 |volume = 59 |pages = 2215–2218 |pmid = 8611745 |doi=10.1271/bbb.59.2215}}</ref><ref>{{cite journal | title = Purification and characterization of thermostable maltooligosyl trehalose trehalohydrolase from the thermoacidophilic archaebacterium ''Sulfolobus acidocaldarius'' |author = Nakada, T. |author2 = Ikegami, S. |author3 = Chaen, H. |author4 = Kubota, M. |author5 = Fukuda, S. |author6 = Sugimoto, T. |author7 = Kurimoto, M. |author8 = Tsujisaka, Y. |journal = Biosci. Biotechnol. Biochem. |year = 1996 |volume = 60 |pages = 267–270 |pmid = 9063974 |doi=10.1271/bbb.60.267}}</ref> This enzyme [[catalysis|catalyses]] the following [[chemical reaction]]
en:4-alpha-D-((1-4)-alpha-D-glucano)trehalose trehalohydrolase
* {{MeshName|4-alpha-D-{(1->4)-alpha-D-glucano}trehalose+trehalohydrolase}}
en:Huallaga Quechua
::'''IIa.''' ø → [-ni-] / {NounRoot [bimoraic σ]}- ___ -{[-syl or (+long)] #σ PosSuffix}
en:Huallaga Quechua
::'''IIb.''' ø → [-ni-] / {NounRoot}- ___ -{PosSuffix}
en:Aplysamine-2
| SystematicName = (2Z)-3-(3-Bromo-4-methoxyphenyl)-N-(2-{3,5-dibromo-4-[3-(dimethylamino)propoxy]phenyl}ethyl)-2-(hydroxyimino)propanamide
en:List of doping cases in sport (V)
|-{CAN}
en:Acetergamine
| SystematicName = ''N''-{[(8β)-6-Methylergolin-8-yl]methyl}acetamide
en:Adolf Stachel
*Beyerle R, Nitz RE, Resag K, Schraven E, Stachel A (1972). [http://www.google.com/patents/US3706739 3-({60 -substituted amino-{62 -alkoxybenzoxy-propyl)-6,7-or-6,7,8-alkoxy-1,2,3-benzotriazine-4(3h)-ones]. US Patent US 3706739 A.
en:Emilia-Romagna regional election, 2014
|-{
en:Pathology of multiple sclerosis
A protein called Interleukin 12 is responsible for the differentiation of naive T cells into inflammatory T cells. An over production of this protein is what causes the increased inflammation in MS patients.<ref>http://wwwchem.csustan.edu/chem4400/sjbr/corey02.htm</ref> Under normal circumstances, these [[lymphocyte]]s can distinguish between self and non-self. However, in a person with MS, these cells recognize healthy parts of the central nervous system as foreign and attack them as if they were an invading virus, triggering [[inflammation|inflammatory]] processes and stimulating other immune cells and soluble factors like [[cytokine]]s and [[antibody|antibodies]]. Many of the myelin-recognizing T cells belong to a terminally differentiated subset called co-stimulation-independent effector-memory T cells.<ref name= "Markovic-Plese">{{cite journal |vauthors=Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R |title=CD4+CD28– costimulation-independent T cells in multiple sclerosis |journal=J Clin Invest |volume=108 |issue=8 |pages=1185–94 |date=October 2001 |pmid=11602626 |pmc=209525 |doi=10.1172/JCI12516 }}</ref><ref name= "Wulff">{{cite journal |vauthors=Wulff H, Calabresi PA, Allie R |title=The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS |journal=J Clin Invest |volume=111 |issue=11 |pages=1703–13 |date=June 2003 |pmid=12782673 |pmc=156104 |doi=10.1172/JCI16921 |displayauthors=etal }}</ref><ref name= "Rus">{{cite journal |vauthors=Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PA |title=The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain |journal=Proc Natl Acad Sci USA |volume=102 |issue=31 |pages=11094–9 |date=August 2005 |pmid=16043714 |pmc=1182417 |doi=10.1073/pnas.0501770102 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=16043714 |displayauthors=1 |bibcode=2005PNAS..10211094R }}</ref><ref name= "BeetonNeuroscientist">{{cite journal |vauthors=Beeton C, Chandy KG |title=Potassium channels, memory T cells, and multiple sclerosis |journal=Neuroscientist |volume=11 |issue=6 |pages=550–62 |date=December 2005 |pmid=16282596 |doi=10.1177/1073858405278016 |url=http://nro.sagepub.com/cgi/pmidlookup?view=long&pmid=16282596 }}</ref><ref name= "Okuda">{{cite journal |vauthors=Okuda Y, Okuda M, Apatoff BR, Posnett DN |title=The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis |journal=J Neurol Sci |volume=235 |issue=1–2 |pages=11–7 |date=August 2005 |pmid=15972217 |doi=10.1016/j.jns.2005.02.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-510X(05)00108-5 }}</ref><ref name= "Krakauer">{{cite journal |vauthors=Krakauer M, Sorensen PS, Sellebjerg F |title=CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis |journal=J Neuroimmunol |volume=181 |issue=1–2 |pages=157–64 |date=December 2006 |pmid=17081623 |doi=10.1016/j.jneuroim.2006.09.006 |url=http://linkinghub.elsevier.com/retrieve/pii/S0165-5728(06)00372-9 }}</ref><ref name= "Ratts">{{cite journal |vauthors=Ratts RB, Karandikar NJ, Hussain RZ |title=Phenotypic characterization of autoreactive T cells in multiple sclerosis |journal=J Neuroimmunol |volume=178 |issue=1–2 |pages=100–10 |date=September 2006 |pmid=16901549 |doi=10.1016/j.jneuroim.2006.06.010 |url=http://linkinghub.elsevier.com/retrieve/pii/S0165-5728(06)00226-8 |displayauthors=etal }}</ref><ref name= "Haegele">{{cite journal |vauthors=Haegele KF, Stueckle CA, Malin JP, Sindern E |title=Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls |journal=J Neuroimmunol |volume=183 |issue=1–2 |pages=168–74 |date=February 2007 |pmid=17084910 |doi=10.1016/j.jneuroim.2006.09.008 |url=http://linkinghub.elsevier.com/retrieve/pii/S0165-5728(06)00376-6 }}</ref><ref name= "Jilek">{{cite journal |vauthors=Jilek S, Schluep M, Rossetti AO |title=CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis |journal=Clin Immunol |volume=123 |issue=1 |pages=105–13 |date=April 2007 |pmid=17188575 |doi=10.1016/j.clim.2006.11.004 |url=http://linkinghub.elsevier.com/retrieve/pii/S1521-6616(06)00946-6 |displayauthors=etal }}</ref><ref name= "Miyazaki">{{cite journal |vauthors=Miyazaki Y, Iwabuchi K, Kikuchi S, Fukazawa T, Niino M, Hirotani M, Sasaki H, Onoé K |title=Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis |journal=Mult Scler |volume=14 |issue=8 |pages=1044–55 |date=September 2008 |pmid=18573819 |doi=10.1177/1352458508092809 |url=http://msj.sagepub.com/cgi/pmidlookup?view=long&pmid=18573819 |displayauthors=1 }}</ref><ref name= "Lünemann">{{cite journal |vauthors=Lünemann JD, Jelcić I, Roberts S |title=EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2 |journal=J Exp Med |volume=205 |issue=8 |pages=1763–73 |date=August 2008 |pmid=18663124 |pmc=2525578 |doi=10.1084/jem.20072397 |url=http://www.jem.org/cgi/pmidlookup?view=long&pmid=18663124 |displayauthors=etal }}</ref>
en:Amarna letter EA 362
:(Line 1)--{[[um (cuneiform)|um]][[ma (cuneiform)|ma]](inferred)} [1.]-[[Rib-Hadda|Rib-Haddi]]([[Ri (cuneiform)|R]][[ib (cuneiform)|ib]]-dHaddi) qabû--({"message"} Rib-Haddi, speaking..!)
en:Drugs controlled by the German Betäubungsmittelgesetz
| || [[Alphamethylthiofentanyl|α-Methylthiofentanyl]] || N-Phenyl-N-{1-[1-(2-thienyl)propan-2-yl]-4-piperidyl}propanamid
en:Drugs controlled by the German Betäubungsmittelgesetz
| || [[Thiofentanyl]] || N-Phenyl-N-{1-[2-(2-thienyl)ethyl]-4-piperidyl}propanamid
en:Drugs controlled by the German Betäubungsmittelgesetz
| || [[AH-7921]] (Doxylam) || 3,4-Dichlor-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamid
en:MMB-2201
'''MMB-2201''' (also known as '''5F-MMB-PICA''', '''5F-AMB-PICA''', and '''I-AMB''') is a potent [[indole]]-3-carboxamide based synthetic [[cannabinoid]],<ref>{{cite journal | author1=Samuel D Banister | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00112 | title=The pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues | date=July 2016 | journal=ACS Chemical Neuroscience | doi=10.1021/acschemneuro.6b00137 | pmid=27421060 | volume=7 | pages=1241–54|display-authors=etal}}</ref> which has been sold as a [[designer drug]] and as an active ingredient in [[synthetic cannabis]] blends.<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/15971 | title=MMB-2201 | publisher=Cayman Chemical | accessdate=16 July 2015}}</ref> It was first reported in Russia and Belarus in January 2014, but has since been sold in a number of other countries. It is the indole core analogue of [[5F-AMB]]. Synthetic cannabinoid compounds with an indole-3-carboxamide or indazole-3-carboxamide core bearing a N-1-methoxycarbonyl group with attached isopropyl or t-butyl substituent, have proved to be much more dangerous than older synthetic cannabinoid compounds previously reported, and have been linked to a large number of deaths in Russia, Japan, Europe and the United States.<ref>{{cite journal | url=http://www.researchgate.net/profile/Vadim_Shevyrin/publication/263853259_New_Synthetic_Cannabinoid_-_Methyl_2-1-%285-Fluoro-Pentyl%29-3-Methyl-1H-Indol-3-Ylcarbonyl-AminoButyrate_-_as_a_Designer_Drug/links/0046353c26d06773b6000000.pdf?disableCoverPage=true | title=New Synthetic Cannabinoid – Methyl 2-{[1-(5-Fluoro-Pentyl)-3-Methyl-1H -Indol-3-Ylcarbonyl]-Amino}Butyrate – as a Designer Drug |author1=V. A. Shevyrin |author2=Yu. Yu. Morzherin |author3=V. P. Melkozerov |author4=A. S. Nevero | journal=Chemistry of Heterocyclic Compounds | year=July 2014 | volume=50 | issue=4 | pages=583–586 | doi=10.1007/s10593-014-1511-6}}</ref><ref name="Shevyrin_2015">{{cite journal | vauthors = Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT | title = Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group | journal = Analytical and Bioanalytical Chemistry | date = Apr 2015 | pmid = 25893797 | doi = 10.1007/s00216-015-8612-7 | url = http://link.springer.com/article/10.1007%2Fs00216-015-8612-7 | volume=407 | pages=6301–15}}</ref>
en:Elagolix
'''Elagolix''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (former developmental code names '''NBI-56418''', '''ABT-620''') is a highly potent, selective, [[oral administration|oral]]ly-active, short-duration, [[non-peptide]] [[gonadotropin-releasing hormone receptor antagonist|antagonist]] of the [[gonadotropin-releasing hormone receptor]] (GnRHR) ([[Dissociation constant|KD]] = 54 [[picomolar|pM]]) that is under development for clinical use by [[Neurocrine Biosciences]] and [[AbbVie]].<ref name="pmid19006286">{{cite journal | vauthors = Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS | title = Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor | journal = J. Med. Chem. | volume = 51 | issue = 23 | pages = 7478–85 | year = 2008 | pmid = 19006286 | doi = 10.1021/jm8006454 | url = }}</ref><ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1411|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=1411–}}</ref> As of 2015, it is in [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for the treatment of [[endometriosis]] and [[uterine leiomyoma]].<ref name="EzzatiCarr2015" /><ref name="Adis">AdisInsight: [http://adisinsight.springer.com/drugs/800020238 Elagolix].</ref> The drug was also under investigation for the treatment of [[prostate cancer]] and [[benign prostatic hyperplasia]], but development for these indications was ultimately not pursued.<ref name="Adis" /> Elagolix is the first of a new class of GnRH inhibitors that have been denoted as ''second-generation'', due to their non-peptide nature and oral [[bioavailability]].<ref name="EzzatiCarr2015" />
en:Osimertinib
Osimertinib is provided as the [[mesylate]]; the chemical formula is C28H33N7O2•CH4O3S, and the molecular weight is 596 g/mol. The chemical name is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide mesylate salt.<ref name=USlabel/>
en:PSNCBAM-1
'''PSNCBAM-1''' is a negative [[allosteric modulator]] of the [[cannabinoid]] [[Cannabinoid receptor 1|CB1]] [[Receptor (biochemistry)|receptor]].<ref name="German2016">{{cite journal | title=Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structure–Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1) | vauthors=German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y | journal=Journal of Medicinal Chemistry | date=September 2014 | volume=57 | issue=18 | pages=7758–7769 | doi=10.1021/jm501042u | pmid=25162172 | PMC=4175001}}</ref><ref>{{cite journal | title=PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats |vauthors=Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, Reynet C, Wong Kai In P | journal=British Journal of Pharmacology | date=November 2007 | volume=152 | issue=5 | pages=805–814 | doi=10.1038/sj.bjp.0707347 | pmid=17592509 | PMC=2190018}}</ref>
en:D v Ireland
|Keywords=(Art. 1) Obligation to respect human rights, (Art. 3) Prohibition of torture, (Art. 8) Right to respect for private and family life, (Art. 10) Freedom of expression -{General}, (Art. 13) Right to an effective remedy, (Art. 14) Prohibition of discrimination
en:Volixibat
| synonyms = ''N''-(3-''O''-Benzyl-6-''O''-sulfo-β-D-glucopyranosyl)-''N''′-{3-[(3''S'',4''R'',5''R'')-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1''H''-1λ6-benzothiepin-5-yl]phenyl}urea; SHP626
en:WAY-166818
'''WAY-166818''' is a [[synthetic compound|synthetic]], [[non-steroidal]] [[estrogen]] related to [[WAY-200070]] which is used in [[scientific research]].<ref name="pmid15456246">{{cite journal | vauthors = Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC, Harris HA | title = Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands | journal = J. Med. Chem. | volume = 47 | issue = 21 | pages = 5021–40 | year = 2004 | pmid = 15456246 | doi = 10.1021/jm049719y | url = }}</ref><ref name="pmid15790727">{{cite journal | vauthors = Merchenthaler I, Hoffman GE, Lane MV | title = Estrogen and estrogen receptor-{beta} (ER{beta})-selective ligands induce galanin expression within gonadotropin hormone-releasing hormone-immunoreactive neurons in the female rat brain | journal = Endocrinology | volume = 146 | issue = 6 | pages = 2760–5 | year = 2005 | pmid = 15790727 | doi = 10.1210/en.2004-1562 | url = }}</ref> It acts as a highly selective [[full agonist]] of the [[ERβ]], with 57- and 164-fold selectivity for the ERβ over the [[ERα]] in the rat and mouse, respectively.<ref name="pmid15456246" /><ref name="pmid15790727" /> At the human ERβ and ERα, WAY-166818 has [[IC50|IC50]] values of 29 nM and 1227 nM (25-fold difference), respectively.<ref name="pmid15456246" /> The compound has been verified to cross the [[blood-brain-barrier]] in rodents.<ref name="pmid15456246" /><ref name="pmid15790727" />

Matches not in article namespace[edit]

en:Wikipedia:Articles for deletion/2004 U.S. presidential election controversy
****I'm pretty sure we can't. :-{ [[User:Baylink|Baylink]] 21:37, 11 Nov 2004 (UTC)
en:Wikipedia:WikiProject Guardians of Time Trilogy
*Templates should follow the naming scheme '''GoT-{name}''' and start off with a capital letter (ex. GoT-Sites)
en:Wikipedia:Meetup/St. Petersburg 2
*Damnit. I was in the edit suite anyway, but still... damnit. :-{ --[[User:Baylink|Baylink]] 02:24, 16 January 2006 (UTC)
en:Wikipedia:Bot requests/Archive 3
Associated with almost all of those Template:VfD-{foo} pages are redirects from Mediawiki:VfD-{foo}, and those also need to be deleted. [[User:Jnc|Noel]] [[User_talk:Jnc|(talk)]] 14:28, 9 Apr 2005 (UTC)
en:Wikipedia:Articles for deletion/Crossed Realmz 4
The result of the debate was delete. This debate was weird... :-{ [[User:Johnleemk|Johnleemk]] | [[User talk:Johnleemk|Talk]] 09:38, 20 December 2005 (UTC)
en:Wikipedia:Administrators' noticeboard/IncidentArchive73
--{.{vandal|anittas}.}-- What is this supposed to mean? I would like to know why an admin accuses me of being a vandal when I have contributed with articles and other improvements of articles. --[[User:Anittas|Candide, or Optimism]] 17:38, 10 February 2006 (UTC)
en:Wikipedia:Stub types for deletion/Log/Not deleted/March 2006
::::Potentially both, I am in disscussion with [[User:Kevinalewis]] (has done a lot of work with [[WP:NOVEL]]). Just give WP:NOVEL and it's members time to fill it up. Note, I am not proposing to keep all of the stub tags {-{Spec-fict-novel-stub}}. is an example. I am only trying to keep the types that my bot can reasonably find (vie [[regex]]). Please give me some time...thats all I'm asking for:-)[[user:Eagle 101|Eagle]] ([[user_talk:Eagle 101|talk]]) ([[user:Eagle 101/Desk|desk]]) 17:32, 4 March 2006 (UTC)
en:Wikipedia:Articles for deletion/The Wotch
** I think the issue here isn't more relevant information so much as it is much, much less ''irrelevant'' information. }:-{D [[User:Redneckgaijin|Redneckgaijin]] 22:25, 25 May 2006 (UTC)
en:Wikipedia:WikiProject Anglicanism/Assessment
|-{| class="wikitable plainlinks" width="100%"
en:File:Frobenius obj coh 1.png
A\otimes A\ar[d]_{\mu}\ar[r]^-{\delta\otimes A}&\ar[d]^{A\otimes\mu}A\otimes A\otimes A\\
en:File:Frobenius obj coh 1.png
A\ar[r]_-{\delta}&A\otimes A
en:File:Frobenius obj coh 2.png
A\otimes A\ar[d]_{\mu}\ar[r]^-{A\otimes\delta}&\ar[d]^{\mu\otimes A}A\otimes A\otimes A\\
en:File:Frobenius obj coh 2.png
A\ar[r]_-{\delta}&A\otimes A
en:Wikipedia:Deletion log/June 2004 (1)
<li>05:12, 11 Jun 2004 [[User:Guanaco|Guanaco]] deleted "User:Guanaco/Sandbox" (content was: '{(test)}{(test2)}{(test3)}{(test4)}{(test5)}----{(spam)}{(spam2)}{(spam3)}{(spam4)}----{(revert)}{(revert2)}{(revert3)}{(rev...')</li>
en:Wikipedia:Deletion log/June 2004 (1)
<li>04:47, 11 Jun 2004 [[User:Guanaco|Guanaco]] deleted "Redeemers" (content was: '== Headline text ==i<math><math><math>------{(User:Brockert/sig)} 23:09, Jan 8, 2005 (UTC)''''''''''' realy love michael arballo so much he is the hottest guy at our school Kassie realy l...')</li>
en:Wikipedia:Deletion log/June 2004 (2)
<li>21:39, 14 Jun 2004 [[User:Guanaco|Guanaco]] deleted "False pride" (vanity - deletion requested by author content was: '----{(delete)}DELETE ME NOW!I ALREADY EXPLAINED MYSELFWHY IS THIS STILL HERE?I was bored one day and also a little excited since i got publi...')</li>
en:Wikipedia:Deletion log/October 2004 (1)
<li>13:22, 3 Oct 2004 [[User:Docu|Docu]] deleted "Category:Test1level2" (content was: 'Start----Hello this is test1 level2----[Category:test1level3]]----{Category:test1level3}}----end')</li>
en:Wikipedia:Reference desk/Archives/Mathematics/2007 January 26
#There exist a unique member of , called "1", such that f is a [[bijection]] from -{1} to .
en:Wikipedia:Featured article candidates/Ernest Emerson
****I may clip that one or remove it. Thanks for pointing that out, on the peer review I was told to make the pictures bigger and add more.--{[User:Mike Searson|Mike Searson]] 23:51, 16 February 2007 (UTC)
en:Wikipedia:Reference desk/Archives/Mathematics/2007 April 18
#There exist a unique member of , called "1", such that f is a [[bijection]] from -{1} to .
en:MediaWiki:Gadget-popups.js
this.data=this.data.replace(RegExp('^-{4,}','mg'),'');
en:Wikipedia:Reliable sources/Noticeboard/Archive 5
:*The English Altermedia had content that was clearly anti-{Muslim, Jew, black}. Is the Romanian site different, or does it have a similar slant? The Romanian site uses the same tagline, "World wide news for people of European descent". The implication is obvious.
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-04
{{User:CheMoBot/Logline|id=4362|level=2|time=14:44:15|date=04-11-2008|user=Fvasconcellos|page=Linezolid|diff=http://en.wikipedia.org/w/index.php?diff=255837391&oldid=252215261|box=drugbox|added=|changed=3-(3-fluoro-4-morpholinophenyl)- 2-oxooxazolidin-5-ylmethylacetamide' -> '''N''-{[(5''S'')-3-(3-fluoro-4-piperidin-1-ylphenyl)-2-oxo- 1,3-oxazolidin-5-yl]methyl}acetamide', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=2|timestamp=1228416255}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-20
{{User:CheMoBot/Logline|id=13785|level=2|time=16:33:33|date=20-11-2008|user=79.121.106.220|page=Cadralazine|diff=http://en.wikipedia.org/w/index.php?diff=259175137&oldid=227662755|box=drugbox|added=|changed=6-(ethyl-(2-hydroxypropyl)amino)pyridazin-3-yl]amino]carbamate' -> 'ethoxy-''N'''-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}carbohydrazide', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229805213}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-21
{{User:CheMoBot/Logline|id=14065|level=2|time=08:02:11|date=21-11-2008|user=79.121.106.220|page=Ramipril|diff=http://en.wikipedia.org/w/index.php?diff=259306435&oldid=258714686|box=drugbox|added=|changed=(1''S'')-1-ethoxycarbonyl-3-phenyl- propyl]amino]propanoyl]-8-azabicyclo[3.3.0]octane-7- carboxylic acid' -> '(2''S'',3''aS'',6''aS'')-1-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[''b'']pyrrole-2-carboxylic acid', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229860931}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-21
{{User:CheMoBot/Logline|id=14068|level=2|time=08:05:18|date=21-11-2008|user=79.121.106.220|page=Quinapril|diff=http://en.wikipedia.org/w/index.php?diff=259306734&oldid=252156526|box=drugbox|added=|changed=(1''S'')-1-ethoxycarbonyl-3-phenyl- propyl]amino]propanoyl]-3,4-dihydro-1''H''-isoquinoline- 3-carboxylic acid' -> '(3''S'')-2-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229861118}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-21
{{User:CheMoBot/Logline|id=14074|level=2|time=08:16:59|date=21-11-2008|user=79.121.106.220|page=Trandolapril|diff=http://en.wikipedia.org/w/index.php?diff=259308121&oldid=251952801|box=drugbox|added=|changed=(1''S'')-1-ethoxycarbonyl-3-phenyl- propyl]amino]propanoyl]-2,3,3''a'',4,5,6,7,7''a''-octahydroindole- 2-carboxylic acid' -> '(2''S'',3''aR'',7''aS'')-1-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1''H''-indole-2-carboxylic acid', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229861819}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-21
{{User:CheMoBot/Logline|id=14075|level=2|time=08:19:06|date=21-11-2008|user=79.121.106.220|page=Spirapril|diff=http://en.wikipedia.org/w/index.php?diff=259308367&oldid=251549209|box=drugbox|added=|changed=(1''S'')-1-ethoxycarbonyl-3-phenyl-propyl] amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8- carboxylic acid' -> '(8''S'')-7-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229861946}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-21
{{User:CheMoBot/Logline|id=14091|level=2|time=08:59:20|date=21-11-2008|user=79.121.106.220|page=Telmisartan|diff=http://en.wikipedia.org/w/index.php?diff=259312359&oldid=251818816|box=drugbox|added=|changed= ' -> '2-(4-{[4-methyl-6-(1-methyl-1''H''-1,3-benzodiazol-2-yl)-2-propyl-1''H''-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229864360}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-21
{{User:CheMoBot/Logline|id=14163|level=2|time=11:06:45|date=21-11-2008|user=79.121.106.220|page=Ketoconazole|diff=http://en.wikipedia.org/w/index.php?diff=259322085&oldid=254562071|box=drugbox|added=|changed=(2''S'',4''R'')-2-(2,4-dichlorophenyl)- 2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy] phenyl]piperazin-1-yl]ethanone' -> '1-[4-(4-{[(2''R'',4''S'')-2-(2,4-dichlorophenyl)-2-(1''H''-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229872005}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-21
{{User:CheMoBot/Logline|id=14190|level=2|time=11:43:57|date=21-11-2008|user=79.121.106.220|page=Posaconazole|diff=http://en.wikipedia.org/w/index.php?diff=259325408&oldid=257363302|box=drugbox|added=|changed=(3''R'',5''R'')-5-(2,4-difluorophenyl)tetrahydro- 5-(1''H''-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy] phenyl]-1-piperazinyl]phenyl]-2-[(1''S'',2''S'')-1-ethyl- 2-hydroxypropyl]-2,4-dihydro-3''H''-1,2,4-triazol-3-one' -> '4-{4-[4-(4-{[(5''R'')-5-(2,4-difluorophenyl)-5-(1''H''-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2''S'',3''S'')-2-hydroxypentan-3-yl]-4,5-dihydro-1''H''-1,2,4-triazol-5-one', UNSET)</nowiki>|deleted=|urls=|isIP=1|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229874237}}
en:Wikipedia:WikiProject Chemicals/Log/2008-12-22
{{User:CheMoBot/Logline|id=14697|level=5|time=11:21:05|date=22-11-2008|user=P-kun80|page=Glutathione|diff=http://en.wikipedia.org/w/index.php?diff=259505710&oldid=258933211|box=chembox|added=|changed=(2''R'')-1-(carboxymethylamino)-1-oxo- 3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid' -> '(2''S'')-2-amino-4-{[(1''R'')-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229959265}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-22
{{User:CheMoBot/Logline|id=14734|level=2|time=12:36:13|date=22-11-2008|user=P-kun80|page=Iocarmic_acid|diff=http://en.wikipedia.org/w/index.php?diff=259512566&oldid=255206105|box=drugbox|added=|changed=6-3-Carboxy-2,4,6-triiodo-5-(methylcarbamoyl)phenyl]amino]-6-oxohexanoyl]amino]-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid' -> '3-(5-{[3-carboxy-2,4,6-triiodo-5-(methylcarbamoyl)phenyl]carbamoyl}pentanamido)-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229963773}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-22
{{User:CheMoBot/Logline|id=14763|level=2|time=13:02:35|date=22-11-2008|user=P-kun80|page=Ioglycamic_acid|diff=http://en.wikipedia.org/w/index.php?diff=259515077&oldid=255218546|box=drugbox|added=|changed=2-[2-[(3-Carboxy-2,4,6-triiodophenyl)amino]-2-oxoethoxy]acetyl]amino]-2,4,6-triiodobenzoic acid' -> '3-(2-{[(3-carboxy-2,4,6-triiodophenyl)carbamoyl]methoxy}acetamido)-2,4,6-triiodobenzoic acid', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229965355}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-22
{{User:CheMoBot/Logline|id=15066|level=2|time=21:59:04|date=22-11-2008|user=P-kun80|page=Doramectin|diff=http://en.wikipedia.org/w/index.php?diff=259589690&oldid=259588680|box=drugbox|added=|changed=''R'',2''S'',4''S'',5''S'',6''R'',8''R'',10''E'',12''R'',13''S'',14''E'',20''R'',21''R'',24''S'')-6-cyclohexyl-21',24'-dihydroxy-12'-{[(2''R'',4''S'',5''S'',6''S'')-5-{[(2''S'',4''S'',5''S'',6''S'')-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-5,6-dihydro-3',7',19'-trioxaspiro[pyran-2,6'-tetracyclo[15.6.1.14,8.020,24]pentacosane]-10',14',16',22'-tetraen-2'-one', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1229997544}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-25
{{User:CheMoBot/Logline|id=16213|level=2|time=11:17:19|date=25-11-2008|user=P-kun80|page=Ibodutant|diff=http://en.wikipedia.org/w/index.php?diff=260031912&oldid=252094395|box=drugbox|added=|changed=' -> '''N''Î±-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-''N''-{[1-(tetrahydro-2''H''-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1230218239}}
en:Wikipedia:WikiProject Chemicals/Log/2008-12-26
{{User:CheMoBot/Logline|id=16712|level=5|time=12:46:01|date=26-11-2008|user=P-kun80|page=Metiamide|diff=http://en.wikipedia.org/w/index.php?diff=260162545&oldid=208018198|box=chembox|added=''-(2-{[(4-methyl-1''H''-imidazol-5-yl)methyl]thio}ethyl)thiourea', UNSET)</nowiki>|changed=|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1230309961}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-27
{{User:CheMoBot/Logline|id=17670|level=2|time=19:55:21|date=27-11-2008|user=P-kun80|page=Pramiconazole|diff=http://en.wikipedia.org/w/index.php?diff=260358213&oldid=224483985|box=drugbox|added=|changed=(2''R'',4S)-2-(2,4-Difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,' -> '1-{4-[4-(4-{[(2''R'',4''S'')-2-(2,4-difluorophenyl)-2-(1''H''-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-3-isopropylimidazolidin-2-one', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1230422121}}
en:Wikipedia:WikiProject Pharmacology/Log/2008-12-29
{{User:CheMoBot/Logline|id=18462|level=2|time=16:19:04|date=29-11-2008|user=P-kun80|page=Terlipressin|diff=http://en.wikipedia.org/w/index.php?diff=260681998&oldid=255896462|box=drugbox|added=|changed=2- 2-[(2-Aminoacetyl)amino]acetyl]amino] acetyl]amino]-13-benzyl-10-(2-carbamoylethyl)- 7-(carbamoylmethyl)-16-[(4-hydroxyphenyl) methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8, 11,14,17-pentazacycloicosane-4-carbonyl]-''N''- [(1''S'')-5-amino-1-(carbamoylmethylcarbamoyl) pentyl]pyrrolidine-2-carboxamide' -> '1-{[(4''R'',7''S'',10''S'',13''S'',16''S'',19''R'')-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-''N''-(2-amino-2-oxoethyl)-L-lysinamide', UNSET)</nowiki>|deleted=|urls=|isIP=0|function=EDIT|reason=edit to watched box containing page|whitelisted=0|timestamp=1230581944}}
en:Template:Hands/numdisp
-- negative amounts, the &minus with inverse -{1} is padded
en:Template:Hands/numdisp/sandbox
-- negative amounts, the &minus with inverse -{1} is padded
en:File:Homotopy lifting property.svg
Y \times I \ar[r]_-{f} \ar@{-->}[ur]^{\tilde{f}}& B
en:Wikipedia:Articles for deletion/Greenfinger (3rd nomination)
* ''' Thought:''' Find an article on eco-{terrorism, activism, extermism, etc} and put in a sentence and a source of two. Debate it there. Somtimes a passing mention of a word that is clever or useful for a given topic may be helpful.[[User:Nerdseeksblonde|Nerdseeksblonde]] ([[User talk:Nerdseeksblonde|talk]]) 17:39, 15 June 2009 (UTC)
en:Template:PDB Gallery/1017
|Image:PDB_1ke5_EBI.jpg|'''1ke5''': CDK2 complexed with N-methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
en:Template:PDB Gallery/1017
|Image:PDB_1ke6_EBI.jpg|'''1ke6''': CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
en:Template:PDB Gallery/1017
|Image:PDB_1ke9_EBI.jpg|'''1ke9''': CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
en:Wikipedia:Bots/Requests for approval/ContentCreationBOT
*A "1" in the valid column means it is currently listed as a valid genus, "NoData" means it couldn't be determined - most likely because there are two genus with the same name, and "No-{explanation}" means it is not currently listed as a valid genus.
en:Wikipedia:The Great Wikipedia Dramaout/2nd
<!--uncomment this when the Dramaout starts-- --{| width=100% style="border: 3px black; padding: 15px; background:none"
en:Template:Rndpad
-->}}<!--endif-{1}>100thousand
en:Wikipedia:Reference desk/Archives/Science/2010 April 19
::::...oops, I meant ''thar'' population as me kin foke would harv me say. :-{ [[Special:Contributions/71.100.1.71|71.100.1.71]] ([[User talk:71.100.1.71|talk]]) 07:20, 22 April 2010 (UTC)
en:Wikipedia:The Great Wikipedia Dramaout/3rd
<!--uncomment this when the Dramaout starts-- --{| width=100% style="border: 3px black; padding: 15px; background:none"
en:Wikipedia:Reference desk/Archives/Mathematics/2010 June 15
:::::::::You didn't explicitly say I could use , either, but if I'm using bound variables you've got to let me bind them. If you like, I can remove the -{0} bit and add "or y+y=y" to the bit in brackets. --[[User:Tango|Tango]] ([[User talk:Tango|talk]]) 22:23, 16 June 2010 (UTC)
en:Wikipedia:Reference desk/Archives/Mathematics/2010 October 28
We call a set of propositions S independent if for all s in S, we can not deduce s from S-{s} (i.e. s is required to deduce s from S). We call 2 proposition sets S, T equivalent if for every s in S, we can deduce s from T, and for every t in T, we can deduce t from S. I've shown that for every proposition set (countable), there exists an independent set equivalent to it, but now what happens if we allow our initial propositions to be uncountable? Is there still always an independent equivalent subset?
en:Wikipedia:Reference desk/Archives/Mathematics/2010 October 28
: I'm not terribly well versed in logic, or set theory for that matter, but I believe the uncountable case follows from [[Zorn's lemma]]. Take P as the set of all subsets of S, an uncountable set of propositions. Take E as the set of all elements of P equivalent to S, which is clearly nonempty, since it contains s. Partially order E by reverse inclusion. Zorn's lemma provides us with at least one maximal element M, which, from our reverse ordering, is actually minimal under standard inclusion. Any subset M' in E of M would be comparable to M under our partial order, so, since M is minimal, M' must be M. That is, no proper subset of M is equivalent to S, therefore, to M. Take M-{m} for any m, which is now not equivalent to M, so m cannot be deduced from M-{m}. Thus M is independent and equivalent to S.
en:Wikipedia:Reference desk/Archives/Mathematics/2010 October 28
:::Bah, how embarassing. Forgetting to check for bounded chains when applying Zorn's lemma is a bit like making an omelet while forgetting the eggs.... Modifying the above, I've gotten a bit farther, at least. If you take P to be the set of all independent sets provable from S, P contains the singletons from S so is nonempty. Any chain C = {I_a} has upper bound J = Union of C. To the contrary, if J isn't independent, some j in J is proven by J-{j}. Assuming proofs are of finite length, they can apply at most finitely many axioms in J-{j}, so say the finite subset J_0 of J-{j} proves j. J_0 + {j} are each contained in some finite set of I_a's, where the union of this finite set must itself be an I_a since they form a totally ordered finite sequence through inclusion. Call this union I_0. But then I_0 is independent and contains J_0 + {j}, so I_0 - {j} doesn't prove j, so J_0 doesn't prove j, a contradiction. So, each chain is bounded and Zorn's lemma gives a maximal independent set containing elements provable from S. Unfortunately, I haven't been able to show such a maximal set is equivalent to S, or to provide a counterexample. [[Special:Contributions/67.158.43.41|67.158.43.41]] ([[User talk:67.158.43.41|talk]]) 02:39, 30 October 2010 (UTC)
en:Template:Rndpad/sandbox
-->}}<!--endif-{1}>100thousand
en:Wikipedia:Reference desk/Archives/Science/2011 February 17
:It's all part of [[IUPAC nomenclature of organic chemistry]]. You treat the main attachment as itself a parent to which are attached more groups: "(A attached to B) attached to C". When identifying the A on B, with the same rules of group-names, precedence, etc as usual are used, with the additional detail that the carbon in B that attaches to C is considered position #1 in the B sidechain. So instead of propyl, you have 2-methylpropyl, and that whole thing is at position 5 on nonane: 5-{2-methylpropyl)nonane. [[IUPAC nomenclature]]. You may also see it named as some relationship to "a four-carbon unit" attached, with some name related to [[Butyl]] used to indicate that it's not a literally a -CH2-CH2-CH2-CH3 attached. [[User:DMacks|DMacks]] ([[User talk:DMacks|talk]]) 01:37, 17 February 2011 (UTC)
en:Wikipedia:Reference desk/Archives/Language/2011 February 28
::Also, I think the fact that "mathematics" ''is'' a singular noun is the reason why the abbreviation is "math" in American English, not "maths". There's just no reason to keep the -s when the word is abbreviated, since the word is ultimately a single morpheme (it's {mathematics}, not {mathematic}-{s}). The form "maths" would make sense to me only if "mathematics" were also treated as a plural, so that {mathematic}-{s} is shortened to {math}-{s}, without any awkward cutting out of the middle of a morpheme. But that's just my American perspective! [[User:Voikya|Voikya]] ([[User talk:Voikya|talk]]) 15:19, 28 February 2011 (UTC)
en:Wikipedia:Village pump (technical)/Archive AJ
(something like : R = R_{\|} = -{2GM \over {c^2 r^3}} = -{8 \pi G \over {3 c^2 } }\rho (r) )
en:Wikipedia:Village pump/Archive O
Some manoevres become automaized. A typical example might be the two spaces after a period-sign for US typewriters, or the space-before-{colon, exclamation mark, question mark} typical for French typists. Another example, relevant for me, is the process of inserting a carriage-return in a paragraph. Due to some reason, unknown to me, I've got used to making ''one'' jump forward from the period-sign before I hit the carriage-return buttom. If I write fast and don't concentrate on it, I won't discover that there is an extra space on the new line ...at least not until I've hit show-preview (if I'm lucky).
en:Template:Internal link helper
<includeonly>[[Category:pages with blue links that have been tagged with an internal link helper template]]|Item">}}[[{{{1}}}|{{#if:{{{d|}}}|{{{d}}}|{{{1}}}}}]]（{{{lang}}}：-{[[:{{{lang-code}}}:{{{2}}}|{{{2}}}]]}-）</includeonly><noinclude>{{doc}}</noinclude>
en:Wikipedia:Village pump (proposals)/Archive 83
:::Good point that if it's visible, people will try it and find themselves confused at times, in the same process of discovery of everyone who's tried the temporary-{reflist} trick. The tick box would definitely need a "what's this?" link beside it, similar to "This is a minor edit". As far as hiding errors (in re Fred), errors generated within the section itself would presumably need to be shown, as that is what the final output would show. The one "external" error we are aware of is invoking a named reference. This is the MediaWiki "cite_error_references_no_text" message [http://en.wikipedia.org/w/index.php?title=Special%3AAllMessages&prefix=cite_error_references_&filter=all&lang=en&limit=50], generated by the referenceText() function in [http://svn.wikimedia.org/viewvc/mediawiki/trunk/extensions/Cite/Cite_body.php?revision=108031&view=markup Cite_body.php]. I'm not a MediaWiki dev, but it does look to me like adding a "friendly" mode to emit "cite_preview_references_no_text" instead would be a fairly lightweight code change, and each project could write it's own message and help page. The help info would explain that if you are trying to reuse a named ref defined within the section, you've done something wrong, but if it's a named ref defined elsewhere you will still need to check the final output. This more limited proposal still looks quite doable. [[User:Franamax|Franamax]] ([[User talk:Franamax|talk]]) 00:45, 5 January 2012 (UTC)
en:Wikipedia:The Great Wikipedia Dramaout/4th
<!--uncomment this when the Dramaout starts-- --{| width=100% style="border: 3px black; padding: 15px; background:none"
en:Wikipedia:Miscellany for deletion/User:JamikaPolama/sandbox
***If you are an editor in good standing with constructive contributions to article space, I'd personally say "yes, go for it!". I'm in the minority though. The userspace police around here love picking on userspace pages that might imply you are a real human with interests outside WP :-{ --[[User:Surturz|Surturz]] ([[User talk:Surturz|talk]]) 21:08, 11 July 2012 (UTC)
en:Wikipedia:Village pump (technical)/Archive 103
* citation help and {-{Harvnb}}
en:Wikipedia:WikiProject Record Production/Workshop/List of Country Music Hall of Fame inductees/Interactive
|-{
en:Module:Convert
if id:sub(1, 2) == '-{' then -- for "-{...}-" content language variant
en:Module:Convert/sandbox
if id:sub(1, 2) == '-{' then -- for "-{...}-" content language variant
en:Wikipedia:VisualEditor/Feedback/Archive 2013 6
#I want to move some text from the body to a {-{efn. I cntl-x the text.I go to the recieving spot and hit the jigsaw- I add the template efn. I have the text in the buffer and a screen that is asking for a parameter name- efn only has one parameter- but it doesn't have or need a name. Add parameter is greyed out- and stays that way until you give the template a name. No hint, no hover to help and nowhere to paste the buffer. ''(Issue 10)''
en:Wikipedia:VisualEditor/Feedback/Archive 2013 6
:::::::::I have a work around but I don't think that is the point- but it also handles PamD's concerns about maintenance tags. I'll share it. On the tool bar you just add an extra icon, '@' would do it would open up a popup box with a single text-enter box- the contents are the raw contents of a template- for instance I would type sfn|Dickinson|2002|p=47 and press return (or ) . This would have have any matching outer {-{ stripped to cater for people who are c&p known templates,and then {-{ }-} would be added to build the template - a validation check *a could be done- then the raw code could be written into the text. On rendering would appear like '[14]' a normal reference. This system could be used for any template *b - personally I would also use it for . Whenever there is a hover event, the raw code comes up as a alertbox. We don't even need an icon, a double-click event in the text could take you into raw. Keep it simple, dont attempt to do multiple line that adds a degree of complexity.
en:Module:Sandbox/Hellknowz/Test/testcases
--{ '{{Start date|2012|12|10}}', 'Has metadata template' },
en:Module:Sandbox/Hellknowz/Test/testcases
--{ '{{Enddate|2013|12|10}}', 'Has metadata template' },
en:Module:Infobox date field metadata/testcases
--{ '{{Start date|2012|12|10}}', 'Has metadata template' },
en:Module:Infobox date field metadata/testcases
--{ '{{Enddate|2013|12|10}}', 'Has metadata template' },
en:Wikipedia:VisualEditor/Feedback/Archive 2013 12
::The concept of a VE if fine- this just isn't a VE. We need to seemlessly move between infoboxes, lede and subsections. We need to start by making {-{ sfn }-}{-{ efn }-}s and then prompt the {-{ cite for the antomatically generated /= = Bibliography. We need predictive text to detect double brace, double square brace and flip into a template editor. I suspect that WMF has failed to understand that the user base is a couple of generations ahead in in their requirements for a VE, and WMF sees considered rejection of the current VE experiment as Luddism.
en:Module:Citation/CS1/autofix
else --{'audio-visual', 'AV-media-notes', 'DVD-notes', 'episode', 'interview', 'mailinglist', 'map', 'newsgroup', 'podcast', 'press release', 'serial', 'sign', 'speech', 'web'}
en:Module:FindFeatures/displayDatabase
pagecontent = mw.ustring.gsub(pagecontent, "^.-{|", "{|") -- remove all before first table
en:Module:FindFeatures/displayDatabase
pagecontent = mw.ustring.gsub(pagecontent, "|}.-{|", "") or pagecontent -- remove all between tables
en:Wikipedia:Graphics Lab/Map workshop/Archive/Jan 2014
::* it is convenient to use a file naming convention such '''File:{Subject name in English} relief location map-{language}.svg''', for you: '''File:Serbian_Empire_1355_CE_relief_location_map-en.svg'''. This naming scheme is within the [[Wikipedia:WikiProject_Maps/Conventions/Topographic_maps|our topographic toolbox]]. If you plan to fully complete the request, the final name is ok. Otherwise, you may add "~~(draft01).svg".
en:Wikipedia:WikiProject Wikify/Drives/2014/April/Track
{{Backlog progress bar |initial=34435 |goal=33500 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Wikipedia:WikiProject Wikify/Drives/2014/June/Track
{{Backlog progress bar |initial=37000 |goal=36000 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Module:Syrian Civil War detailed map
--{ lat = 34.885, long = 36.996, mark = m.gov, marksize = 6, label = "[[Tal Khazneh]]", link = "Tal Khazneh", label_size = 0 },
en:Module:Syrian Civil War detailed map
--{ lat = 35.265, long = 40.188, mark = m.IS_base, marksize = 4, label = "[[Al-‘Alam Farm]]", label_size = 0 },
en:Module:Syrian Civil War detailed map
--{ lat = 35.274, long = 40.201, mark = m.IS_base, marksize = 4, label = "[[Abu Waleed Farm]]", label_size = 0 },
en:Module:Syrian Civil War detailed map
--{ lat = 35.237, long = 36.603, mark = m.gov_base, marksize = 4, label = "[[Al Tarabia Checkpoint]]", label_size = 0 },
en:Wikipedia:WikiProject Wikify/Drives/2014/August/Track
{{Backlog progress bar |initial=37977 |goal=36500 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Module:Syrian Civil War detailed map/sandbox
--{ lat = 34.885, long = 36.996, mark = m.gov, marksize = 6, label = "[[Tal Khazneh]]", link = "Tal Khazneh", label_size = 0 },
en:Module:Syrian Civil War detailed map/sandbox
--{ lat = 35.265, long = 40.188, mark = m.IS_base, marksize = 4, label = "[[Al-‘Alam Farm]]", label_size = 0 },
en:Module:Syrian Civil War detailed map/sandbox
--{ lat = 35.274, long = 40.201, mark = m.IS_base, marksize = 4, label = "[[Abu Waleed Farm]]", label_size = 0 },
en:Module:Iraqi insurgency detailed map
--{ lat = "36.279707", long = "42.944870 ", mark = m.opp, marksize = "2", label = "[[Sahaji]]", label_size = "0" }, used to adjust "Mosul city small map" to have the exact size and location as in reality. One of 2 reference points/towns at 2 extremes of the map.
en:Module:Iraqi insurgency detailed map
--{ lat = "36.353292", long = "43.381577", mark = m.opp, marksize = "2", label = "[[Bard Allah]]", label_size = "0" }, used to adjust "Mosul city small map" to have the exact size and location as in reality. One of 2 reference points/towns at 2 extremes of the map.
en:Wikipedia:WikiProject Wikify/Drives/2014/October/Track
{{Backlog progress bar |initial=39240 |goal=38500 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Category:Old subpages of template:convert that are potentially used in mainspace
The templates should be fully documented. Old {convert/...} templates in wikicode that are replaceable by Lua-{convert} (and so are ''deprecated'') are not listed here. Note that other subpages, like {convert/doc}, can relate to Lua-{convert}.
en:Wikipedia:WikiProject Wikify/Drives/2014/December/Track
{{Backlog progress bar |initial=35578 |goal=35000 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Module:User:Lesser Cartographies/MR
p.mr[1945.99] = [==[@article {MR1526260, AUTHOR = {Campbell, W. B. and Thebault, Victor and Kaplansky, Irving and Erdos, Paul and Scherk, Peter}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {P}roblems for {S}olution: {E}681-{E}685}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {52}, YEAR = {1945}, NUMBER = {7}, PAGES = {395}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1526260}, DOI = {10.2307/2304646}, URL = {http://dx.doi.org/10.2307/2304646}, }]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1946.99] = [==[@article {MR1544009, AUTHOR = {Grossman, Howard and Thebault, Victor and Schell, E. D. and Scheffe, Henry and Erdos, Paul}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {P}roblems for {S}olution: {E}731-{E}735}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {53}, YEAR = {1946}, NUMBER = {7}, PAGES = {394}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1544009}, DOI = {10.2307/2305860}, URL = {http://dx.doi.org/10.2307/2305860}, }]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1946.96] = [==[@article {MR1526562, AUTHOR = {Sandham, H. F. and Becker, H. W. and Polya, George and Thebault, Victor and Erdos, Paul}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {P}roblems for {S}olution: {E}746-{E}750}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {53}, YEAR = {1946}, NUMBER = {10}, PAGES = {591}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1526562}, DOI = {10.2307/2305245}, URL = {http://dx.doi.org/10.2307/2305245}, }]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1946.94] = [==[@article {MR1526541, AUTHOR = {Scott, William and Laposky, B. F. and Starke, E. P. and Erdos, Paul and Thebault, Victor}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {P}roblems for {S}olution: {E}741-{E}745}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {53}, YEAR = {1946}, NUMBER = {9}, PAGES = {532}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1526541}, DOI = {10.2307/2305076}, URL = {http://dx.doi.org/10.2307/2305076}, }]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1946.93] = [==[@article {MR1526515, AUTHOR = {Erdos, Paul and Klee, Jr., V. L. and Thebault, Victor and Kelly, L. M. and Szekeres, Esther}, TITLE = {Problems and {S}olutions: {P}roblems for {S}olution: {E}736-{E}740}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {53}, YEAR = {1946}, NUMBER = {8}, PAGES = {462}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1526515}, DOI = {10.2307/2306251}, URL = {http://dx.doi.org/10.2307/2306251}, }]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1950.97] = [==[@article {MR1527667, AUTHOR = {Larsen, H. D. and Erdos, Paul and Langr, Joseph and Oakley, C. O. and Olds, C. D.}, TITLE = {Elementary {P}roblems and {S}olutions: {P}roblems for {S}olution: {E}931-{E}935}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {57}, YEAR = {1950}, NUMBER = {8}, PAGES = {556--557}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1527667}, DOI = {10.2307/2307946}, URL = {http://dx.doi.org/10.2307/2307946}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1952.06] = [==[@article {MR0045327, AUTHOR = {Chung, K. L. and Erd{\"o}s, P.}, TITLE = {On the application of the {B}orel-{C}antelli lemma}, JOURNAL = {Trans. Amer. Math. Soc.}, FJOURNAL = {Transactions of the American Mathematical Society}, VOLUME = {72}, YEAR = {1952}, PAGES = {179--186}, ISSN = {0002-9947}, MRCLASS = {60.0X}, MRNUMBER = {0045327 (13,567b)}, MRREVIEWER = {M. Lo{\`e}ve}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1957.17] = [==[@article {MR0092000, AUTHOR = {Erd{\"o}s, Paul}, TITLE = {\"{U}ber eine {F}ragestellung von {G}aier und {M}eyer-{K}\"onig}, JOURNAL = {Jber. Deutsch. Math. Verein.}, FJOURNAL = {Jahresbericht der Deutschen Mathematiker-Vereinigung}, VOLUME = {60}, YEAR = {1957}, NUMBER = {Abt. 1}, PAGES = {89--92}, ISSN = {0012-0456}, MRCLASS = {30.0X}, MRNUMBER = {0092000 (19,1045b)}, MRREVIEWER = {G. Piranian}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1962.09] = [==[@article {MR0137661, AUTHOR = {Erd{\H{o}}s, P.}, TITLE = {On a theorem of {R}ademacher-{T}ur\'an}, JOURNAL = {Illinois J. Math.}, FJOURNAL = {Illinois Journal of Mathematics}, VOLUME = {6}, YEAR = {1962}, PAGES = {122--127}, ISSN = {0019-2082}, MRCLASS = {05.40}, MRNUMBER = {0137661 (25 \#1111)}, MRREVIEWER = {C. Y. Chao}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1968.17] = [==[@article {MR0226479, AUTHOR = {Erd{\H{o}}s, Paul and Straus, E. G.}, TITLE = {\"{U}ber eine geometrische {F}rage von {F}ejes-{T}\'oth}, JOURNAL = {Elem. Math.}, FJOURNAL = {Elemente der Mathematik. Revue de Math\'ematiques \'El\'ementaires. Rivista de Matematica Elementare}, VOLUME = {23}, YEAR = {1968}, PAGES = {11--14}, ISSN = {0013-6018}, MRCLASS = {50.10}, MRNUMBER = {0226479 (37 \#2068)}, MRREVIEWER = {H. W. Guggenheimer}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1970.06] = [==[@incollection {MR0297601, AUTHOR = {Erd{\H{o}}s, P.}, TITLE = {On a lemma of {H}ajnal-{F}olkman}, BOOKTITLE = {Combinatorial theory and its applications, {I} ({P}roc. {C}olloq., {B}alatonf\"ured, 1969)}, PAGES = {311--316}, PUBLISHER = {North-Holland, Amsterdam}, YEAR = {1970}, MRCLASS = {05C99}, MRNUMBER = {0297601 (45 \#6655)}, MRREVIEWER = {Andras Hajnal}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1973.24] = [==[@incollection {MR0396376, AUTHOR = {Erd{\H{o}}s, Paul}, TITLE = {R\'esultats et probl\`emes en th\'eorie des nombres}, BOOKTITLE = {S\'eminaire {D}elange-{P}isot-{P}oitou (14e ann\'ee: 1972/73), {T}h\'eorie des nombres, {F}asc. 2, {E}xp. {N}o. 24}, PAGES = {7}, PUBLISHER = {Secr\'etariat Math\'ematique, Paris}, YEAR = {1973}, MRCLASS = {10-02}, MRNUMBER = {0396376 (53 \#243)}, MRREVIEWER = {R. L. Graham}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1975.31] = [==[@incollection {MR0412138, AUTHOR = {Erd{\H{o}}s, P.}, TITLE = {Problems and results on {D}iophantine approximations. {II}}, BOOKTITLE = {R\'epartition modulo 1 ({A}ctes {C}olloq., {M}arseille-{L}uminy, 1974)}, PAGES = {89--99. Lecture Notes in Math., Vol. 475}, PUBLISHER = {Springer, Berlin}, YEAR = {1975}, MRCLASS = {10K15}, MRNUMBER = {0412138 (54 \#265)}, MRREVIEWER = {I. Niven}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1975.18] = [==[@incollection {MR0409399, AUTHOR = {Erd{\H{o}}s, Paul}, TITLE = {M\'ethodes probabilistes en th\'eorie des nombres}, BOOKTITLE = {S\'eminaire {D}elange-{P}isot-{P}oitou (15e ann\'ee: 1973/74), {T}h\'eorie des nombres, {F}asc. 1, {E}xp. {N}o. 1}, PAGES = {4}, PUBLISHER = {Secr\'etariat Math\'ematique, Paris}, YEAR = {1975}, MRCLASS = {10K20 (10H15 10L99)}, MRNUMBER = {0409399 (53 \#13154)}, MRREVIEWER = {J. Kubilius}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1975.38] = [==[@incollection {MR0396438, AUTHOR = {Erd{\H{o}}s, Paul and Nicolas, Jean-Louis}, TITLE = {R\'epartition des nombres superabondants}, BOOKTITLE = {S\'eminaire {D}elange-{P}isot-{P}oitou (15e ann\'ee: 1973/74), {T}h\'eorie des nombres, {F}asc. 1, {E}xp. {N}o. 5}, PAGES = {18}, PUBLISHER = {Secr\'etariat Math\'ematique, Paris}, YEAR = {1975}, MRCLASS = {10H15 (10A40)}, MRNUMBER = {0396438 (53 \#303)}, MRREVIEWER = {S. Ikehara}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1975.05] = [==[@incollection {MR0379258, AUTHOR = {Erd{\H{o}}s, P. and Simonovits, M. and S{\'o}s, V. T.}, TITLE = {Anti-{R}amsey theorems}, BOOKTITLE = {Infinite and finite sets ({C}olloq., {K}eszthely, 1973; dedicated to {P}. {E}rd{\H o}s on his 60th birthday), {V}ol. {II}}, PAGES = {633--643. Colloq. Math. Soc. J\'anos Bolyai, Vol. 10}, PUBLISHER = {North-Holland, Amsterdam}, YEAR = {1975}, MRCLASS = {05C15}, MRNUMBER = {0379258 (52 \#164)}, MRREVIEWER = {Rudolf Halin}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1976.01] = [==[@article {MR0430596, AUTHOR = {Erd{\H{o}}s, P. and Magidor, M.}, TITLE = {A note on regular methods of summability and the {B}anach-{S}aks property}, JOURNAL = {Proc. Amer. Math. Soc.}, FJOURNAL = {Proceedings of the American Mathematical Society}, VOLUME = {59}, YEAR = {1976}, NUMBER = {2}, PAGES = {232--234}, ISSN = {0002-9939}, MRCLASS = {40H05 (46B15)}, MRNUMBER = {0430596 (55 \#3601)}, MRREVIEWER = {Robert DeVos}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1976.20] = [==[@article {MR0424613, AUTHOR = {Bollob{\'a}s, B{\'e}la and Erd{\H{o}}s, Paul}, TITLE = {On a {R}amsey-{T}ur\'an type problem}, JOURNAL = {J. Combinatorial Theory Ser. B}, FJOURNAL = {Journal of Combinatorial Theory. Series B}, VOLUME = {21}, YEAR = {1976}, NUMBER = {2}, PAGES = {166--168}, MRCLASS = {05C99}, MRNUMBER = {0424613 (54 \#12572)}, MRREVIEWER = {R. L. Graham}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1977.97] = [==[@article {MR1538330, AUTHOR = {Gallin, Daniel and Nederpelt, R. P. and Eggleton, R. B. and Loxton, John H. and Oppenheim, A. and Pelling, M. J. and Erdos, Paul and Rackusin, Jeffrey L.}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}2647-{E}2652}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {84}, YEAR = {1977}, NUMBER = {4}, PAGES = {294--295}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1538330}, DOI = {10.2307/2318876}, URL = {http://dx.doi.org/10.2307/2318876}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1977.24] = [==[@incollection {MR0554189, AUTHOR = {Erd{\H{o}}s, Paul}, TITLE = {Probl\`emes extr\'emaux et combinatoires en th\'eorie des nombres}, BOOKTITLE = {S\'eminaire {D}elange-{P}isot-{P}oitou, 17e ann\'ee (1975/76), {T}h\'eorie des nombres: {F}asc. 2, {E}xp. {N}o. {G}7}, PAGES = {5}, PUBLISHER = {Secr\'etariat Math., Paris}, YEAR = {1977}, MRCLASS = {10-02 (10L99)}, MRNUMBER = {0554189 (58 \#27705)}, MRREVIEWER = {G. J. Rieger}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1982.21] = [==[@article {MR645509, AUTHOR = {Erd{\H{o}}s, P. and S{\'o}s, Vera T.}, TITLE = {On {T}ur\'an-{R}amsey type theorems. {II}}, JOURNAL = {Studia Sci. Math. Hungar.}, FJOURNAL = {Consilium Instituti Mathematici Academiae Scientiarum Hungaricae. Studia Scientiarum Mathematicarum Hungarica}, VOLUME = {14}, YEAR = {1979}, NUMBER = {1-3}, PAGES = {27--36 (1982)}, ISSN = {0081-6906}, CODEN = {SSMHAX}, MRCLASS = {05C55 (04A20 05C15 10H22)}, MRNUMBER = {645509 (84j:05081)}, MRREVIEWER = {D. J. Kleitman}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1980.44] = [==[@incollection {MR582438, AUTHOR = {Erd{\H{o}}s, Paul and Nicolas, Jean-Louis}, TITLE = {Sur la fonction ``nombre de facteurs premiers de {$n$}''}, BOOKTITLE = {S\'eminaire {D}elange-{P}isot-{P}oitou, 20e ann\'ee: 1978/1979. {T}h\'eorie des nombres, {F}asc. 2 ({F}rench)}, PAGES = {Exp. No. 32, 19}, PUBLISHER = {Secr\'etariat Math., Paris}, YEAR = {1980}, MRCLASS = {10H15}, MRNUMBER = {582438 (83a:10074a)}, MRREVIEWER = {Carl Pomerance}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1980.32] = [==[@inproceedings {MR593893, AUTHOR = {Erd{\H{o}}s, P. and S{\'o}s, Vera T.}, TITLE = {Problems and results on {R}amsey-{T}ur\'an type theorems (preliminary report)}, BOOKTITLE = {Proceedings of the {W}est {C}oast {C}onference on {C}ombinatorics, {G}raph {T}heory and {C}omputing ({H}umboldt {S}tate {U}niv., {A}rcata, {C}alif., 1979)}, SERIES = {Congress. Numer., XXVI}, PAGES = {17--23}, PUBLISHER = {Utilitas Math., Winnipeg, Man.}, YEAR = {1980}, MRCLASS = {05C35 (05C55)}, MRNUMBER = {593893 (82a:05055)}, MRREVIEWER = {Jerrold W. Grossman}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1981.30] = [==[@article {MR607039, AUTHOR = {Erd{\H{o}}s, Paul and Mills, George}, TITLE = {Some bounds for the {R}amsey-{P}aris-{H}arrington numbers}, JOURNAL = {J. Combin. Theory Ser. A}, FJOURNAL = {Journal of Combinatorial Theory. Series A}, VOLUME = {30}, YEAR = {1981}, NUMBER = {1}, PAGES = {53--70}, ISSN = {0097-3165}, CODEN = {JCBTA7}, MRCLASS = {03F30 (03C62 03D20 05A17)}, MRNUMBER = {607039 (84c:03099)}, MRREVIEWER = {Leonard Lipshitz}, DOI = {10.1016/0097-3165(81)90040-6}, URL = {http://dx.doi.org/10.1016/0097-3165(81)90040-6}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1982.95] = [==[@article {MR1539916, AUTHOR = {Erdos, P. and Jinghuang, Tian and Leonard, Andrew and Johnsonbaugh, Richard and Norton, Vic and Anderson, Eric}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}2938-{E}2943}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {89}, YEAR = {1982}, NUMBER = {4}, PAGES = {273--274}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1539916}, DOI = {10.2307/2320232}, URL = {http://dx.doi.org/10.2307/2320232}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1982.94] = [==[@article {MR1539865, AUTHOR = {Shallit, J. O. and Halmos, P. R. and Cuculiere, Roger and Erdos, P. and Garfunkel, Jack and Keller, T.}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}2920-{E}2925}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {89}, YEAR = {1982}, NUMBER = {1}, PAGES = {63--64}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1539865}, DOI = {10.2307/2321000}, URL = {http://dx.doi.org/10.2307/2321000}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1982.15] = [==[@article {MR698654, AUTHOR = {Erd{\H{o}}s, P. and S{\'o}s, Vera T.}, TITLE = {On {R}amsey-{T}ur\'an type theorems for hypergraphs}, JOURNAL = {Combinatorica}, FJOURNAL = {Combinatorica. An International Journal of the J\'anos Bolyai Mathematical Society}, VOLUME = {2}, YEAR = {1982}, NUMBER = {3}, PAGES = {289--295}, ISSN = {0209-9683}, CODEN = {COMBDI}, MRCLASS = {05C65 (05C35 05C55)}, MRNUMBER = {698654 (85d:05185)}, DOI = {10.1007/BF02579235}, URL = {http://dx.doi.org/10.1007/BF02579235}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1983.96] = [==[@article {MR1540197, AUTHOR = {Asic, Miroslav D. and Novinger, Phil and Oberlin, Daniel and Adler, Irving and Kimberling, Clark and Shallit, J. D. and Erdos, P.}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}2995-{E}3000}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {90}, YEAR = {1983}, NUMBER = {5}, PAGES = {334--335}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1540197}, DOI = {10.2307/2975788}, URL = {http://dx.doi.org/10.2307/2975788}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1983.30] = [==[@incollection {MR841305, AUTHOR = {Erd{\H{o}}s, P. and F{\"u}redi, Z.}, TITLE = {The greatest angle among {$n$} points in the {$d$}-dimensional {E}uclidean space}, BOOKTITLE = {Combinatorial mathematics ({M}arseille-{L}uminy, 1981)}, SERIES = {North-Holland Math. Stud.}, VOLUME = {75}, PAGES = {275--283}, PUBLISHER = {North-Holland, Amsterdam}, YEAR = {1983}, MRCLASS = {52A37}, MRNUMBER = {841305 (87g:52018)}, MRREVIEWER = {L. M. Kelly}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1983.09] = [==[@article {MR716422, AUTHOR = {Erd{\H{o}}s, P. and Hajnal, A. and S{\'o}s, Vera T. and Szemer{\'e}di, E.}, TITLE = {More results on {R}amsey-{T}ur\'an type problems}, JOURNAL = {Combinatorica}, FJOURNAL = {Combinatorica. An International Journal of the J\'anos Bolyai Mathematical Society}, VOLUME = {3}, YEAR = {1983}, NUMBER = {1}, PAGES = {69--81}, ISSN = {0209-9683}, CODEN = {COMBDI}, MRCLASS = {05C55 (05C35)}, MRNUMBER = {716422 (85b:05129)}, MRREVIEWER = {Stefan A. Burr}, DOI = {10.1007/BF02579342}, URL = {http://dx.doi.org/10.1007/BF02579342}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1983.12] = [==[@article {MR693030, AUTHOR = {Erd{\H{o}}s, Paul and Pach, J{\'a}nos}, TITLE = {On a quasi-{R}amsey problem}, JOURNAL = {J. Graph Theory}, FJOURNAL = {Journal of Graph Theory}, VOLUME = {7}, YEAR = {1983}, NUMBER = {1}, PAGES = {137--147}, ISSN = {0364-9024}, CODEN = {JGTHDO}, MRCLASS = {05C55 (05C80)}, MRNUMBER = {693030 (84d:05127)}, MRREVIEWER = {C. C. Rousseau}, DOI = {10.1002/jgt.3190070117}, URL = {http://dx.doi.org/10.1002/jgt.3190070117}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1983.19] = [==[@article {MR701806, AUTHOR = {Brillhart, John and Erd{\H{o}}s, Paul and Morton, Patrick}, TITLE = {On sums of {R}udin-{S}hapiro coefficients. {II}}, JOURNAL = {Pacific J. Math.}, FJOURNAL = {Pacific Journal of Mathematics}, VOLUME = {107}, YEAR = {1983}, NUMBER = {1}, PAGES = {39--69}, ISSN = {0030-8730}, CODEN = {PJMAAI}, MRCLASS = {11N60 (11N99)}, MRNUMBER = {701806 (85i:11080)}, MRREVIEWER = {G. J. Rieger}, URL = {http://projecteuclid.org/euclid.pjm/1102720737}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1985.35] = [==[@article {MR775969, AUTHOR = {Anderson, J. M. and Erd{\H{o}}s, Paul and Pinkus, Allan and Shisha, Oved}, TITLE = {The closed linear span of {$\{x^k$}--{$c_k\}^\infty_1$}}, JOURNAL = {J. Approx. Theory}, FJOURNAL = {Journal of Approximation Theory}, VOLUME = {43}, YEAR = {1985}, NUMBER = {1}, PAGES = {75--80}, ISSN = {0021-9045}, CODEN = {JAXTAZ}, MRCLASS = {41A10}, MRNUMBER = {775969 (86m:41005)}, MRREVIEWER = {D. Leviatan}, DOI = {10.1016/0021-9045(85)90150-9}, URL = {http://dx.doi.org/10.1016/0021-9045(85)90150-9}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1987.98] = [==[@article {MR1541076, AUTHOR = {Bennett, Grahame and Erdos, Paul and Montgomery, Hugh L. and Gessel, Ira and Clark, Dean S. and Group, Chico Problem}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3201-{E}3206}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {94}, YEAR = {1987}, NUMBER = {4}, PAGES = {371--373}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541076}, DOI = {10.2307/2323102}, URL = {http://dx.doi.org/10.2307/2323102}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1987.97] = [==[@article {MR1541060, AUTHOR = {Kuipers, L. and Isaacs, I. Martin and Rubel, L. A. and Schoenberg, I. J. and Guelicher, H. and Erdos, Paul}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3195-{E}3200}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {94}, YEAR = {1987}, NUMBER = {3}, PAGES = {300--301}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541060}, DOI = {10.2307/2323402}, URL = {http://dx.doi.org/10.2307/2323402}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1988.96] = [==[@article {MR1541376, AUTHOR = {Milosevic, D. M. and Frink, Orrin and Erdos, Paul and Nicholson, W. K. and Waterhouse, William C. and Bloom, David M. and Cade, John J.}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3282-{E}3288}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {95}, YEAR = {1988}, NUMBER = {8}, PAGES = {762--763}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541376}, DOI = {10.2307/2322261}, URL = {http://dx.doi.org/10.2307/2322261}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1988.94] = [==[@article {MR1541280, AUTHOR = {Bulman-Fleming, Sydney and Wang, Edward T. H. and Singmaster, David and Erdos, Paul and Isbell, John and Sakmar, I. A. and Gonciulea, Nicolae}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3253-{E}3258}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {95}, YEAR = {1988}, NUMBER = {3}, PAGES = {258--259}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541280}, DOI = {10.2307/2323631}, URL = {http://dx.doi.org/10.2307/2323631}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1988.93] = [==[@article {MR1541238, AUTHOR = {Trench, William F. and Rodriguez, R. S. and Sherwood, H. and Reznick, Bruce A. and Rubel, Lee A. and Golomb, Solomon W. and Kinnon, Nick M. and Erdos, Paul and Selfridge, John}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3243-{E}3248}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {95}, YEAR = {1988}, NUMBER = {1}, PAGES = {50--51}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541238}, DOI = {10.2307/2323449}, URL = {http://dx.doi.org/10.2307/2323449}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1989.98] = [==[@article {MR1541602, AUTHOR = {Szekely, Laszlo A. and Erdos, Paul and Wimp, Jet and Bencharit, Um and Senum, G. I. and Alexandrov, V. A. and Dairbekov, N. S. and Diamond, H. G.}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3349-{E}3352,{E}3354,{E}3353}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {96}, YEAR = {1989}, NUMBER = {9}, PAGES = {837--838}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541602}, DOI = {10.2307/2324851}, URL = {http://dx.doi.org/10.2307/2324851}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1989.95] = [==[@article {MR1541495, AUTHOR = {Erdos, Paul and Klamkin, M. S. and Spira, Robert and Lupas, Alexandru and Plambeck, Thane and Meyerson, Mark D. and Richter, R. Bruce}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3319-{E}3324}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {96}, YEAR = {1989}, NUMBER = {4}, PAGES = {356--357}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541495}, DOI = {10.2307/2324095}, URL = {http://dx.doi.org/10.2307/2324095}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1989.10] = [==[@article {MR1000076, AUTHOR = {Burr, S. A. and Erd{\H{o}}s, P. and Graham, R. L. and S{\'o}s, V. T.}, TITLE = {Maximal anti-{R}amsey graphs and the strong chromatic number}, JOURNAL = {J. Graph Theory}, FJOURNAL = {Journal of Graph Theory}, VOLUME = {13}, YEAR = {1989}, NUMBER = {3}, PAGES = {263--282}, ISSN = {0364-9024}, CODEN = {JGTHDO}, MRCLASS = {05C55 (05C35)}, MRNUMBER = {1000076 (90c:05146)}, MRREVIEWER = {Miros{\l}aw Truszczy{\'n}ski}, DOI = {10.1002/jgt.3190130302}, URL = {http://dx.doi.org/10.1002/jgt.3190130302}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1990.96] = [==[@article {MR1541779, AUTHOR = {Erdos, Paul and Eynden, Charles Vanden and Shallit, Jeffrey and Kimberling, Clark and Savall, Juan V. and Ferrer, Jesus}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3403-{E}3408}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {97}, YEAR = {1990}, NUMBER = {9}, PAGES = {847--848}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541779}, DOI = {10.2307/2324756}, URL = {http://dx.doi.org/10.2307/2324756}, }]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1991.93] = [==[@article {MR1541867, AUTHOR = {Padmanabhan, R. and Mendelsohn, N. S. and Wolk, B. and Boghossian, Artin B. and Knuth, Donald E. and McCarthy, John and Erdos, Paul and Shallit, Jeffrey and Toth, Laszlo}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3427-{E}3432}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {98}, YEAR = {1991}, NUMBER = {3}, PAGES = {263--264}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541867}, DOI = {10.2307/2325034}, URL = {http://dx.doi.org/10.2307/2325034}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1991.92] = [==[@article {MR1541847, AUTHOR = {Janous, Walther and Demir, H. and Tezer, C. and Horwitz, Alan and Erdos, Paul and Rosset, Shmuel and Shalom, Tamir and Steele, J. Michael}, TITLE = {Problems and {S}olutions: {E}lementary {P}roblems: {E}3421-{E}3426}, JOURNAL = {Amer. Math. Monthly}, FJOURNAL = {The American Mathematical Monthly}, VOLUME = {98}, YEAR = {1991}, NUMBER = {2}, PAGES = {158--159}, ISSN = {0002-9890}, CODEN = {AMMYAE}, MRCLASS = {Contributed Item}, MRNUMBER = {1541847}, DOI = {10.2307/2323951}, URL = {http://dx.doi.org/10.2307/2323951}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1991.13] = [==[@incollection {MR1170778, AUTHOR = {Burr, S. A. and Erd{\"o}s, P. and S{\'o}s, V. T. and Frankl, P. and Graham, R. L.}, TITLE = {Further results on maximal anti-{R}amsey graphs}, BOOKTITLE = {Graph theory, combinatorics, and applications, {V}ol.\ 1 ({K}alamazoo, {MI}, 1988)}, SERIES = {Wiley-Intersci. Publ.}, PAGES = {193--206}, PUBLISHER = {Wiley, New York}, YEAR = {1991}, MRCLASS = {05C55}, MRNUMBER = {1170778 (93i:05093)}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1991.11] = [==[@incollection {MR1132890, AUTHOR = {Burr, S. A. and Erd{\H{o}}s, P.}, TITLE = {Extremal non-{R}amsey graphs}, BOOKTITLE = {Graph theory, combinatorics, algorithms, and applications ({S}an {F}rancisco, {CA}, 1989)}, PAGES = {42--66}, PUBLISHER = {SIAM, Philadelphia, PA}, YEAR = {1991}, MRCLASS = {05C55 (05C35)}, MRNUMBER = {1132890 (93b:05118)}, MRREVIEWER = {R. H. Schelp}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1993.30] = [==[@article {MR1221175, AUTHOR = {Erd{\H{o}}s, P. and Hajnal, A. and Simonovits, M. and S{\'o}s, V. T. and Szemer{\'e}di, E.}, TITLE = {Tur\'an-{R}amsey theorems and simple asymptotically extremal structures}, JOURNAL = {Combinatorica}, FJOURNAL = {Combinatorica. An International Journal on Combinatorics and the Theory of Computing}, VOLUME = {13}, YEAR = {1993}, NUMBER = {1}, PAGES = {31--56}, ISSN = {0209-9683}, CODEN = {COMBDI}, MRCLASS = {05C55 (05C35 05C38)}, MRNUMBER = {1221175 (94d:05088)}, MRREVIEWER = {W. G. Brown}, DOI = {10.1007/BF01202788}, URL = {http://dx.doi.org/10.1007/BF01202788}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1993.06] = [==[@incollection {MR1209184, AUTHOR = {Clark, Lane and Entringer, Roger and Erd{\H{o}}s, Paul and Sun, Hui Cheng and Sz{\'e}kely, L{\'a}szl{\'o}}, TITLE = {Extremal problems for the {B}ondy-{C}hv\'atal closure of a graph}, BOOKTITLE = {Graphs, matrices, and designs}, SERIES = {Lecture Notes in Pure and Appl. Math.}, VOLUME = {139}, PAGES = {73--83}, PUBLISHER = {Dekker, New York}, YEAR = {1993}, MRCLASS = {05C35}, MRNUMBER = {1209184 (94a:05105)}, MRREVIEWER = {Theodore C. Enns}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1994.27] = [==[@article {MR1300968, AUTHOR = {Erd{\H{o}}s, P. and Hajnal, A. and Simonovits, M. and S{\'o}s, V. T. and Szemer{\'e}di, E.}, TITLE = {Tur\'an-{R}amsey theorems and {$K_p$}-independence numbers}, JOURNAL = {Combin. Probab. Comput.}, FJOURNAL = {Combinatorics, Probability and Computing}, VOLUME = {3}, YEAR = {1994}, NUMBER = {3}, PAGES = {297--325}, ISSN = {0963-5483}, MRCLASS = {05C35 (05C55)}, MRNUMBER = {1300968 (96b:05078)}, MRREVIEWER = {C. C. Rousseau}, DOI = {10.1017/S0963548300001218}, URL = {http://dx.doi.org/10.1017/S0963548300001218}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1996.28] = [==[@inproceedings {MR1431944, AUTHOR = {Arkin, Joseph and Arney, David C. and Erdos, Paul}, TITLE = {Two theorems of {A}rkin-{A}rney-{E}rdos}, BOOKTITLE = {Proceedings of the {T}wenty-seventh {S}outheastern {I}nternational {C}onference on {C}ombinatorics, {G}raph {T}heory and {C}omputing ({B}aton {R}ouge, {LA}, 1996)}, JOURNAL = {Congr. Numer.}, FJOURNAL = {Congressus Numerantium. A Conference Journal on Numerical Themes}, VOLUME = {119}, YEAR = {1996}, PAGES = {151--159}, ISSN = {0384-9864}, MRCLASS = {11A07}, MRNUMBER = {1431944}, } ]==]
en:Module:User:Lesser Cartographies/MR
p.mr[1997.64] = [==[@incollection {MR1476449, AUTHOR = {Erd{\H{o}}s, P. and Hajnal, A. and Simonovits, M. and S{\'o}s, V. T. and Szemer{\'e}di, E.}, TITLE = {Tur\'an-{R}amsey theorems and {$K_p$}-independence numbers [ {MR}1300968 (96b:05078)]}, BOOKTITLE = {Combinatorics, geometry and probability ({C}ambridge, 1993)}, PAGES = {253--281}, PUBLISHER = {Cambridge Univ. Press, Cambridge}, YEAR = {1997}, MRCLASS = {05C35 (05C55)}, MRNUMBER = {1476449}, } ]==]
en:Module:Libyan Civil War detailed map
--{ lat = "", long = "", mark = "Location dot red.svg", marksize = "14", label = "[[]]", label_size = "140", link = "", position = "left" },
en:Module:Libyan Civil War detailed map/sandbox
--{ lat = , long = , mark = 'Location dot red.svg', marksize = 14, label = '[[]]', label_size = 140, link = '', position = 'left' },
en:Wikipedia:Reference desk/Archives/Mathematics/2014 December 23
#A and B cross at these points, so there is a point of A-{P2, P3} inside B and a point of A-{P2, P3} outside B (and vice versa).
en:Wikipedia:WikiProject Wikify/Drives/2015/February/Track
{{Backlog progress bar |initial=37726 |goal=35000 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Wikipedia:Reference desk/Archives/Science/2015 February 15
: [[chamois leather|I hope they're being used for vegetation control. <:-{ ]] [[User:Snow Rise|'''''Snow''''']] [[User talk:Snow Rise|talk]] 14:22, 16 February 2015 (UTC)
en:Wikipedia:WikiProject Wikify/Drives/2015/April/Track
{{Backlog progress bar |initial=37213 |goal=35000 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Module:Nigerian insurgency detailed map
--{ lat = , long = , mark = 'Location dot red.svg', marksize = 14, label = '[[]]', label_size = 140, link = '', position = 'left' },
en:Wikipedia:WikiProject Wikify/Drives/2015/June/Track
{{Backlog progress bar |initial=37205 |goal=36000 |category=All articles covered by WikiProject Wikify |unit= }}<!--RM_AT_THE_END_OF_THE_DRIVE--{| style="width: 100%; background-color: white; border: 1px solid black"
en:Template:Infobox drug/doc/names and identifiers
| {{longitem|1=<div style="word-wrap:break-word;">(2''S'',5''R'',6''R'')-6-{[(2''R'')-2-amino''etc.''</div>}}
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple gentamicin
| IUPAC_name = (3''R'',4''R'',5''R'')-2-{[(1''S'',2''S'',3''R'',4''S'',6''R'')-4,6- diamino-3-{[(2''R'',3''R'',6''S'')- 3-amino-6-[(1''R'')- 1-(methylamino)ethyl]oxan-2-yl]oxy}- 2-hydroxycyclohexyl]oxy}-5-methyl- 4-(methylamino)oxane-3,5-diol
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple bleomycin
| IUPAC_name = (3-{[(2'-{(5''S'',8''S'',9''S'',10''R'',13''S'')-15-{6-amino-2- [(1''S'')-3-amino-1-{[(2''S'')-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl] -5-methylpyrimidin-4-yl}-13-[{[(2''R'',3''S'',4''S'',5''S'',6''S'')-3- {[(2''R'',3''S'',4''S'',5''R'',6''R'')-4-(carbamoyloxy)-3,5-dihydroxy-6- (hydroxymethyl)tetrahydro-2''H''-pyran-2-yl]oxy} -4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2''H''-pyran-2-yl]oxy} (1''H''-imidazol-5-yl)methyl]-9-hydroxy-5-[(1''R'')-1-hydroxyethyl]-8,10-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazapentadec-1-yl}-2,4'-bi-1,3-thiazol-4-yl)carbonyl]amino}propyl)(dimethyl)sulfonium
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple clarithromycin
| IUPAC_name = (3''R'',4''S'',5''S'',6''R'',7''R'',9''R'',11''S'',12''R'',13''S'',14''S'')-6-{[(2''S'',3''R'',4''S'',6''R'') -4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy} -14-ethyl-12,13-dihydroxy-4-{[(2''R'',4''S'',5''S'',6''S'')-5-hydroxy -4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7 -methoxy-3,5,7,9,11,13-hexamethyl -1-oxacyclotetradecane-2,10-dione
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple ritonavir
| IUPAC_name = 1,3-thiazol-5-ylmethyl ''N''-[(2''S'',3''S'',5''S'')-3-hydroxy-5-[(2''S'')-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate
en:Wikipedia:WikiProject Spam/LinkReports/mycredit--report.com
:* Link is globally blacklisted by \bmycredit-{0,5}report\.com\b
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple ranitidine
| IUPAC_name = ''N''-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-''N'''-methyl-2-nitroethene-1,1-diamine; dimethyl [(5-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine
en:Module:Citation/CS1/COinS
else --{'audio-visual', 'AV-media-notes', 'DVD-notes', 'episode', 'interview', 'mailinglist', 'map', 'newsgroup', 'podcast', 'press release', 'serial', 'sign', 'speech', 'web'}
en:Module:Citation/CS1/COinS/sandbox
else --{'audio-visual', 'AV-media-notes', 'DVD-notes', 'episode', 'interview', 'mailinglist', 'map', 'newsgroup', 'podcast', 'press release', 'serial', 'sign', 'speech', 'web'}
en:Module:PetScan
--{par = "lang", name = ""},
en:Wikipedia:Media copyright questions/Archive/2016/August
I dont know what else as this tag: -{ {Non-free logo|www.rebellegion.com}} i should use. 
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Amiodarone
| IUPAC_name = (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Methotrexate
| IUPAC_name = (2''S'')-2-[(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Folic acid
| synonyms = ''N''-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid, pteroyl-L-glutamic acid, vitamin B9,<ref>{{cite web | last = Ural | first = Serdar H. | title = Folic Acid and Pregnancy | publisher = Kid's Health | date = November 2008 | url = http://kidshealth.org/parent/pregnancy_newborn/pregnancy/folic_acid.html }}</ref> vitamin Bc,<ref>{{cite web|url=http://medical-dictionary.thefreedictionary.com/vitamin+Bc |title=Definition of vitamin Bc|publisher=Medical-dictionary.thefreedictionary.com |accessdate=2012-09-09}}</ref> vitamin M,<ref name=darby1945>{{cite journal|last1=Darby|first1=William J.|last2=Jones|first2=Edgar|title=Treatment of Sprue with Synthetic L. casei Factor (Folic Acid, Vitamin M).|journal=Experimental Biology and Medicine|date=1 November 1945|volume=60|issue=2|pages=259–262|doi=10.3181/00379727-60-15154P|url=http://ebm.sagepub.com/content/60/2/259.short|accessdate=13 December 2014}}</ref> folacin, pteroyl-L-glutamate<ref>{{cite web| last =Weil| first =Andrew| title =Supplements & Herbs (Vitamin B9-- Folate)| work =MD| publisher =www.drweil.com| url =http://www.drweil.com/drw/u/ART02809/vitamin-b9-folate.html| doi =| accessdate = 2 April 2014| archiveurl = | archivedate = }}</ref>
en:Wikipedia:Teahouse/Questions/Archive 536
Unsigned comments signed by [[User:SineBot]] have dates attached to them. However, when I use the template {-{subst:unsignedip|x.x.x.x}}, there's no date. Is there any way to rectify this? [[User:VerifiedCactus|Verified Cactus]] ([[User talk:VerifiedCactus|talk]]) 20:44, 23 October 2016 (UTC)
en:Draft:Fly algorithm
17. ''G''''fitness''(''F''-{''f''''kill''}) ← ''Error''metrics(''p''''reference'', ''p''''estimated'')
en:Draft:Fly algorithm
20. ''L''''fitness''(''f''''kill'') ← ''G''''fitness''(''F''-{''f''''kill''}) - ''G''''fitness''(''F'')
en:Draft:Fly algorithm
39. ''G''''fitness''(''F''-{''f''''reproduce''}) ← ''Error''metrics(''p''''reference'', ''p''''estimated'')
en:Draft:Fly algorithm
42. ''L''''fitness''(''f''''reproduce') ← ''G''''fitness''(''F''-{''f''''reproduce''}) - ''G''''fitness''(''F'')
en:Draft:Tesevatinib
| IUPAC_name = N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-{[(3aR,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy}quinazolin-4-amine
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Suramin
| IUPAC_name = 8,8'-{Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]}di(1,3,5-naphthalenetrisulfonic acid)
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Atazanavir
| IUPAC_name = methyl ''N''-[(1''S'')-1-{[(2''S'',3''S'')-3-hydroxy-4-[(2''S'')-2-[(methoxycarbonyl)amino]-3,3-dimethyl-''N'''-{[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Dasabuvir
| IUPAC_name = ''N''-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2''H'')-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Delamanid
| IUPAC_name = (2''R'')-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-''b''][1,3]oxazole
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Enalapril
| IUPAC_name = (2''S'')-1-[(2''S'')-2-{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Atracurium besilate
| IUPAC_name = 2,2'-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] dibenzenesulfonate
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Sulfasalazine
| IUPAC_name = 2-hydroxy-5-[(''E'')-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Folinic acid
| IUPAC_name = (''2S'')-2-{[4-[(2-amino-5-formyl-4-oxo-5,6,7,8- tetrahydro-1''H''-pteridin-6-yl)methylamino] benzoyl]amino}pentanedioic acid
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Docetaxel
| IUPAC_name = 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2''R'',3''S'')-3-[(''tert''-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Iotroxic acid
| IUPAC_name = 3-{2-[2-(2-{[(3-carboxy-2,4,6-triiodophenyl)carbamoyl]methoxy}ethoxy)ethoxy]acetamido}-2,4,6-triiodobenzoic acid
en:Wikipedia:WikiProject Medicine/Translation task force/RTT/Simple Imatinib
| IUPAC_name = 4-[(4-methylpiperazin-1-yl)methyl]-''N''-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide